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ABSTRACT 
3D scaffold-free spherical micro-tissue (spheroids) holds great potential in tissue 
engineering as building blocks to fabricate the functional tissues or organs in vitro. To 
date, agarose based hydrogel molds have been extensively used to facilitate fusion 
process of tissue spheroids. As a molding material, agarose typically requires low 
temperature plates for gelation and/or heated dispenser units. Here, we developed an 
alginate-based, direct 3D mold-printing technology: 3D printing micro-droplets of 
alginate solution into biocompatible, bio-inert alginate hydrogel molds for the fabrication 
of scaffold-free tissue engineering constructs.  Specifically, we developed a 3D printing 
technology to deposit micro-droplets of alginate solution on calcium containing 
substrates in a layer-by-layer fashion to prepare ring-shaped 3D agarose hydrogel molds. 
Tissue spheroids composed of 50% human endothelial cells and 50% human smooth 
muscle cells were robotically dispensed into the 3D printed alginate molds using a 3D 
printer, and were found to rapidly fuse into toroid-shaped tissue units. Histological and 
immunofluorescence analysis indicated that the cells secreted collagen type I playing a 
critical role in promoting cell-cell adhesion, tissue formation and maturation.  
The current inability to derive mature cardiomyocytes (CMs) from human 
pluripotent stem cells (hiPSC) has been the limiting step for transitioning this powerful 
technology into clinical therapies.  To address this, scaffold-based tissue engineering 
approaches have been utilized to mimic heart development in vitro and promote 
maturation of CMs derived from hiPSC. While scaffolds can provide 3D 
microenvironments, current scaffolds lack the matched physical/chemical/biological 
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properties of native extracellular environments. On the other hand, scaffold-free, 3D 
cardiac spheroids prepared by seeding CMs into agarose microwells were shown to 
improve cardiac functions. However, CMs within the spheroids could not assemble in a 
controlled manner and led to compromised, unsynchronized contractions. Here we show, 
for the first time, that incorporation of a trace amount (i.e., ~0.004% w/v) of electrically 
conductive silicon nanowires (e-SiNWs) in otherwise scaffold-free cardiac spheroids can 
form an electrically conductive network, leading to synchronized and significantly 
enhanced contraction (i.e., >55% increase in average contraction amplitude), resulting in 
significantly more advanced cellular structural and contractile maturation. 
Our previous results showed addition of e-SiNWs effectively enhanced the 
functions of the cardiac spheroids and improved the cellular maturation of hiPSC-CMs. 
Here, we examined two important factors that can affect functions of the nanowired 
hiPSC cardiac spheroids: (1) cell number per spheroid (i.e., size of the spheroids), and (2) 
the electrical conductivity of the e-SiNWs. To examine the first factor, we prepared 
hiPSC cardiac spheroids with four different sizes by varying cell number per spheroid 
(~0.5k, ~1k, ~3k, ~7k cells/spheroid). Spheroids with ~3k cells/spheroid was found to 
maximize the beneficial effects of the 3D spheroid microenvironment. This result was 
explained with a semi-quantitative theory that considers two competing factors: 1) the 
improved 3D cell-cell adhesion, and 2) the reduced oxygen supply to the center of 
spheroids with the increase of cell number.  Also, the critical role of electrical 
conductivity of silicon nanowires has been confirmed in improving tissue function of 
hiPSC cardiac spheroids. These results lay down a solid foundation to develop suitable 
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nanowired hiPSC cardiac spheroids as an innovative cell delivery system to treat 
cardiovascular diseases. 
We reasoned that the presence of e-SiNWs in the injectable spheroids improves 
their ability to receive exogenous electromechanical pacing from the host myocardium to 
enhance their integration with host tissue post-transplantation. In this study, we examined 
the cardiac biocompatibility of the e-SiNWs and cell retention, engraftment and 
integration after injection of the nanowired hiPSC cardiac spheroids into adult rat hearts. 
Our results showed that the e-SiNWs caused minimal toxicity to rat adult hearts after 
intramyocardial injection. Further, the nanowired spheroids were shown to significantly 
improve cell retention and engraftment, when compared to dissociated hiPSC-CMs and 
unwired spheroids. The 7-days-old nanowired spheroid grafts showed alignment with the 
host myocardium and development of sarcomere structures. The 28-days-old nanowired 
spheroid grafts showed gap junctions, mechanical junctions and vascular integration with 
host myocardium. Together, our results clearly demonstrate the remarkable potential of 
the nanowired spheroids as cell delivery vehicles to treat cardiovascular diseases. 
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CHAPTER ONE 
 
BACKGROUND AND SIGNIFICANCE 
1. Introduction: 
1.1. Cardiovascular diseases (CVD) and myocardial infarction (MI) 
CVD can be attributed to about 1 in every 4 deaths in the United States and are 
regarded as the leading cause of death in the world [1]. The American Heart Association 
reports that there were 780,000 patient deaths from CVD in the United States in 2011. 
The most common type of CVD is coronary artery disease (CAD), which accounts for 
370,000 deaths and costs $109 billion each year in United States, imposing a huge 
economic burden on our society [2]. CAD is a chronic process that is characterized by 
gradually occurring atherosclerosis in the epicardial coronary arteries of the heart. As 
shown in the Fig. 1.1, the progressive accumulation of a waxy substance named plaques 
(the hallmark of atherosclerosis) leads to the hardening of the coronary artery and 
narrowing of the lumen, impairing blood flow crucial to bring enough oxygen and 
nutrients to supply the heart tissue and maintain the normal function of the heart. In 
addition, the thrombosis caused by ruptured plaques could block the coronary arteries in 
the heart, which is known as MI [3-5].  
MI is the irreversible necrosis of heart muscle due to the blocked coronary 
arteries, and approximately 1.5 million cases of MI occurred annually in the United 
States. Briefly, the first incidence of MI is the blockage of the coronary arteries, as 
consequence the blood supply to the myocardium is insufficient which result in 
cardiomyocytes death permanently. The pathological development of MI includes 
inflammation occurrence, myocardium necrosis (cardiac cells death), fibrosis formation, 
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the extension of the infarction area, and the remodeling of the heart (thinning and dilation 
of the left ventricular (LV) wall, enhanced roundness of LV cavity). MI causes a 
significant amount (around 25%) of irreversible cardiac cells death within the LV 
myocardium. The impaired heart function and the pathological development of MI could 
lead to some serious complications like atrial fibrillation, ventricular tachycardia, 
regurgitation of blood through the mitral valve, and fatal heart failure [4]. 
 3 
 
Figure 1.1 Schematics of myocardial infarction. As plaques encroach the coronary artery 
lumen, blood flow becomes limited on demand of the heart; alternatively, rupture or 
erosion of plaques can result in the formation of blood clot in the coronary artery. And 
the complete blockage of coronary artery would lead to a transmural MI. Reproduced 
from [5]. 
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1.2 Current clinical treatments of MI 
The regular treatments for MI is aiming of prompting revascularization with 
clinical interventions (coronary angioplasty, coronary artery bypass), or antiplatelet 
/anticoagulant therapy. While above mentioned strategies are helpful in promoting the 
revascularization of injured area to restore the blood supply post MI and prevent 
expansion of the infarction, they are limited in restoring impaired heart function resulted 
from the significant amount of myocardium death. Alternatively, the whole heart 
transplantation, the long-term solution for the treatment of MI, is regarded as the last 
resort providing effective treatment for heart failure patients but is greatly restricted by 
the severe shortage of donor hearts and tremendous cost burden [6]. On the other hand, 
the survival rates of whole heart transplantation is still not very satisfied and greatly 
influenced by the conditions of the recipient and donor.  83% of patients post whole heart 
transplantation could survive for over 1 year, while 5 years survival rate covers 72% 
patients and only 50% could survive over 9.4 years [7]. In addition, heart transplant 
recipients have to take immunosuppressive medicines routinely for the rest of their lives 
to avoid organ rejection, and the side effects brought by these drugs, can include 
tiredness, lack of strength, and nervousness [8, 9]. 
While above mentioned clinical interventions have shown to slow down the 
progression of heart failure, none of them can reverse this deleterious process and 
regenerate new myocardium to replace the necrotic regions of the LV [10].  Although the 
clinical treatment and understanding of the problem has improved over the last decade, 
the impact of MI on public health calls for further scientific exploration into new 
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technologies and tools to enable better treatment  allowing for myocardium regeneration 
to restore the normal function of the heart. 
1.3 Pathophysiology of MI 
MI is mainly caused by the narrowing or blockage of the coronary arteries due to 
atherosclerotic processes and thrombotic incidence.  Ischemic conditions caused by 
insufficient blood supply to the heart muscle lead to a significant amount of 
cardiomyocyte death, which could form necrotic area in the LV myocardium, causing 
heart function to deteriorate. Consequently, the defects of contractile function will initiate 
the LV remodeling (wall thinning and dilation of the heart, enhanced roundness of LV 
cavity) and fibrotic scar tissue will take over the infarction area over time. Although the 
following in situ fiborosis provides a temporary solution to maintain total LV wall 
integration, the progression of MI eventually leads to fatal heart failure [11]. 
2. Cell therapies for MI treatment 
Current clinical approaches for the treatment of MI may improve symptoms and 
prolong life, but none of them can address the fundamental problem posed by MI: 
regeneration or remuscularization of the lost myocardium post MI. Cells therapies have 
emerged as a potential alternative strategy aiming heart tissue repair and regeneration. 
Since the first time of cell transplantation, the ultimate goal is not to control damage done 
to the heart, but to eliminate damage altogether with de novo myocardium replacement. 
The translational efforts of cell therapy with various cell types for MI treatment have 
proceeded rapidly since the beginning of the 21
st
 century as shown in Fig. 1.2.  
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Figure 1.2. Trend of various types of cell therapies in patients with CVDs. Produced 
from [12]. 
During the past two decades, numerous studies and clinical trials have been 
conducted to demonstrate that various cell based therapies could improve cardiac 
function, reduce fibrosis, promote angiogenesis and attenuate adverse LV remodeling 
post MI. Despite this great advance achieved in this field, many fundamental issues 
remain in order to achieve a stable and consistent outcome after cell transplantation.  
There are five key aspects regarding cell therapy (shown in Fig. 1.3), which will be 
discussed in detail as below. 
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Figure 1.3. The summarized five key elements of cell therapies for cardiac regeneration. 
Produced from [13]. 
2.1 Resources for cell therapies 
The types of cell to be used in cell therapy could be classified as xenogeneic, 
allogeneic, or autologous in origin. Nonhuman xenogeneic cells have restrictions in 
clinical outcomes due to considerable differences in antigens compared with human, 
which could lead to immune rejection after transplantation. Instead, human originated 
allogeneic cells are possible to have better outcomes post cell transplantation. However, 
these allogeneic cells may still have high possibility for severe immune response and 
graft rejection. In order to eliminate the risk of immune rejection post transplantation, the 
same individual derived autologous cells have become the best choice for cell therapy. 
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This autologous cells includes several types such as skeletal myoblasts, bone marrow 
derived cells, resident cardiac stem or progenitor cells, induced pluripotent stem cells and 
terminally differentiated cardiac cells.  
It remains unknown which cell type is most effective for treatment of MI amongst 
the different types of stem/progenitor/terminally differentiated cells. Here we will review 
all the cell types of cell therapies for the treatment of MI, and we establish our standard to 
choose one cell type for our study as the cell should be 1) autologous: no 
immunoresponse after transplantation in vivo; 2) able to mass remuscularization: has 
solid evidence to regenerate large amount of myocardium in vivo; 3) capable of mass 
expansion in vitro: sufficient number of cells for transplantation to replace large area 
damaged myocardium. 
2.1.1 Skeletal Myoblasts (SkMs)  
The first cell type investigated for cardiac cell therapy is the skeletal myoblasts, 
which are defined as muscle progenitor cells that mediate regeneration of skeletal muscle 
[14-16]. Interestingly, some studies show that transplanted SkMs in rat MI model result 
in some beneficial effects like decreased LV diastolic dimension and MI size, improved 
heart function with increased fractional area change and reversed LV remodeling [17]. 
SkMs also have a lot of advantages for cell therapy including autologous derivation from 
muscle biopsies, large scale in vitro expansion and relative ischemia resistance. On the 
other hand, SkMs do have some negative aspect limited its efficacy for the treatment of 
MI, such as only differentiation into the wrong form of muscle like skeletal rather than 
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cardiac and lacking adhesion and gap junction proteins to form functional integration 
with host myocardium upon transplantation [18].  
In addition, there is a clinical trial named MAGIC shows disappointing outcomes 
and an increased risk of arrhythmias in patients who received transplantation of 
autologous SkMs obtained via thigh muscle biopsy in patients [19]. Because of above 
mentioned discouraging results from clinical trials, studies of SkMs transplantation have 
decreased in recent decade. 
2.1.2 Bone marrow derived cells (BMCs) 
 Many cell types have been studied as cell therapy resource for the MI treatment, 
but most clinical trials have applied autologous BMCs due to its proven clinical safety  
and familiarity in the hematopoietic disorders but it still has some problems such as 
heterogeneous results in terms of efficacy [20]. Bone marrow contains multiple types of 
cells, including mononuclear cells (MNCs), hematopoietic stem cells (HSCs), endothelial 
progenitor cells (EPCs), and mesenchymal stem cells (MSCs), which will be discussed in 
details later in this chapter.  Transplanted BMCs in the damaged heart could enhance 
angiogenisis, reduce LV remodeling progress, and improve heart function in both animals 
model and humans clinical trials [21-25].  
Bone marrow derived MNCs play an critical role in immune defense, 
inflammation suppression, and tissue healing process [26]. In addition, MNCs could 
promote angiogenesis post MI which has been proved by recent studies that MNCs 
include a population of potent EPCs actively contributed in postnatal vasculogenesis, 
although it is unsure if MNCs can become fully functional endothelial cells in vivo. Thus 
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transplantation of extracardiac MNCs harvested from bone marrow in patients could have 
potential to improve heart repair after MI occurs. However, no solid evidence has been 
shown to prove implanted MNCs have the capability to generate large amount of 
myocardium for heart repair, instead paracrine effects are the major mechanism 
underlying the beneficial effect from MNCs transplantation in both numerous animal 
studies and clinical trials in the past decades. 
Bone marrow derived HSCs can differentiate into cells of myeloid and lymphoid 
lineages [27]. Interestingly, several reports suggest that HSCs has possibility to 
transdifferentiate into cardiomyocytes for cardiac repair [21, 28]. These promising results 
have prompted several clinical trials to investigate the potential application of HSCs in 
the treatment of MI. HSCs are a rare population of cells in bone marrow (1 in 10,000cells 
) and (1 in 100,000 cells ) blood. The phenotype of human HSCs is still difficult to well 
defined due to the complexity of the specific markers. Generally, human HSCs are 
CD59+ CD34+ Lin- CD38- c-kit- cells, but several other cell types could express the Lin- 
CD34+, and CD38 is not a well-defined marker [29, 30]. On the other hand, some 
research indicates that HSCs readily adopt the hematopoietic phenotype post implantation 
into MI heart [31-33]. 
Bone marrow derived EPCs could migrate to peripheral blood post MI incidence 
and promote angiogenisis by differentiating into blood vessel lining cells (endothelial 
cells) [34, 35]. Their specific markers are CD34, CD133, and VEGFR-2 (vascular 
endothelial growth factor). Several researchers have shown that bone marrow-derived 
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EPC transplantation is capable of restoring vasculogenesis, reducing the myocardial 
infarcted area and improving cardiac function in MI models [36-39].  
Bone marrow derived MSCs are the second most population of stem cells located 
in bone marrow as structural component cells without little ability to enter circulation. 
Their specific markers are a Lin-, CD34-, c-kit+, Sca-1+, CD45- and they can 
differentiate into multiple cell lines including chondrocytes, adipocytes, osteoblasts, 
skeletal muscle cells and cardiomyocytes [40, 41]. Although this cardiogenic potential 
remains controversial [42], the results of MSCs transplantation in animal models of MI 
are still encouraging to improve heart function and reduce fibrosis. 
In summary, MNCs, HSCs, EPCs and MSCs are distinct stem/progenitor cell 
populations or mixture cells in bone marrow. These autologous cell types differ in size, 
surface markers, and the ability to proliferate and differentiate after transplantation in 
myocardium. Despite the lack of a significant amount of myocardium regeneration after 
transplantation, current research with BMCs based cell administration will be able to 
provide further evidence for a nonmyogenic and clinical safe pathway for the MI 
treatment.   
2.1.3 Cardiac stem cells/ progenitor cells (CPCs) 
During the past several decades, tremendous studies have proved that three 
fundamental principles for cardiac regeneration have now been established [43]. First, in 
the embryonic mammalian heart there is a small population of resident multi-potent 
CPCs, which are committed to differentiate into cardiac cells (cardiomyocytes, smooth 
muscle cells and endothelial cells) [44-50]; second, a limited number of new 
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cardiomyocytes after birth in mammals has been observed [51, 52]; and third, some 
vertebrates, such as amphibians [53, 54] and zebrafish [55-57] retain a very robust 
capacity for self cardiac regeneration throughout life, while only early stage of mammals, 
like neonatal mice, can fully regenerate damaged myocardium following experimental 
injury [58]. Actually, some studies have also shown that cardiomyocytes can continue to 
proliferate in adult mammals including humans, but with a very low rate (around 1% per 
year), and that the rate will decline over time [59, 60]. 
The obvious question would be: where does the regenerated myocardium come 
from? There are two major theories that have occurred over the past decade‟s research to 
implicate the cell sources of regenerated cardiomyocytes in adult mammals. First, the 
resident CPCs located in the heart possess the capacity to differentiate into 
cardiomyocytes, smooth muscle cells, and endothelial cells, which could lead to new 
myocardium; second, the mature cardiomyocytes could reenter the mitotic cell cycle to 
divide into more new cardiomyocytes for heart repair as shown in Fig 1.4. 
In 2003, a special population of cells isolated from the adult rat myocardium that 
expressed the tyrosine kinase receptor c-kit (a marker of stemness) is commonly named 
CPCs, which may reside in the heart itself, or derive from a circulating bone marrow 
stem cell [61]. These cells have been proven to have capabilities as stem cells through 
self-renewing properties and multi-potent differentiation into cardiomyocytes, smooth 
muscle cells, and endothelial cells both in vitro and in vivo [46, 62]. Thus most 
researchers use the presence of the c-kit as a specific marker for identification of CPCs 
for cell harvesting and purification [63, 64].  Briefly, these CPCs can be isolated from 
 13 
myocardium biopsy during heart surgery and then expanded in culture in vitro for 
application in autologous transplantation. However, a single specific marker as c-kit to 
harvest CPCs from myocardium has some limitations and the isolated c-kit+ CPCs are 
highly susceptible to contamination by non-CPCs, which may lead to compromised and 
inconsistent outcome after transplantation in vivo.  
In the past decade, the ability of CPCs from both humans and rodents to improve 
heart function, promote cardiac regeneration and reduce fibrosis has been repeatedly 
demonstrated by several researchers in various animal models (mice, rat, dog and etc) of 
MI [62, 65-68]. In addition, there are two prominent clinical trials with CPSs 
transplantation in humans, which have reported early results post transplantation. The 
phase 1 results of the first clinical trial, SCIPIO, showed a 12.3% improvement in LV 
ejection fraction in patients post 1 year with intracoronary injection of autologous c-kit+ 
CPCs following MI [69].  And the second clinical trial (CADUCEUS) phase 1 trial 
recruited randomized patients with 2–4 weeks post MI receiving cardiosphere-derived 
autologous CPCs transplantation or regular treatment as control [70]. However, CPCs 
transplantation results in no critical benefits to improve heart function but only has 
reduced fibrosis and increased viable heart tissue and regional contractility evaluated 
MRI post half year [70]. 
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Figure 1.4  The mechanism of cardiac self –repair in mammals. Produced from [43]. 
There is another sub-type of CPCs [71, 72]in the adult mouse heart named Sca-1+ 
CPCs, which are capable to be differentiated into functional cardiomyocytes in vitro. In 
addition, in vivo data indicates that transplanted Sca-1+ CPCs into damaged myocardium 
in mouse MI model could attenuate LV remodeling due to their committed differentiation 
 15 
into cardiac linage cells. However, the lack of homolog of Sca-1in human hinders this 
translational application in clinical trials [71, 72]. 
The side population cells (SPs) were considered as a sub-population of CPCs, 
which is first described in 1996 [73] as a way to enrich HSCs from the bone marrow of 
adult mice. First identified in mouse bone marrow as HSCs, SPs were subsequently 
isolated from both adult and embryonic mouse hearts with specific markers (CD31-, Sca-
1+, c-kit-, CD34-, and CD45-). In vitro study shows that cardiac SPs have abilities to 
differentiate into cardiac cells and animal study indicates their potentials for cardac 
regeneration in cryoinjured heart. However, it is necessary to test their effectiveness in 
MI models before clinical trials [74-77]. 
The LIM-homeobox transcription factor islet-1 (Isl-1) is a distinct marker of 
undifferentiated CPCs [78]. The Isl-1+ CPCs are able to differentiate into myocardium, 
blood vessels and the conduction system in the heart. However, based on my knowledge 
there is no research shows that the Isl-1+ CPCs could induce myocardium regeneration in 
animal study. On the other hand, these Isl-1+ CPCs do not exist in the adult heart, which 
make them less possible in clinical application [79-81]. 
Initially cardiosphere-derived cells (CDCs) were found in 2004 [82]. The 
researchers are able to isolate CDCs from myocardium biopsy of both human and animal 
origins. The CDCs could grow into colonies in vitro and be able to differentiate into 
cardiac cells. These injected CDCs could improve cardiac function in mouse, rat, pig and 
dog MI models due to their cardiac regeneration in vivo [83-86].  
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Cardiac stem/progenitor cells cannot considerably repair injured myocardium, 
adverse LV remodeling and prevent deterioration in heart function post MI. In fact, the 
main mechanism underlying the efficacy of CPCs transplantation in vivo is paracrine 
effect, which could induce endogenous resident CSCs for in situ proliferation and 
differentiation of cardiac cells resulted in limited myocardium regeneration.  
2.1.4 Embryonic Stem Cells 
Human embryonic stem cells can proliferate without limit, and maintain the 
potential to differentiate into all the cells of the body. This remarkable potential makes 
them a useful cell resource for basic research on the function of the human body, drug 
screening and testing, and transplantation medicine. In 1998, James Thomson first 
successfully isolated embryonic stem cells (ESCs) from the inner cell mass of blastocysts 
stage (4–5 days post fertilization of egg) [87]. ESCs have been proven to be able to 
differentiate into all the derivatives of the three primary germ layers: ectoderm, 
mesoderm and endoderm. ESCs are considered as an unlimited supply of cardiac cells 
produced in vitro as the cell resource of cell therapy for heart repair and regeneration [88, 
89].  
Despite the proved capacity of ESCs for heart repair in vivo, they have restricted 
in clinical application for the treatment of MI patients due to both biological and ethical 
issues. Specifically, their allogeneic nature could induce graft rejection post 
transplantation and their pluripotency has potential of teratoma formation in vivo [90]. 
However, the recent development of autologous human induced pluripotent stem cells 
which have similar pluripotency comparable with ESCs is a more promising clinical cell 
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resource that could avoid these two major problems of ESCs (ethical and biological 
concerns). 
2.1.5 Induced pluripotent stem cells (iPSCs) 
In 2006, Yamanaka discovered that differentiated cells such as fibroblasts can be 
reprogramed into an undifferentiated state named „iPSCs‟, which have similar 
characteristics with ESCs [91]. The beneficial effects in terms of cardiac contractility 
have been observed after transplantation of iPSCs into mice MI model [92].  In addition, 
a similar outcome involving enhanced regional perfusion and improved cardiac function, 
was reported in a porcine MI model [93]. However, the tumorgenetic stemness of iPSCs 
is not clinically safe in vivo and may lead to some negative effects such as in situ tumor 
incidence after iPSCs transplantation. And a study shows that heterogeneous teratoma 
formation in the heart was induced by transplantation of undifferentiated rat iPSCs in a 
rat model [94].  
Thus terminally differentiated iPSCs cardiac cells (cardiomyocytes, endothelial 
cells and smooth muscle cells) have been widely used as cell resources for cell therapy to 
avoid the iPSCs tumorgenicity in vivo. The transplanted murine iPSCMs in adult mouse 
hearts can survive in long term in vivo and form electrical integration with host 
myocardium, which proves their potential application for the cardiac regeneration and 
heart repair [95]. The implanted bioengineered myocardium from mouse iPSCs in adult 
rat MI model could survive at the epicardial implantation site and result in attenuated LV 
remodeling [96]. The above mentioned research indicated iPSCs derived cardiomyocytes 
are a new promising cell resource for the treatment of MI.  
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hiPSC-CMs emerged as an unlimited supply of autologus cardiomyocytes 
produced in vitro as the cell resource of cell therapy for heart repair and regeneration. 
The transplanted hiPSC-CMs could engraft, survive and functional integrate with host 
myocardium to form electromechanical junctions within the healthy rat heart [97]. The 
inherent features of hiPSC-CMs strongly indicate that they are the ideal cell resource of 
cell therapy for MI treatment.  
2.2 Delivery for cell therapies 
2.2.1 Route for delivery 
The most effective way to deliver targeted cells into myocardium for maximized 
outcomes post transplantation is still on the way to explore. The major applied delivery 
routes are intracoronary infusion and direct injection into the injured myocardium 
(intramyocardial). Practically in the clinical setting, the cell delivery by intracoronary 
infusion is the most favorable route for cell transplantation in MI patients. Compared 
with directly intramyocardial injection, intracoronary delivery provides several 
advantages: 1) it could induce much more uniformed cells distribution within injured 
myocardium, 2) it has minimal invasion to the infarcted myocardium during 
transplantation, and 3) it is relatively easier for physician to follow the similar existing 
procedure (bone marrow cells transplantation for leukemia) to conduct the operation. 
However, this intracoronary route has raised some negative effects compared with 
intramyocardial route: 1) the very low immediate retention of transplanted cells (eg, 
intracoronary: 2.6±0.3% vs intramyocardial: 11±3%), could be caused of the migration of 
major cell population into circulation, 2) the larger cells populations such as CDCs (≈21 
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µm in diameter), SkMs (≈20 µm in diameter), MSCs (10–20 µm in diameter) have high 
possibility to block the vascular structure to hinder the additional cells infusion into the 
injured myocardium once occlusion formation and 3) the blocked coronary arteries 
prevent the delivery of cells into myocardium in situ [98-101]. 
Intramyocardial injection through epicardial route offers direct visualization of 
infarcted myocardium but it is restricted by invasive opening chest procedure. On the 
other hand, endocardial injection route is a less invasive way to delivery cells by using an 
image-guided catheter to enter into the cavity of the heart, which has been widely used in 
the clinical settings. There are two advantages of endocardial injection route over 
intracoronary ones 1) the application of NOGA system can trace the distribution of the 
heart tissue with ischemia and fibrosis, which could enable precisely transplantation of 
cells into targeted area of injured myocardium such as border zone or center part of 
infarction; 2) in case of the totally blocked coronary artery it is feasible to delivery cells 
into infarcted area for targeted in situ cardiac regeneration. However, intramyocardial 
route also has some limitations and risks: 1) the distribution of transplanted cells within 
myocardium is not homogeneous and bulk transplanted cells could form big engraftment 
in situ without vascularization to maintain the long term survival in the heart. 2)direct 
delivery itself could invasively disrupt myocardium architecture and cause further 
damage to the myocardium in the injection location.  
2.2.2 Engineered method for cell delivery 
Single cell suspension in medium based injection is the first way to test cell 
therapy for the efficacy of the MI treatment, and this simple method achieved some 
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promising results in some studies [102, 103]. However, the consequence of very low cell 
retention and engraftment underestimates its great potential for better improvement of 
heart function post transplantation [104, 105]. 
In recent decade, new strategy has emerged by focusing on tissue engineering 
methods that could mimic native myocardium environment with the biological, physical 
and chemical cues to better maintain transplanted cell phenotype and survival. There are 
three engineered methods for cell delivery: 1) biomimetic scaffolds; 2) decellularized 
extracellular matrix (ECM); 3) scaffold-free engineered tissue. The scaffolding materials 
can provide a structural environment that supports cell adhesion, migration, 
differentiation, and organization with delivering soluble and insoluble biochemical cues, 
which leads to new tissue formation [106]. Engineered method for cell delivery has great 
potential to improve the cell engraftment and survival compared with single cell 
suspension in medium based injection. In a recent review, five natural materials 
(collagen, gelatin, Matrigel, alginate and fibrin) and seven synthetic materials 
(polyethylene glycol, polyhydroxyethylmethacrylate, polylactide-glycolic acid, and 
poly(N-isopropylacrylamide) and copolymers) have been discussed in application for 
cardiac regeneration but none of them seems the optimal scaffolding materials for  cell 
transplantation for heart repair [107].  
Natural biomaterials are biodegradable, biocompatible and less immunogenic than 
synthetic materials with better cell adhesion, migration, differentiation, and organization. 
Because they are naturally originated as the proteins or polysaccharides with similar 
structures to the native component of ECM [108-113]. The disadvantage of using natural 
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biomaterials as scaffolds for cell transplantation is their untailored poor mechanical 
property. In addition, the degradable byproducts from natural materials may be toxic or 
immunogenic in vivo. 
While synthetic materials for the application in cardiac tissue engineering are 
easily tailored with predictable physical and chemical properties, but their potential 
adverse effects (induce inflammatory and immune response) might affect beneficial 
outcome post cell transplantation [113-116].  
In summary, the optimal materials for cardiac tissue engineering should has no 
immunogenicity and should has mechanical stability, electrical conductivity for electrical 
signals propagation. Furthermore, it  could allow sufficient oxygen and nutrient supply to 
cells, and have a appropriate degradation rate with native ECM replacement. 
Recent study shows that decellularized ECM based injectable materials are very 
promising in the cardiac tissue engineering. In addition, some research indicates the 
composites of natural and synthetic materials could take advantage of both components to 
maxim the outcome for cell transplantation. However, the field in decellularization of 
ECM is developing to fulfill the need as scaffold materials cardiac tissue engineering  
[117, 118]. 
2.2.3 Cell patch 
Engineered cardiac patches can be fabricated from stacking scaffold free cell 
sheets or by seeding the cells into the scaffolding material designed to mimic the native 
ECM. The tissue-engineered cardiac patch provides a better method to deliver cardiac 
cells to the injured myocardium to achieve better outcomes such as higher cell retention 
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and survival, larger and more controlled infarction area coverage, reduced LV 
remodeling post MI [119-122]. 
Though cardiac patch based cell transplantation leds to better engraftment, long-
term survival, and progressive maturation of human cardiomyocytes, the human 
engraftment is totally isolated from host tissue by fibrosis and it does not contribute to 
functional improvements in MI model [123, 124]. 
2.2.4 Scaffold free cardiac tissue engineering 
The cell density inside the material-engineered cardiac construct is very low 
compared with the very dense cell distribution in the natural myocardium. In addition, 
inflammatory reaction, immune response and fibrosis formation caused by the 
degradation of scaffolding materials led to the reconsideration of engineering tissue 
without the use of xenogeneic or  allogenious scaffolding materials. 
2.2.5 Cell sheet 
As intact layers of cells, the scaffold-free two-dimensional (2D) myocardial 
sheets can be used to stack them in multiple layers to produce a 3D cardiac construct for 
cell transplantation. 
The cell culture surface is coated with temperature-responsive hydrogel (poly N-
isopropylacrylamide), which is hydrophobic at 37°C and allows for the cell attachment in 
the incubator; the surface becomes hydrophilic under 32°C and leads to the detachment 
of the cells as an intact layer to preserve the cell-to-cell junction proteins without 
digesting the ECM secreted by cells. .When the 2D cell sheets are stacked together, they 
can rapidly fuse into scaffold-free cardiac patch due to the presence of the intact ECM 
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secreted by cells. The research shows that spontaneously beating cardiac patch with rapid 
electrical coupling between the sheets from stacking multiple monolayers of neonatal rat 
cardiomyocytes indicate the rapid formation of functional gap junctions within patch 
[125, 126]. 
After transplantation of mono-layer of adipose tissue-derived MSCs in mouse MI 
model, angiogenesis, prevention of LV remodeling and improved cardiac function were 
observed post four weeks transplantation [127]. 
Another study shows that transplanted 3D sheets of neonatal rat cardiomyocytes 
in MI models in rats could attach to the host tissue with improved heart function, highly 
expressed gap junctions and enhanced angiogenesis in situ.[128] 
However, application of scaffold-free cell sheets is still facing some problems. 
Firstly, the diffusion limitation of avascular tissue limit the thickness of sheets in vivo  
(only 80 μm), or three layers; even thicker engineered cardiac sheet resulted in cell death 
as necrosis [129]. Secondly, the transplantation of cell sheets in vivo is invasive 
procedure requiring opening the check and induce more damage to the mycadium post 
operation. Several strategies have been explored to increase the vascular structure within 
the cell sheets and thickness of engineered tissue like coculture with endothelial cells and 
treatment with VEGF and culture under bioreactor [130]. 
2.2.6 Spheroid 
The survival rate of single cell transplantation for heart repair is very low partially 
due to harsh conditions within the damaged myocardium including hypoxia, fibrosis and 
inflammatory environment [131]. It is necessary to optimize delivery approach and form 
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of cell therapy, which includes intactness of the cell harvesting or specific cell 
pretreatment procedures prior to transplantation. Compared with cell sheet, spheroids can 
be tailored for suitable size for less invasive cell delivery as direct injection into 
myocardium post MI. Regarding cell delivery, spheroids avoid the harsh enzymatic 
treatment step in cell harvesting procedure  of monolayer cultured single cells and reduce 
anoikis by multi-cellular interaction in the hypoxia environment post transplantation. In 
addition, spheroids could improve cell retention after transplantation due to their 
significantly bigger size compared with single cells.  
The 3D spheroids mimic the natural microenvironment of tissue and enhance 
cell–cell interactions to better maintain the function and phenotype of cells compared 
with traditional 2D monolayer cell cultures. It has been reported that MSCs spheroids 
have better survive under ischemia compared with 2D cultured cells [132] And cells in 
3D spheroid culture could up-regulate expression levels of hypoxia-inducible factor 1 and 
manganese superoxide dismutase, which could improve the resistance to cell apoptosis 
induced by oxidative stress [133]. Enhanced survival and engraftment post 
transplantation of 3D MSC spheroids transplantation was observed in the rat MI model 
[134].  
Another study shows human CPCs spheroids transplantation significantly 
improve the engraftment capacity compare with single cell injection in both mouse 
healthy and injured hearts [135]. After 10 spheroids injection into the healthy 
myocardium of mice, human engraftment formed from transplanted CPC spheroids could 
be detected for 1 week post transplantation. While, no grafted cells could be observed 
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post three days following injection with the same amount of single cells delivery. In 
addition, the same level of engraftment capability has been observed with cells 
transplantation in spheroids in cardiotoxin-injured heart model [135]. 
The form of 3D scaffold-free spheroids for cell delivery represents unique 
opportunities in the improvement of the therapeutic potential post cell transplantation. 
Less invasive procedure, less harsh cell harvesting process, enhanced cell-cell 
interactions, and anti-anoikis features of cells in ischemic environment demonstrate this 
promising strategy of cell delivery for hiPSC-CMs transplantation aiming cardiac repair 
and regeneration in clinical settings.  
2.3 Survival for cell therapies 
hiPSCs and hESCs can be differentiated into functional cardiomyocytes and have 
the potential to repair large scale of injured heart tissue post MI. One of the key 
challenges towards clinical application of hiPSC-CMs is to enhance survival, retention 
and engraftment of the transplanted cells in hash infarction environment (ischemic, 
fibrosis and avascular). Immediately post transplantation, most cardiomyocytes are lost as 
a result of combined mechanical, cellular and host factors.  In addition, a large portion of 
the remained cells in host tissue will undergo apoptosis or necrosis in short term due to 
incidence of inflammation and immunological response and the lacking adhesion signals, 
oxygen and nutrients supply in the ischemia environment. In order to improve cell 
retention and survival post transplantation, many strategies have been applied such as 
conditioning cells before transplantation, promoting angiogenesis in infraction regions, 
using pro-survival cocktails to delivery cells,  blocking the apoptotic signaling pathways, 
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immunosuppressing the host myocardium and application of bioengineered methods 
[136]. 
Several studies have shown 10–30% of transplanted cells could remain post a few 
days, and only 1–5% of cells could survive post 10–12 weeks [137, 138]. Mechanical 
factors could extrude cell out of the host tissue by spontaneous contraction of the hearts 
[139]. Studies of radio-labeled cells [140] and microspheres [141] in a porcine MI model 
indicated that less than 10% cells remained immediately post transplantation. Here we 
summarize current strategies to improve cell retention and survival post transplantation 
listed in the Table 1.1-1.2.  
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Cell conditioning Heat shock 
Hypoxic pre-conditioning 
Hypoxia inducible factor-1 
Diazoxide 
Isoflurane 
Erythropoietin 
Anti-apoptotic pathways Rho-associated kinase inhibition 
TGF-β2 treatment 
SDF-1 signalling of PI3K/Akt 
p38 MAPK inhibition 
Pro-survival cocktail Akt and Bcl overexpression 
Pinacidil 
Cyclosporine 
ZVAD-fmk 
Insulin-like growth factor-1 
 
Table 1.1 Cellular protection strategies described to improve transplanted cell survival. 
Reproduced from [136] 
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Inflammation inhibition CD4/CD8/C3 inhibition 
Prednisone 
Cyclosporine 
Angiogenic and homing factors FGF 
VGEF 
SDF-1a/CXCR4 
Co-transplant Mesenchymal stem cells 
Fibroblasts 
Endothelial cell progenitors 
Hydrogels and bioengineering solutions Collagen 
Hyaluronic acid 
Matrigel 
Fibrin 
Chitosan 
Oligopolyethylene 
Alginate 
Magnetic targeting 
Engineered cell sheets 
Spheroid 
 
Table 1.2 Optimizing host myocardium strategies described to improve transplanted cell 
survival. Reproduced from [136].  
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2.4 Function integration for cell therapies 
The functional integration of graft with host myocardium is necessarily required 
to transmit contractile force and propagate the action potential for pumping out blood 
properly. Firstly, the mechanical integration between graft and host requires cell-cell and 
cell-ECM junction formation. Interestingly, the electrical integration is more complicated 
because of the complex gap junction coupling and ion channel expression required for 
action potential propagation [142]. Successful electromechanical integration could 
reverse the conduction block, synchronize the graft contraction with the host myocardium 
and prevent arrhythmogenicity of the heart [143]. 
The immature phenotypes of hESC-CMs or hiPSC-CMs pose a potential risk for 
arrhythmogenicity in vivo, which could hamper host conducting system and functional 
integration of transplanted cardiomyocytes with the host myocardium [43, 144]. In the 
past decade, physical stimuli (e.g. electrical and mechanical stimulation) has been applied 
to advance the immature cardiomyocytes towards more matured phenotypes with more 
organized sarcomere structures (width, length and alignment) and unregulated expression 
level of gap junction protein (Connexin-43) [145]. In order to mimic the electrically 
conductive properties of native myocardium, conductive nanomaterials (gold nanowires, 
carbon tubes) have been used as scaffolding materials to fabricate engineered cardiac 
tissue with stronger contractile and electrical properties for promoting cardiomyocyte 
maturation in vitro and in vivo [146, 147].  
We recently utilized e-SiNWs to facilitate the self-assembly of hiPSC-CMs to 
form nanowired hiPSC cardiac spheroids and improve the functions of the microtissues, 
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which lead to  significantly more advanced cellular structural and contractile maturation 
of hiPSC-CMs in nanowired spheroids system [148, 149]. Here, we reasoned that the 
presence of the e-SiNWs in the injectable cardiac spheroids improves their ability to 
receive exogenous electromechanical pacing from the host myocardium and enhance 
their functional integration with host tissues post-transplantation. 
2.5 Stability and safety for cell therapies 
The hiPSC-CMs or hESC-CMs can be directly differentiated into cardiomyoctes 
with high efficiency [150], which have emerged as an unlimited cell source for in vitro 
disease modeling for drug discovery and in vivo transplantation for heart repair post MI 
[151]. Although the electrophysiology of single hiPSC-CMs or hESC-CMs has been 
characterized in several studies [7–13], their risks of arrhythmogenicity in vivo has not 
yet been systematically and comprehensively investigated due to unmatched animal 
models with human [152]. Given the immature phenotypes of hiPSC-CMs and hESC-
CMs at the single-cell level, both of them have risks of arrhythmias in vivo post 
transplantation. A recent study showed substantial arrhythmia development after injection 
of hESC-CMs into the myocardium of nonhuman primates [153]. In addition, hiPSC-
CMs or hESC-CMs are heterogenous cell populations consisted of a mixture of 
ventricular, atrial and pacemaker cardiomyocytes [154]. In order to avoid the arrhythmia 
post transplantation, more mature homogenous cardiomyocyte types, like purified 
ventricular cardiomyocytes, should be used in vivo for cell transplantation. 
The other safety issue associated with cell therapies is tumorgenicity in vivo post 
transplantation. Although the host myocardium released cardiotrophic factors guide 
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transplanted ESCs toward cardiac differentiation, the noncardiogenic signaling associated 
with pluripotency of ESCs for unguided differentiation can overcome the limited 
endogenous cardioinstructive signaling to form neoplastic transformation [155]. Thus 
transplantation of terminally differentiated cardiomyocytes may avoid this risk of 
tumorgenicity in vivo. A recent study shows that no teratomas or tumors were found in a 
rat MI model with engineered hESC-CMs patch transplantation at long term monitoring 
(110 or 220 days respectively) [123].  
2.6 Other consideration regarding cell therapies 
2.6.1 Timing for cell transplantation 
There is a study aiming to determine the optimal time point for bone marrow 
derived MSCs transplantation post MI. The rats underwent MI procedure by LAD 
ligation, and received direct intramyocardial injection of MSCs at time points of 1h, 1 
week and 2 weeks post MI, respectively. MSCs transplantation was shown to improve 
heart function and reduce infarct size in MI model rats with attenuated LV chamber 
dilation. Interestingly, the greatest benefit was observed in rats that received MSCs 1 
week post MI with more abundant engrafted MSCs survival, in situ angiogenesis and 
functional cardiomyocytes than the other two groups. At the time point of one week post 
MI, scar formation had not occurred and the acute inflammation and immune response 
was reduced and stable, which could facilitate survival, engraftment and integration of 
transplanted MSCs with functional recovery [156]. Thus one week post MI is a good time 
point to perform the cell transplantation to achieve the better efficacy by avoiding the 
acute inflammation reaction, immune response and fibrosis formation.  
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2.6.2 Dose for cell therapies 
The optimal cell dose of cell therapies aiming the treatment of MI still remains an 
open question. Obviously, a higher dose of cell transplantation could have better 
outcomes upon cell delivery to the injured myocardium. A study by direct 
intramyocardial injection of bone marrow derived MNCs or MSCs in rat MI models 
shows the maximum cell number after increasing injected cell number into the 
myocardium [157]. However, it is not always safe and feasible to deliver a large number 
of cells into the injured myocardium. One study that used the swine MI model while 
delivering CDCs isolated from human biopsies found that over 2.5 x 10
7 
intracoronary-
administrated cells infusion could increase the size of engraftment but meanwhile results 
in side effects such as partial myocardial damage, as evidenced by the elevating level of 
Troponin I (ischemia maker in blood serum) [158]. In addition, more transplanted cells 
can be found in other organs such the lungs, liver, kidneys and spleen with increased 
number of transplanted cells in short term, but few or no grafted cells were detected in 
long term (over six weeks). The long term low survival rate of transplanted cells in the 
heart may limit therapeutic efficacy of cell therapies, while the distribution of 
transplanted cells to other organs rather than heart must be manipulated to avoid adverse 
effects in all cell therapy applications [157].  Interestingly, there is a study using 
allogeneic mesenchymal precursor cell (MPCs) isolated from male crossbred sheep for 
transplantation in a female sheep transmural MI model. This study investigated the 
effects of different doses with injection of 25, 75, 225, or 450 x 10
6
 MPCs respectively 
on the heart functional improvement post cell transplantation, and only the low dose cell 
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transplantation (25 and 75 x 10
6
 MPCs) significantly attenuated infarct expansion and 
increased both LV end diastole  and systole volumes [159].  The researchers concluded 
that the high cell doses lead to intense competition for limited oxygen and nutrient supply 
in the ischemia environment of injured heart, which could result in the limited cell 
survival and functional improvement. In addition, the large number of transplanted cells 
may initiate a more profound inflammation reaction and immune response that 
accelerates cell apoptosis and clearance [159]. The alternative strategy using multiple 
small doses for transplantation over an extended period (e.g. days to weeks) may 
represent a promising direction for optimizing the dose of cell therapies to achieve the 
better outcomes for the MI treatment. 
Though cell therapies are promising approaches to heart regeneration post MI, the 
outcomes of the most current clinical trials show  inconsistent, modest, borderline, or 
undetectable benefits (most of them applied only one dose of cells) [12, 160-162]. 
Roberto Bolli raised a good point, asserting that most pharmacological drugs are 
ineffective when only given one dose but can be highly effective when given repeatedly, 
so one time cell therapy may have no effect, or only be modestly effective, but multiple 
transplantations may turn out to be very effective due to the accumulated improvement.  
His studies in rodents have shown that repeated cell therapy is much more effective than 
single-dose therapy. When the rats with chronic ischemic cardiomyopathy (old MI) were 
given three doses of c-kit
+
 CPCs 35 days respectively, each dose generated a similar 
increase in LV function, so the total cumulative improvement was approximately triple 
than that observed with one dose administered . In a following study in mice with chronic 
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ischemic cardiomyopathy, they found that three doses of cardiac mesenchymal cells 
(CMCs), given 14 days separately, generated a significantly greater outcomes as the 
bigger improvement in LV function and led to less myocardial fibrosis in the 
noninfarcted region compared with single dose [163, 164]. 
2.7 Cell therapy based future strategies for the treatment of MI 
Recent researches on MI treatment are focused on reversing heart remodeling and 
reducing scar formation with stem/ progenitor/ terminally differentiated cells injection or 
replacing scar tissue with a functional engineered myocardium.  
Among all the cell types for cell therapies for the MI treatment, hiPSCs have 
emerged as a more promising cell resource for heart repair due to their proven capacity to 
produce patient-specific functional cardiomyocytes (hiPSC-CMs) [165-169]. In addition, 
recent progress in cardiac differentiation of hiPSCs allows for the derivation of a large 
number of hiPSC-CMs (>10
9
 cells/patient) needed for cardiac repair [124, 170-172]. To 
realize the therapeutic potential of hiPSC-CMs or hESC-CMs (cardiomyocytes derived 
from human embryonic stem cells), significant efforts have been made, transplanting 
hiPSC-CMs or hESC-CMs into animal MI models to improve cardiac function, with 
limited myocardium regeneration [97, 104, 124, 170, 173-178].  
While most of research utilizes direct injection of the dissociated hiPSC-CMs or 
hESC-CMs into healthy/injured myocardium, the success of this cell delivery approach is 
limited by low cell retention and survival after cell transplantation. Dissociated hiPSC-
CMs are rapidly redistributed to other organs (e.g., lung) after injection due to 
mechanical dispersion of beating hearts [140]. Additionally, lack of cell-to-cell adhesion 
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amongst single cells leads to cell death caused by anoikis and/or ischemia [179]. To 
improve the efficiency of cell delivery, significant efforts have been devoted to the 
development of tissue-engineered epicardial patches [175, 180-182]. In addition to the 
invasive surgical procedure to transplant the patches, recent research has shown there is 
limited electrical integration between the transplanted patches and host myocardium, 
largely attributed to the chronic fibrotic response that occurs after transplantation [180-
182]. This highlights an urgent need to develop an innovative platform to improve the 
retention, engraftment and integration of the injected hiPSC-CMs with the adult 
myocardium after transplantation.  
hiPSC cardiac spheroids have been proposed as an attractive cell delivery system 
for heart repair, given the recent literature showing spheroid/aggregate delivery improves 
cellular retention and post transplantation survival [183-189]. To this end, we recently 
utilized electrically conductive silicon nanowires (e-SiNWs) to facilitate the self-
assembly of hiPSC-CMs to form nanowired hiPSC cardiac spheroids and improve the 
functions of the microtissues, resulting in significantly more advanced cellular structural 
and contractile maturation of hiPSC-CMs [148]. Here we reasoned that the presence of 
the e-SiNWs in the injectable spheroids improves their ability to receive exogenous 
electromechanical pacing from the host myocardium and enhances their integration with 
host tissues post-transplantation. This theory was inspired by our recent finding that the 
addition of e-SiNWs in hiPSC-CM spheroids are essential for exogenous electrical 
stimulation/pacing to promote hiPSC-CM development and maturation [190]. 
Furthermore, recent reports showed the presence of electrical nanomaterials (e.g., gold 
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nanowires) in cardiac tissue engineering constructs synergizes with exogenous electrical 
pacing to improve the function of the constructs [147, 191]. Compared to other electrical 
nanomaterials (e.g. gold nanowires, carbon nanotubes), e-SiNWs have distinct 
advantages, including their controllable electrical conductivity, tunable dimensions, and 
convenient surface tailorability [192, 193]. Additionally, both in vitro and in vivo 
biocompatibility studies have shown no significant cytotoxic effects for either undoped or 
n-type e-SiNWs [194-196]. Notably, the absence of a pre-aligned structure within the 
nanowired hiPSC cardiac spheroids has raised concerns over their suitability for 
transplantation. The ability of hiPSC-CMs from hiPSC cardiac spheroids to align and 
functionally engraft/integrate with the host tissue after transplantation remains an open 
question that needs to be investigated. 
In our study, we plan to inject nanowired hiPSC cardiac spheroids into adult rat 
hearts and examine cell retention, engraftment and integration with host myocardium. In 
addition, we will examine the cardiac biocompatibility of e-SiNWs in the adult rat hearts 
to verify the safety of the application of nanowired cardiac spheroids in vivo.  
3. Study objectives 
3.1 Significance 
The current inability to derive mature cardiomyocytes from hiPSCs has been the 
limiting step for transitioning this powerful technology into clinical therapies.  To address 
this, scaffold-based tissue engineering approaches have been utilized to mimic heart 
development in vitro and promote maturation of cardiomyocytes derived from human 
pluripotent stem cells. While scaffolds can provide 3D microenvironments, current 
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scaffolds lack the matched physical/chemical/biological properties of native extracellular 
environments. On the other hand, scaffold-free, 3D cardiac spheroids (i.e., spherical-
shaped microtissues) prepared by seeding cardiomyocytes into agarose microwells were 
shown to improve cardiac functions. However, cardiomyocytes within the spheroids 
could not assemble in a controlled manner and led to compromised, unsynchronized 
contractions.  
To realize the enormous potential of hiPSC-CMs for heart repair and 
regeneration, significant efforts have been devoted during the last decade to the 
transplantation of hiPSC-CMs into damaged animal hearts to restore their. However, low 
cell retention and limited cell survival have been found regardless of cell delivery 
methods. For example, several researchers demonstrated that less than 10% cells stay in 
the hearts immediately after injection in the rat, porcine or monkey infarct models, and 
even lower cell retention was found for intracoronary and intravenous injection. For the 
cells retained in the hearts, most of them were found to undertake apoptotic and necrotic 
pathways.  Murry and coworkers showed that as high as 90% retained cardiomyocytes 
died within the first few days after transplantation. This high cell death after injection has 
mainly been attributed to three major pathways: anoikis, due to the lack of matrix support 
after harvesting cells from culture substrates; ischemia, due to the lack of oxygen and 
nutrient supply within the avascular infarct regions; and inflammation as attributed to 
cytokines and free radicals. The low cell retention and engraftment after transplantation 
are major limiting factors to develop clinically applicable hiPSC-CM based therapies to 
treat cardiovascular diseases.  Notably, both low retention and low survival of hiPSC-
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CMs after transplantation can be attributed to the current utilization of dissociated single 
hiPSC-CM for cell transplantation. After injection, single cells can be rapidly 
redistributed to the other organs due to the mechanical dispersion of beating hearts and its 
small size going through circulation system. Further, the lack of cell-cell adhesion of 
single cell can lead to anoikis mediated cell death and/or low expression of pro-survival 
factors in a hypoxia environment and result in low cell survival after transplantation.  
We propose that application of nanowired spheroids as cell delivery system could 
improve cell retention and survival after transplantation. The underlying hypotheses are: 
1) spheroids can improve cell retention after transplantation due to their size, 2) the 
spheroid grafting can avoid the harsh enzymatic treatment step in cell harvesting 
procedure and reduce anoikis by multi-cellular interaction, 3) spheroids improve cell 
survival in a hypoxia environment due to their 3D microtissue configuration, and 4) the 
addition of electrically conductive e-SiNWs into spheroids effectively enhance electrical 
integration of transplanted cardiac spheroids with host myocardium and reduce the risk of 
arrhythmia. 
3.2 Specific aims 
To collectively address these challenges, we plan to use e-SiNWs to facilitate the 
self-assembly of hiPSC-CMs to form nanowired hiPSC cardiac spheroids aiming to 
accelerate structural and contractile maturation of hiPSC-CMs in vitro. Our central goal 
is to utilize nanowired human cardiac spheroids as a cell delivery system to improve cell 
retention, survival and integration after transplantation through intramyocardium 
delivery.   
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Aim #1: Accelerate structural and contractile maturation of hiPSC-CMs by using 
electrically conductive e-SiNWs in scaffold-free 3D spheroids system. We hypothesize 
that incorporation of e-SiNWs into hiPSC cardiac spheroids can create an electrically 
conductive microenvironment, leading to synchronized and enhanced contractions of 
hiPSC-CMs and resulting in hiPSC-CM maturation.  
Aim #2: Optimize cell number per spheroid (i.e, spheroid size) to improve the 
functional maturation of hiPSC-CMs and examine the effects of electrical conductivity of 
e-SiNWs on the function of cardiac spheroids. We hypothesize that the optimal cell 
number per spheroid is determined by two competing factors: 1) the improved 3D cell-
cell interaction with the increase of cell number, and 2) the reduced oxygen supply to the 
center of spheroids with the increase of cell number. In addition, we hypothesize that 
electrical conductivity of e-SiNWs plays a critical role in improving the function of 
cardiac spheroids, which leads to structural and contractile maturation of hiPSC-CMs. 
Aim #3: Investigate the cardiac compatibility of e-SiNWs and validate the 
concept that cell delivery with nanowired spheroids can improve cell retention, survival 
and functional integration with host myocardium post transplantation in rat adult health 
hearts. We hypothesize that the e-SiNWs are biocompatible in vivo and would be 
degraded in the heart tissue over time with limited inflammatory and toxic effects. We 
also hypothesize that nanowired spheroids are not prone to leak out or migrate to other 
organ through blood circulation after transplantation, when compared with dissociated 
single cells due to their size. In addition, spheroids can avoid the harsh enzymatic 
treatment step in cell harvesting procedure  of monolayer cultured single cells and reduce 
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anoikis by multi-cellular interaction in the hypoxia environment post transplantation. 
Most importantly, the presence of e-SiNWs within spheroids could improve their ability 
to receive exogenous electromechanical pacing from the host myocardium and enhances 
their integration with host tissues post-transplantation. 
4. Organization of Dissertation 
The following manuscript is arranged in chapters that highlight individual studies 
that relate to the overall aims of my project studying cardiac regenerative medicine.  
Chapter 2 focuses on application of 3D printing technology to facilitate scaffold-
free vascular tissue unit fabrication for engineered blood vessels construction. Briefly, we 
proposed and developed a 3D mold-printing technology to produce biocompatible, bio-
inert alginate hydrogel molds, which can facilitate the fusion process of tissue spheroids 
to form scaffold-free tissue-engineered constructs with defined 3D structures. 
Specifically, we developed a 3D printing technology to print micro-droplets of alginate 
solution on calcium-containing substrates in a layer-by-layer manner to fabricate a 
variety of 3D structures.  Further, we utilized this technology to fabricate ring-shaped 3D 
hydrogel molds for toroid-shaped tissue unit fabrication. Tissue spheroids composed of 
50% endothelial cells and 50% smooth muscle cells were robotically placed into the 3D 
printed alginate molds, and they were found to rapidly fuse together into toroid-shaped 
tissue units.  Histological and immunofluorescence analyses indicated the critical role of 
cell-secreted collagen I in tissue formation and maturation. These scaffold-free toroid-
shaped tissue units could be used to stack together to fabricate a blood vessel-like tube 
for further clinical research and application.  
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In Chapter 3, we will present my core research on the application of trace 
amounts of electrically conductive silicon nanowires to induce maturation of 
cardiomyocytes derived from human induced pluripotent stem cells. Briefly, we 
incorporated a trace amount of e-SiNWs into rat-neonatal and hiPSC cardiac spheroids to 
create electrically conductive microenvironments and induce synchronized and enhanced 
contraction, which was shown to promote structural and contractile maturation. Although 
powerful, the addition of e-SiNWs into the human cardiac spheroids alone may not be 
able to derive fully matured hiPSC-derived cardiomyocytes. A longer term experiment 
(i.e., 3 weeks) was explored, and the improvements in hiPSC-WC spheroids in 
contraction amplitude and sarcomere structure seen at Day 7 were maintained through 
Day 21. However, the extended culture did not indicate further improvements in the 
maturation of hiPSC-derived cardiomyocytes. The sarcomere structure and nuclear shape 
in hiPSC-WC spheroids and hiPSC-NC spheroids at Day 21 resembled that of the Day 7 
spheroids. Our future research will combine additional chemical/physical stimuli (e.g., 
growth factors, miRNA) with e-SiNW-reinforced human cardiac spheroids to produce 
fully matured hiPSC-cardiomyocytes.  
 In Chapter 4, we have experimentally identified the optimal cell number in the 
spheroids and developed a semi-quantitative theory to explain the finding. Briefly, the 
existence of the two competing factors (reduced oxygen supply vs. enhanced 3D cell 
adhesion with the increase of cell number per spheroid) indicates there could be an 
optimal cell number for spheroid fabrication, and our experimental data indicates that 
spheroids contain ~3k cells per spheroid maximizes the benefits of the 3D environment 
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of nanowired spheroids. In our previous report, we showed the addition of e-SiNWs in 
the human cardiac spheroids improved cellular maturation and tissue function. However, 
the role of electrical conductivity of the e-SiNWs has not been examined. In the second 
part of the chapter, we prepared three types of the spheroids: spheroids without the 
addition of nanowires (NC), spheroids with the addition of phosphorus doped silicon 
nanowires (WCD), and undoped silicon nanowires (WCN). We studied the functions of 
these three different types of spheroids and confirmed the critical role of electrical 
conductivity of e-SiNWs in improving tissue function for the hiPSC cardiac spheroids. 
In Chapter 5, we examined the cardiac biocompatibility of the e-SiNWs and cell 
retention, engraftment and integration after injection of the nanowired hiPSC cardiac 
spheroids into adult rat hearts. Our results showed that the e-SiNWs caused minimal 
toxicity to rat adult hearts after intramyocardial injection. Further, the nanowired 
spheroids were shown to significantly improve cell retention and engraftment, when 
compared to dissociated hiPSC-CMs and unwired spheroids. The 7-days-old nanowired 
spheroid grafts showed alignment with the host myocardium and development of 
sarcomere structures. The 28-days-old nanowired spheroid grafts showed gap junctions, 
mechanical junctions and vascular integration with host myocardium. Together, our 
results clearly demonstrate the remarkable potential of the nanowired spheroids as cell 
delivery vehicles to treat cardiovascular diseases. 
In Chapter 6, we will summarize overall conclusions drawn from the body of our 
research, discuss challenges and limitations involved in nanowired spheroids system 
regarding therapeutic efficacy and potential risks, establish research directions in the 
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future to apply our nanowired spheroids system in MI rat models aiming heart functional 
improvement, and suggest some potential applications of nanowired spheroids system in 
brain tissue regeneration. 
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CHAPTER TWO 
 
3D PRINTING FACILITATED SCAFFOLD-FREE TISSUE UNIT 
FABRICATION 
 
1. Abstract: 
3D scaffold-free spherical microtissue (spheroids) holds great potential in tissue 
engineering as building blocks to fabricate the functional tissues or organs in vitro. To 
date, agarose based hydrogel molds have been extensively used to facilitate fusion 
process of tissue spheroids. As a molding material, agarose typically requires low 
temperature plates for gelation and/or heated dispenser units. Here, we proposed and 
developed an alginate-based, direct 3D mold-printing technology: 3D printing micro-
droplets of alginate solution into biocompatible, bio-inert alginate hydrogel molds for the 
fabrication of scaffold-free tissue engineering constructs.  Specifically, we developed a 
3D printing technology to deposit micro-droplets of alginate solution on calcium 
containing substrates in a layer-by-layer fashion to prepare ring-shaped 3D hydrogel 
molds. Tissue spheroids composed of 50% endothelial cells and 50% smooth muscle 
cells were robotically placed into the 3D printed alginate molds using a 3D printer, and 
were found to rapidly fuse into toroid-shaped tissue units. Histological and 
immunofluorescence analysis indicated that the cells secreted collagen type I playing a 
critical role in promoting cell-cell adhesion, tissue formation and maturation.  
2. Introduction: 
Tissue engineering holds remarkable promise for providing architecturally and 
functionally competent replacements for tissues damaged by injury, disease and aging 
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[197-203]. During the last decades, both scaffold and scaffold-free tissue engineering 
strategies have been explored [184, 188, 204-207]. As the central portion of scaffold-
based tissue engineering, biomaterials can provide molecular and mechanical signals to 
promote cell adhesion and proliferation, and enhance extracellular matrix (i.e., ECM) 
protein deposition and tissue formation [208, 209]. Although it retains a high potential for 
application, the scaffold-based approach faces numerous challenges.  One of the key 
problems is that the ideal material to satisfy all the requirements for tissue engineering 
applications remains elusive.  In addition, scaffold materials and their degradation 
products can introduce a variety of adverse effects [210]. As an alternative, bioprinting-
based, scaffold-free tissue fabrication methods (i.e., organ printing) have been explored 
[210, 211].  For example, Cyrille Norotte and coworkers developed a 3D printing 
technology to fabricate scaffold-free, vascular tissue engineered constructs. This 
approach has several distinct advantages.  In particular, it can allow for the creation of 
tissues with a high cell density.  In addition, it can facilitate rapid tissue formation and 
accelerate tissue maturation [210, 212].  
One core concept of organ printing is the use of tissue spheroids as building 
blocks to assemble functional tissues [210, 211]. Tissue spheroids are sphere-shaped 
micro-tissues formed by spontaneous self-assembly of cell suspensions in the absence of 
cell-adhesive substrates (e.g., inside agarose microwells). They hold great promise as a 
bioink for organ printing because they could potentially accelerate tissue formation and 
maturation [210, 211].  Notably, we have developed a robotic technology for rapid and 
scalable fabrication of a large number of tissue spheroids needed for organ printing [213].  
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To date, agarose molds have been extensively used to facilitate the assembly of 
tissue spheroids. The agarose molds can be fabricated by both direct (i.e., 3D printing) 
and indirect (i.e., casting) methods. In the case of indirect mold fabrication, the current 
technology typically involves microfabrication, including 3D printing, of the master mold 
(e.g., wax mold) for the subsequent agarose mold fabrication [214]. For direct mold 
fabrication, agarose has been printed into a mold to fabricate a small diameter vessel 
tissue engineering construct [212]. Here, we describe a proof-of-concept method to 
directly print a customized alginate mold for tissue fabrication. This has a distinct 
advantage in that printing alginate does not require low temperature plates for gelation 
nor heated dispenser units, as may be the case for printing agarose [212, 215, 216]. 
Similar to agarose, alginate is essentially a non-biodegradable, bio-inert, and 
biocompatible material. These are all highly desirable characteristics for printing a mold 
structure because it would maintain its shape fidelity to direct tissue morphology and not 
interact with the forming tissue. Also, it allows for the fabrication of customized molds 
for specific applications.  
In this study, we proposed and developed a 3D mold-printing technology to 
produce biocompatible, bio-inert alginate hydrogel molds, which can facilitate the fusion 
process of tissue spheroids to form scaffold-free tissue-engineered constructs with 
defined 3D structures. Specifically, we have developed a 3D printing technology to print 
micro-droplets of alginate solution on calcium-containing substrates in a layer-by-layer 
manner to fabricate a variety of 3D structures.  Further, we utilized this technology to 
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fabricate ring-shaped 3D hydrogel molds for toroid-shaped tissue unit fabrication. Tissue 
spheroids composed of 50% endothelial cells and 50% smooth muscle cells were 
robotically placed into the 3D printed alginate molds, and they were found to rapidly fuse 
together into toroid-shaped tissue units.  Histological and immunofluorescence analyses 
indicated the critical role of cell-secreted collagen I in tissue formation and maturation. 
These scaffold-free toroid-shaped tissue units could be used to stack together to fabricate 
blood vessel-like tube for further clinical research and application.  
3. Materials and methods: 
3.1 Configuration of the Palmetto 3D bioprinter 
The Palmetto 3D Printer (Fig. 2.1), is a fully automated 3D printer developed by 
the Medical University of South Carolina and Clemson University, and assembled by 
Izumi International (Greenville, SC). The core devices for 3D printing include a three-
axis motion control stage (Janome R2300N, Mahwah, NJ), a linear liquid dispensing 
system (Fishman, Hopkinton, MA) and a digital microscope (Dino Lite, Torrance, CA) to 
record the printing process. The printing hardware is housed in a sterile chamber, and the 
control and monitoring systems are set outside of the chamber. This 3D printer is capable 
of accurately dispensing micro-droplets of 1 µl volume per second at a resolution of 10 
-flow tips with 
a range of 250-840 µm inner diameters (Fishman, Hopkinton, MA) as printing nozzles. In 
this application, 250 µm inner diameter tips were used as a printing nozzle for alginate 
and Pasteur pipettes (diameter ~1000 µm) were used to deposit tissue spheroids. 
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Figure 2.1. A picture of the Palmetto 3D Printer. 
3.2 Alginate solution for 3D printing  
3% sodium alginate solution (w/v) (FMC BioPolymer Co., Philadelphia, PA, 
USA) was selected as ink for 3D bioprinting because: 1) it can rapidly form hydrogels at 
the physiological condition by reacting with calcium ions and 2) it has suitable viscosity 
for robotic liquid dispensing, while maintaining the droplet shape after dispensing (i.e., a 
high contact angle). To rapidly crosslink micro-droplets of alginate solution into 
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hydrogel, 100 mM CaCl2 in 2% gelatin solution were utilized to prepare printing 
substrates according to the report of Brugger and coworkers [217].   
3.3 Cell culture and spheroids fabrication 
Human aortic smooth muscle cells (hSMCs) and human umbilical vein 
endothelial cells (HUVECs) (passage 3) were purchased from Lonza (Catalogue number: 
CC-2571 and C2517A respectively; Lonza, Basel, Switzerland). They were cultivated in 
media as suggested by the manufacturer (cell culture media: Lonza CC-3162 and CC-
3182, respectively). At passage 5, the two cell types were mixed at a 1:1 ratio and then 
seeded into non-adhesive agarose hydrogels molds containing 35 concave recesses with 
hemispheric bottoms (400 µm diameter, 800 µm deep) to facilitate the formation of tissue 
cell spheroids. 
The agarose hydrogel molds were prepared using commercial master micro-molds 
from Microtissues, Inc (Providence, RI) as negative replicates. 330 µl 1% sterile agarose 
solution was pipetted into the master micro-molds to form an agarose hydrogel mold, 
which was then carefully detached from the master mold and transferred into one well of 
a 24 well tissue culture plate.  
The schematic presentation of cell spheroids fabrication is shown in the Fig. 2.  
3M hSMCs (Passage 5) and 3M HUVECs (Passage 5) were suspended in 2ml media 
composed of 50% hSMC media and 50% HUVEC media. 75 µl of the cell suspension 
was pipetted into each agarose mold.  After the cells had settled down into the recesses of 
the mold (10 min), additional media was added (1.0ml/well for a 24 well plate) and 
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exchanged as needed.  In this way, 840 cell spheroids with diameter 300 µm can be 
routinely prepared using a 24 well plate containing 24 agarose hydrogel molds. 
 
Figure 2.2: A: Schematic presentation of the protocol for spheroid fabrication by seeding 
the cells suspension into non-adhesive agarose model; B: bright field images of a 3-day-
old tissue spheroids in low and high magnification. Scale bar is 200μm. 
 
3.4 Histological and immunofluorescence analysis of tissue units 
The printed tissue units were fixed for 30 minutes in 4% paraformaldehyde 
solution. After dehydration, tissues were processed for paraffin infiltration and 
embedding and sectioned. The paraffin sections were stained with hematoxylin–eosin and 
the images were captured using light microscope (Olympus BX40 equipped with a DP25 
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digital camera).  For immunofluorescence staining, primary antibodies were rabbit anti-
human collagen I (Cedarlane USA, Burlington, NC), mouse anti human α-smooth muscle 
actin (Sigma Aldrich, St. Louis, MO), and secondary antibodies were Alexa Fluor 546 
and Alexa Fluor 647 (Invitrogen, Carlsbad, CA). First, a heat-induced epitope retrieval 
step was performed by 5 minutes pressure-cooking of the deparaffinized sections in 1.6 L 
PBS and 15ml antigen unmasking solution (H-3300, Vector Laboratories, Burlingame, 
CA). The sections were then permeabilized in a 0.1% Triton X-100 in PBS for 15 min at 
ambient temperature. After washing in PBS (3x), the tissues were incubated in 
Background Buster (Innovex Biosciences, Richmond, CA) for 30 minutes at ambient 
temperature. After washing in PBS (3 × 5 min), sections were incubated with primary 
antibodies diluted in 1.0% BSA in PBSA (PBS + 0.01% sodium azide) overnight in 
refrigerator. After washing in PBS (3 × 5 min), tissues were incubated with coordinate 
secondary antibodies diluted in 1.0% BSA in PBSA for 1h at ambient temperature. After 
copious washing in PBS, nuclei were counterstained with DAPI (Molecular 
Probes/Invitrogen, Eugene, OR) diluted in PBSA for 15 min at ambient temperature. 
Following the final wash procedure, individual slides were mounted under cover glass 
using Fluoro-Gel (Electron Microscopy Sciences, Hatfield, PA). A  TCS SP5 AOBS laser 
scanning confocal microscope (Leica Microsystems, Inc., Exton, PA) was used to obtain 
fluorescent images. 
4. Results and discussion 
4.1 Optimization of printing parameters and printing algorithm 
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Alginate has been extensively used in the 3D bioprinting because it can robustly 
form cell compatible hydrogels in physiological conditions [218, 219]. Notably, native 
alginate is not adhesive for cells and is also not broken down enzymatically in mammals 
[220, 221]. These are all highly desirable characteristics as molding materials to facilitate 
tissue formation. As a bio-inert material, alginate does not compete with cell-cell 
adhesion and therefore promote fusion process of tissue spheroids.  In addition, it has 
limited biodegradability and sufficient mechanical property for molding [222].  
In this work, we have developed a technology to robotically deposit micro-
droplets of alginate solution onto calcium-containing gelatin substrates to construct 3D 
hydrogels (Fig. 2.4) [218]. A substrate of 100 mM CaCl2 in 2% gelatin solution were 
prepare to serve as a reservoir for calcium ion.  A lower concentration of calcium ions in 
the gelatin solution can lead to slow gelation process and undefined shape of 
microdroplets. It is important to note that some cell types may be sensitive to the free 
calcium ion that slowly diffuses from the physically crosslinked alginate mold [223, 224]. 
However, auxiliary tests confirmed high viability (>90%) post-printing using Ca2+-
sensitive porcine chondrocytes with an atypical calcium concentration (100mM) (Fig. 
2.3) [225, 226]. By using a layer-by-layer approach, we can fabricate hydrogels with a 
number of defined 3D structures.  This has been attributed to the upward diffusion of 
calcium ion from the gelatin substrates (Fig. 2.4) [217].  
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Figure 2.3:  Live dead staining indicated high viability (>90%) post-printing using 
Ca
2+
sensitive porcine chondrocytes suspended in an alginate solution printed on a high 
calcium concentration-containing gelatin substrate (100mM). 
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Figure 2.4: Schematic presentation of 3D alginate hydrogel printing on calcium-
containing gelatin substrate. Adapted from the reference [217].   
 
To ensure a high consistency among the alginate hydrogel micro-droplet formed 
on calcium-containing substrates, we have optimized both concentration of alginate 
solution and the volume of each droplet.  A 3% sodium alginate solution (w/v) was found 
suitable for 3D printing because 1) it can rapidly form hydrogel micro-droplets on the 
calcium ion-containing gelatin substrates, and 2) it has proper viscosity for robotic liquid 
dispensing while maintaining the droplet shape after dispensing. The dispensing volume 
for 3% (w/v) alginate solution was set as 1 µl in this study because a smaller volume (0.5 
µl) can give rise to larger variation among printed droplets (Fig. 2.5).  To prevent the 
coalescence of newly printed droplets with their neighbors (Fig. 2.6a), we developed a 
printing algorithm to ensure that no printed droplet lands next to an un-gelled droplet and 
the final printed product maintained a defined structure as designed (Fig. 2.6b) [217]. 
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Figure 2.5: The different size of alginate microdroplets (A=0.5, B=1.0, and  C=1.5µl) 
printed on calcium containing gelatin substrates. D: The averaged diameter of alginate 
microdroplets with different volume. 
 
 56 
 
Figure 2.6: (a) Printing algorithm before optimization: printing microdroplets of alginate 
solution next to each other can lead to the coalescence of newly printed droplets. (b) 
Printing algorithm after optimization: printing microdroplets of alginate solution in 4 
steps to to ensure that no printed droplet lands next to an un-gelled droplet and the final 
printed product can maintain a defined structure as designed.        
 
To prove the feasibility of 3D hydrogel printing, we designed and printed 
hydrogels with different 3D geometries (cube, square frame, and pyramid). Both the 
printing scheme and the printed alginate hydrogel structures are shown in Fig. 2.7. This 
demonstrates the 3D hydrogel printing we developed here can allow for a proof-of-
concept for the fabrication of alginate hydrogels with defined 3D structures. To quantify 
the printing accuracy, we measured the dimensions of a 3D printed cube structure and 
compared them to the design. As shown in Figure 2.7D, the cube structure was designed 
to have dimensions of 9.6 x 9.6 x 1.75 mm (X, Y, Z), which is a result of a printing 
design with dimensions of 9 mm x 9 mm (based on the center of dot) and a Z dimension 
defined by 5 layers. Typically, the first layer of alginate, which is printed onto the gelatin 
surface, has a height of ~0.7-0.8 mm, while the second and above layers of alginate, 
which is printed onto alginate surface, have heights of ~0.2-0.3 mm.  The actual printed 
cube structure has dimensions of 9.6 x 9.8 x 1.8 mm, and it thus can be defined as an 
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accurate printed structure [227]. Using the cube structure as a model, overnight culture in 
PBS resulted in an average increase in dimension (X, Y) of 1.8%, thus maintaining the 
designed parameters. This demonstrates the 3D hydrogel printing we developed here can 
allow for a proof-of-concept for the fabrication of alginate hydrogels with defined 3D 
structures.  Given the quickly advancing field in biofabrication, improved parameters and 
limitations to bioprinting must be further optimized to achieve the highest needed control. 
 
 
Figure 2.7: Microdroplets facilitated 3D printing alginate hydrogels with different 
geometries (cube (a), square frame (b) and pyramid (c)). : the left is the schematic 
presentation of 3D printing algorithm used to print 3D structures shown in the right. Each 
layer was printed using an multi-step algorithm similar to the one shown in Figure 3. The 
optimal expected dimensions  of 9.6 x 9.6 x 1.75 mm were based on a design of 9 mm x 9 
mm in the X and Y dimension (measured from the dot center) and a Z dimension defined 
by 5 layers (d).  The scale bar for (a),(b), and (c) is 1 mm. The scale bar for (d) is 2 mm. 
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The blue, green, yellow, grey and red represent the 1st, 2nd, 3rd, 4th, and 5th layer of 
bioprinted alginate microdroplets, respectively. 
 
    
4.2 3D Printing alginate molds and robotically seeded spheroids  
To utilize the 3D printed alginate hydrogel molds to facilitate fusion processes of 
tissue spheroids, we have designed ring-shaped alginate molds to fabricate toroid-shaped 
tissue units, which can be utilized to produce tissue engineering constructs (Fig 2.8) 
[228]. To prepare the mold, 24 layers of alginate hydrogel was printed in a layer-by-layer 
fashion to generate ring-shaped molds with inner diameter 5 mm, outer diameter 7 mm 
and height 3 mm over a time span of approximately 30 min (~30 secs/layer with ~1 min 
gelation time between layers). Subsequently, 840 spheroids (average diameter ~300 µm) 
composed of 50% hSMCs and 50% HUVECs was robotically seeded into the mold to 
achieve a connected tissue [229, 230]. Tissue spheroids were selected as bioink for 3D 
bioprinting in this study because they have the potential to accelerate tissue formation 
and maturation [210, 211].  
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Figure 2.8: Schematic presentation (a) and actual product (b) of 3D alginate hydrogel 
printing for tissue unit fabrication using vascular spheroids (i.e., containing smooth 
muscle cells and endothelial cells). Scale bar is 1mm 
 
To utilize the Palmetto 3D Printer to robotically seed the cell spheroids, a variety 
of dispensing nozzles have been examined.  Interestingly, Pasteur pipettes have been 
found most suitable for robotic dispensing of cell spheroid due to the smooth transition 
from upper portion of the pipette to the tip of the pipette (i.e., dispensing nozzle) and the 
diameter of pipette tip (~1000 µm) (Fig. 2.9). Customized Pasteur pipettes with a smaller 
tip diameter (~750 µm) were found difficult to seed cell spheroids since spheroids often 
blocked the dispensing nozzle. 
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Figure 2.9: A picture showing the pasture pipette printing tip loaded with tissue 
spheroids for dispensing. 
 
4.3 Fabrication of toroid-shaped tissue units 
After seeding into ring-shaped molds, the construct was moved to an incubator for 
15 min to melt the calcium-containing gelatin. The melted gelatin solution was 
immediately replaced with fresh cell culture media to minimize exposure to high calcium 
concentration environment. The cell spheroids quickly began fusing into toroid-shaped 
 61 
tissue units after 3 days culture in a reliable manner, which is in agreement with previous 
research [210, 212].  Notably, the quality of the 3D printed mold can effectively affect 
the shape of the formed tissue units.  These tissue units were cultivated for an additional 
13 days to facilitate their maturation. To examine the fusion and maturation process, 
histological and immunofluorescence analysis were conducted.  At day 4, the boundaries 
of many individual spheroids were clearly visible (Fig. 2.10a, b, j, and k) with many open 
spaces between spheroids (white arrow in Fig 2.10k). Notably, collagen I was often found 
between the boundaries of two adjacent spheroids (Fig. 2.10k and l).   As a structural 
ECM protein with cell adhesion motifs (e.g., RGD peptide sequence), collagen I was 
thought to function as adhesive to facilitate the fusion process of the spheroids. At day 8, 
most spheroids were found to be closely associated to each other, while gaps between 
some spheroids were still found (white arrows in Fig. 2.10d and e).  At day 16, the 
spheroids had fused into a complete tissue with abundant, newly synthesized collagen I 
(Fig. 2.10m). In addition, the collage I had filled all the gaps between spheroids (white 
arrows in Fig. 2.10o). This data indicates collagen I plays a critical role in promoting cell-
cell adhesion, tissue formation and maturation.  This is consistent with the previous 
report that cell-adhesive ECM proteins can crosslink adjacent cells together by binding to 
their cell surface receptor (e.g., integrin) and promote tissue cohesion [231].  In addition, 
the day 16-tissue units were stained for smooth muscle cells and endothelial cells (Fig 
2.10p-r). The high expression of specific molecular markers for both cell types (i.e., 
smooth muscle actin and VWF) indicates high cell viability and normal cell behavior 
after 16-day cell culture.    
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Figure 2.10: Histological and immunofluorescence analysis of the tissue units cultured 
for 4, 8 and 16 days.  (a,b,c) H&E staining for tissue units cultured for 4 days at 10x, 20x 
and 40x magnification, respectively. (d,e,f) H&E staining for tissue units cultured for 8 
days at 10x, 20x and 40x magnification, respectively.  (g,h,i) H&E staining for tissue 
units cultured for 16 days at 10x, 20x and 40x magnification, respectively. (j,k,l) 
immunofluorescence analysis of tissue units cultured for 4 days at 20x, 40x and 63 x 
magnification.  (m,n,o) immunofluorescence analysis of tissue units cultured for 16 days 
at 20x, 40x and 63 x magnification. (p,q,r) immunofluorescence analysis of tissue units 
cultured for 16 days at 40x magnification for smooth muscle actin, anti VWF and merge 
picture. Scale bar is 100μm 
 
5. Conclusion 
3D printing holds great promise for rapid, scalable fabrication of tissue 
engineering constructs.  Here, we have developed a robust technology to robotically 3D 
print alginate hydrogel molds to facilitate fusion process of tissue-cell spheroids for the 
fabrication of scaffold-free tissue units. To this end, we have optimized both printing 
parameters and printing algorithm for constructions of alginate hydrogels with defined 
3D architectures. In addition, we also utilized the Palmetto 3D Printer to robotically place 
tissues spheroids into the alginate molds to rapidly fuse into toroid-shaped tissue units. 
Our system has displayed the proof-of-concept for using alginate as a 3D printable, 
molding material to facilitate scaffold-free tissue unit fabrication. The approach 
developed in this manuscript could be used to fabricate various open-structured molds 
(e.g., honeycomb-shaped molds) for the construction of complex structures [214]. Further 
calibrations and improvements to the system are needed for the fabrication of non-open-
structured molds to prepare tissues with more complex shapes, such as small diameter 
blood vessels, which require printing spheroids and alginate in a more controlled manner. 
Given the rapid development in printing technology, we expect that the technology 
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developed here can be used to fabricate tissues with complex structures for tissue 
engineering and drug testing applications. 
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CHAPTER THREE 
SILICON NANOWIRE-INDUCED MATURATION OF CARDIOMYOCYTES 
DERIVED FROM HUMAN INDUCED PLURIPOTENT STEM CELLS 
 
1. Abstract: 
The current inability to derive mature cardiomyocytes from human pluripotent 
stem cells has been the limiting step for transitioning this powerful technology into 
clinical therapies.  To address this, scaffold-based tissue engineering approaches have 
been utilized to mimic heart development in vitro and promote maturation of 
cardiomyocytes derived from human pluripotent stem cells. While scaffolds can provide 
3D microenvironments, current scaffolds lack the matched physical/chemical/biological 
properties of native extracellular environments. On the other hand, scaffold-free, 3D 
cardiac spheroids (i.e., spherical-shaped microtissues) prepared by seeding 
cardiomyocytes into agarose microwells were shown to improve cardiac functions. 
However, cardiomyocytes within the spheroids could not assemble in a controlled 
manner and led to compromised, unsynchronized contractions. Here we show, for the 
first time, that incorporation of a trace amount (i.e., ~0.004% w/v) of electrically 
conductive silicon nanowires (e-SiNWs) in otherwise scaffold-free cardiac spheroids can 
form an electrically conductive network, leading to synchronized and significantly 
enhanced contraction (i.e., >55% increase in average contraction amplitude), resulting in 
significantly more advanced cellular structural and contractile maturation. 
2. Introduction: 
Cardiovascular disease is the leading cause of death worldwide [232]. Due to the 
limited regenerative capacity of adult hearts, human embryonic stem cell (hESC)- and 
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human induced pluripotent stem cell (hiPSC)-based therapy has been the focus of a 
significant amount of research [4, 233].  This is due to their proven capacity to produce 
de novo cardiomyocytes.  However, the current cardiomyocytes derived from hESCs and 
hiPSCs retain an immature phenotype, including poorly organized sarcomere structures 
(i.e., functional units of the contractile machinery) [234-236]. Thus, these cells lack the 
ability to generate sufficient, anisotropic forces as adult cardiomyocytes. This has led to 
difficulties for electrical and mechanical integration with human adult myocardium [153, 
174], which has limited the applications of hESC and hiPSC technology for cardiac 
repair.  
During embryonic development, environmental factors (e.g., extracellular matrix, 
growth factors, mechanical and electrical stimulation) have major effects on the 
maturation of cardiomyocytes. To mimic the maturation process in vitro, hESC- and 
hiPSC-derived cardiomyocytes have been mixed with scaffolding materials (e.g., 
Matrigel and collagen type I gel) to prepare cardiac tissue-engineered constructs and then 
conditioned with electrical and/or mechanical stimulation [234, 237-239].  While these 
scaffolds can provide tissue-like 3D microenvironments, current scaffolding materials 
lack the matched physical/chemical/biological properties with the native extracellular 
environments during heart development. On the other hand, scaffold-free, 3D cardiac 
spheroids have emerged as promising model systems to mimic cardiac tissues [184, 187].  
Unlike in the myocardium, cardiomyocytes in the spheroids do not organize in a 
controlled manner and led to compromised, unsynchronized contractions. To improve 
this, we reasoned the incorporation of e-SiNWs in cardiac spheroids can facilitate the 
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formation of an electrically conductive network, and provide synchronized and improved 
electrical/mechanical signals to advance structural and contractile maturation of the 
cardiomyocytes (Fig. 3.1 and Fig. 3.2). 
100µm 20µm 
 
Figure 3.1. DIC image of the e-SiNW-reinforced human cardiac spheroids shows the 
uniform distribution of e-SiNWs within the spheroids at a 1:1 ratio (number of 
cells/number of e-SiNWs). 
 
3. Materials and Methods: 
3.1 Electrically conductive silicon nanowire fabrication and harvesting.  
Single-crystalline SiNWs were synthesized using the nanocluster-catalyzed 
vapor-liquid-solid method described previously in a quartz tube connected to a gas 
manifold and vacuum pump and heated by a temperature controlled tube furnace.1 
Monodisperse gold nanoparticles (100 nm, Ted Pella) were dispersed on SiO2/silicon 
substrates, which were placed within the central region of the quartz tube reactor. The 
SiNWs were synthesized at 470-485 oC using silane (SiH4) as the silicon reactant source, 
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H2 as the carrier gas, and phosphine (PH3, 1000 ppm in H2) as the n-type dopants. In a 
typical synthesis of uniform n-type, 100 nm SiNWs, the flow rates of SiH4, PH3 and H2 
were 1-2, 2-4 and 60 standard cubic centimetres per minute, respectively, and the total 
pressure 40 torr. The nanowires were collected from the oxidized silicon substrates by 
sonication in isopropanol for 1 min followed by centrifugation to obtain SiNWs with an 
average dimension of 100 nm diameter and 10 µm length. The electrical conductivity of 
the SiNWs were measured by using four-probe transport measurement. 
3.2 Cell harvest and culture.  
Rat-neonatal cardiac cells were isolated from 2-day-old Sprague-Dawley rats by 
using the neonatal isolation kit (Worthington Biochemical Corporation, Lakewood, NJ). 
Rat-neonatal cardiac cells and spheroids were cultured in Dulbecco's Modified Eagle 
Medium (DMEM, 4500 mg/L glucose) (Thermo Scientific, Pittsburgh, PA) containing 
10% heat inactivated fetal bovine serum (HI FBS) (Life Technologies, Carlsbad, CA), 
1% penicillin-streptomycin (Life Technologies, Carlsbad, CA), and 1% non-essential 
amino acids (Life Technologies, Carlsbad, CA). hiPSC-derived cardiomyocytes (iCell 
Cardiomyocytes, Cellular Dynamics International, Madison, WI, USA) were cultured 
according to the manufacturer's protocol. Briefly, hiPSC-derived cardiomyocytes were 
plated on 0.1% gelatin coated 6-well plates in iCell Cardiomyocyte Plating Medium 
(Cellular Dynamics International) at a density of about 3 × 105 to 4.0 × 105 cells/well 
and incubated at 37 °C in 5% CO2 for 4 days. Two days after plating, the plating medium 
was removed and replaced with 4 mL of iCell Cardiomyocytes Maintenance Medium 
(Cellular Dynamics International). After 4 days of monolayer pre-culture, cells were 
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detached using trypLE Express (Gibco Life Technologies, Grand Island, NY) and 
prepared for spheroid fabrication.  
3.3 Spheroid fabrication and electrical stimulation.  
The agarose hydrogel molds were prepared using commercial master micro-molds 
from Microtissues, Inc (Providence, RI) as negative replicates to create non-adhesive 
agarose hydrogels molds containing 35 concave recesses with hemispheric bottoms (800 
µm diameter, 800 µm deep) to facilitate the formation of tissue cell spheroids. 330 µL 
1% sterile agarose solution was pipetted into the master micro-molds and was then 
carefully detached after gelation from the master mold and transferred into one well of a 
24-well tissue culture plate. The schematic presentation of cell spheroids fabrication is 
shown in the Fig. 2C. A suspension of rat-neonatal cardiac cells and e-SiNWs in media 
was prepared at a 1:1 ratio (number of cells/number of SiNWs) with a concentration of 
5.0 x 10
6 
cells/mL. Similarly, hiPSC-derived cardiomyocytes were mixed with e-SiNWs 
in the Maintenance media at a 1:1 ratio (number of cells/number of SiNWs) with a 
concentration of 3.0 x 106 cells/mL. Approximately 75 µl of the cell/e-SiNW suspension 
(rat-neonatal cardiac cells, 5.0 x 106 cells/mL; hiPSC-CMs, 3.0 x 106 cells/mL) was 
pipetted into each agarose mold.  After the cells had settled down into the recesses of the 
mold (10 min), additional media was added (5 mL) and exchanged every 2 days for the 
length of the experiment. After 4 days of spheroid culture, an electrical stimulation 
treatment (C-Pace unit, Ion Optix, Milton, MA 02186) was started for designated groups 
for 7 days (15 V, 1 Hz, 2 ms). For the long term culture experiment of hiPSC cardiac 
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spheroids, the electrical stimulation treatment was performed for 21 days for the 
designated groups after the initial 4 days of spheroid culture. 
3.4 Video and image analysis of beating spheroids.  
Videos of 6 spheroids from each group were recorded starting after the initial 4 
days of spheroid culture using Zen 2011 software (Zeiss, Göttingen, Germany) with 
capture rate of 14 frames per second.  Then the videos were converted to a series of TIFF 
format pictures by Adobe Premiere (Adobe, San Jose, CA). Threshold edge-detecting in 
ImageJ software (National Institutes of Health) was used on high contrast spheroid 
pictures and graphed to realize contraction profiles, from which other quantifiers were 
calculated (i.e., fractional area change and beats per minute). 
3.5 Histological and immunofluorescent analysis of spheroids and cells.  
Freshly collected spheroids (~30-35) were placed onto a pre-labeled tissue base 
mold and the entire tissue block was covered with OCT. Immediately, the base mold 
containing spheroids was transferred into pre-cooled ethanol with dry ice to ensure that 
the spheroids were frozen completely. By using the cryotome, the frozen spheroids block 
were sectioned into 7 µm thickness layers onto glass slides for immunohistochemistry. 
The sections were fixed with pre-cooled acetone (-20 °C) for 10 min. The fixative was 
poured off and the acetone was allowed to evaporate from the sections for 20 min at room 
temperature. After washing (3 times at 5 min) in PBS with 0.1% Triton X-100 (PBST), 
100 µl blocking buffer was added (10% goat serum in PBS) onto the sections of the 
slides and incubated in a humidified chamber at room temperature for 1 h. Sections were 
incubated with appropriately diluted primary antibody: alpha sarcomeric actinin (Abcam, 
 71 
Cambridge, UK), troponin I (Santa Cruz, Dallas, TX), connexin-43 (Sigma Aldrich, St. 
Louis, MO) and beta myosin heavy chain (Millipore, Billerica, MA) overnight at 4 °C. 
After washing in PBST (3 times at 5 min), tissues were incubated with coordinate 
secondary antibodies diluted in PBST for 1h at ambient temperature. After washing in 
PBST (3 times at 5 min), nuclei were counterstained with DAPI (Molecular 
Probes/Invitrogen, Eugene, OR) diluted in PBST for 15 min at ambient temperature. 
Following the final wash procedure (PBST, 3 times at 5 min), glass cover slips were 
added to the slides using Fluoro-Gel (Electron Microscopy Sciences, Hatfield, PA). 
Finally, TCS SP5 AOBS laser scanning confocal microscope (Leica Microsystems, Inc., 
Exton, PA) was used to get fluorescent images. Fluorescent protein expression was 
calculated as the fluorescence area coverage divided by the number of nuclei. 
3.6 TUNEL staining for the frozen section of spheroids.  
In Situ Cell Death Detection Kit (Roche, Penzberg, Germany) was used to 
determine the viability of the cell in the frozen section of spheroids based on the protocol 
from website of Roche. Briefly, the frozen sections of spheroids were fixed with 4% 
paraformaldehyde in PBS for half hour at room temperature. Following washing in PBS 
for 30 minutes, samples were incubated in a permeabilization solution (0.1% Triton X-
100 and 0.1% sodium citrate in PBS) for 2 minutes on ice. Then 50ul of the TUNEL 
reaction mixture were added to samples and incubated in 37 °C for 1 hour. After washing 
in PBST (3 times at 5 min), nuclei were counterstained with DAPI (Molecular 
Probes/Invitrogen, Eugene, OR) diluted in PBS for 15 min at ambient temperature. 
Following the final wash procedure (PBS, 3 times at 5 min), glass cover slips were added 
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to the slides using Fluoro-Gel (Electron Microscopy Sciences, Hatfield, PA). Finally, 
TCS SP5 AOBS laser scanning confocal microscope (Leica Microsystems, Inc., Exton, 
PA) was used to get fluorescent images.  
3.7 Western blotting analysis.  
Following 7 days of cell culture with or without electrical stimulation, 30-35 
spheroids from each rat-neonatal group were harvested from agarose molds. After 
centrifugation and washing by PBS once, 30 µl lysis buffer with 1% protease and 
phosphatase inhibitor cocktails (Pierce Biotechnology, Rockford, IL) was added into the 
vials containing pellet of spheroids. Thereafter, the mixture was homogenized by the 
FastPrep24 instrument (MP Biomedicals, Santa Ana, CA ) to break down spheroids into 
single cells. After 30 minutes to lyse cells on ice, then tubes were centrifuged for 10 min 
at 10 000g at 4 °C and the supernatant was collected as protein solution. After 
quantifying the protein concentration by using the bicinchoninic acid methods, the 
protein solution was mixed with 4x LDS sample loading buffer (Pierce Biotechnology) 
and boiled for 5 min. Protein samples of equal amount were separated in a 4%–12% Bis 
Tris NuPAGE gel (Life Technologies, Carlsbad, CA). Proteins were transferred to a 
PVDF membrane (Life Technologies) and blocked with 5% nonfat milk for one hour, 
followed by incubation with the following primary antibodies: alpha sarcomeric actinin 
(Abcam, Cambridge, UK), connexin-43 (Sigma Aldrich, St. Louis, MO), beta myosin 
heavy chain (Millipore, Billerica, MA), and GAPDH (Sigma Aldrich) overnight at 4°C. 
Blots were then probed with horseradish peroxidase-labeled secondary antibodies (Cell 
Signal, Danvers, MA) and visualized by an enhanced chemiluminescence detection kit 
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(Amersham Pharmacia Biotech (GE Healthcare), Pittsburgh, PA). The intensity of each 
signal was analyzed by using ImageJ software. 
3.8 Spheroid spreading assay.  
Spheroids were seeded onto 0.1% gelatin-coated glass cover slips and incubated 
at 37 °C, 5% CO2, 20% O2.  Cell culture medium was changed every other day. After 12 
days culture, the spheroids spread into a monolayer structure, which was suitable for 
immunofluorescent staining for high resolution, single cell, sarcomere structure analysis. 
3.9 Single cell cardiomyocyte analysis.  
The average sarcomere length was defined as spacing between α-SA striations 
and was measured using black and white renderings of confocal α-SA-stained 
cardiomyocyte images, according to previous methods.2 Using ImageJ, fluorescence 
profiles along lines passing perpendicular through 3 different striated regions of at least 9 
cells, containing at least 6 consecutive sarcomere structures, were measured and divided 
by the number of sarcomeres (space between profile peaks). Z-line width, as previously 
explored,3 was measured directly on α-SA-stained cardiomyocyte images in 12 cells with 
15 measurements per cell. Z-line alignment was defined to establish a sensitive method 
for sarcomere alignment to reflect the enhanced contraction and synchronization. 
Calculations were made using an ImageJ plug-in, OrientationJ, which creates an 
orientation distribution output.4 The area under the curve at ±20° the peak orientation 
degree divided by the total area under the curve was established as the fraction Z-line 
alignment. 
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3.10 Calcium transient imaging of cardiac spheroids.  
Fluo-4 Direct Calcium Assay Kits (Life Technologies, Carlsbad, CA) was used to 
label calcium ion in the whole spheroids based on the protocol from Life Technologies. 
Briefly, spheroids were seeded onto 0.1% gelatin-coated glass cover slips and incubated 
at 37 °C, 5% CO2, 20% O2.  Cell culture medium was changed every other day. After 4 
days culture, the spheroids were rooted on the cover slips. Then cover slips with the 
spheroids were put into 12 wells plates with 2 ml calcium dye solution per well and 
incubated at 37 °C, 5% CO2, 20% O2 for 1h. TCS SP5 AOBS laser scanning confocal 
microscope (Leica Microsystems, Inc., Exton, PA) was used to collect the videos of the 
calcium transient of whole spheroids with a capture rate of 14 frames per second. Finally, 
we used the software of LAS AF from Leica to conduct the quantification of videos 
collected by confocal. 
3.11 qRT-PCR analysis.  
Total RNA was isolated according to the kit and protocol of an RNeasy Micro Kit 
(Qiagen, Vinlo, Netherlands) with the addition of the QIAShredder (Qiagen) during the 
homogenization step for spheroids. For each group, 20-35 spheroids were used for RNA 
isolation. At least 25 ng of total RNA for each group was subjected to cDNA synthesis 
using the Bio-Rad (Hercules, USA) iScript cDNA synthesis kit. qRT-PCR step was 
performed using “best coverage” validated Taqman primers (Life Technologies, 
Carlsbad, USA) in 10 μl reactions for the following genes: CACNA1C, CACNA1G, 
GAPDH, GJA1, MYL2, ACTB. Data was normalized as the change in cycle threshold 
(Ct) to GAPDH and ACTB (dCt) and analyzed using, mRNA expression = 2^(-(dCt)). 
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3.12 Transmission Electron Microscopy.  
SiNWs were gently sonicated in isopropyl alcohol (IPA) and dispersed onto lacey 
carbon grids (Ted Pella Inc.). TEM imaging was conducted using a 300kv FEI Tecnai G2 
F30 Super Twin Transmission Electron Microscope.  
Spheroids were fixed with 2.5% glutaraldehyde, postfixed in PBS buffered 1% 
osmium tetroxide with 1.5% K+ ferricyanide, dehydrated in graded ethanol and 
Acetonitrile, and embedded in PolyBed 812 (Polysciences). 70-nm thick spheroid 
sections were prepared by using a Leica UltraCut R and a diamond knife, stained with 
Hanaichi Pb citrate and uranyl acetate, and imagined using a JOEL 200 CX transmission 
electron microscope. 
3.13 Statistics Analysis  
Differences between experimental groups were analyzed using a independent 
Student T-tests and one-way ANOVA followed by Tukey‟s post-hoc test. P< 0.05 was 
considered significantly difference for all statistical tests. 
4. Results and Discussion: 
This approach has the distinct advantage in that only a trace amount of e-SiNWs 
is utilized, minimizing the adverse effects of traditional scaffolds, such as unmatched 
physical/chemical/biological properties with the native extracellular environments during 
heart development. e-SiNWs were selected because of their controllable electrical 
conductivity, tunable dimensions, and convenient surface tailorability [240, 241]. 
Although SiNWs might not be well known as biocompatible materials, in vitro 
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biocompatibility studies have shown no significant cytotoxic effects for both undoped 
and n-type SiNWs [242]. Further, the recent research showed SiNWs are biodegradable, 
and their degradation products are found mainly in the form of Si(OH)4 and are 
metabolically tolerant in vivo [195, 243-246].  This makes them advantageous over other 
non-biodegradable, electrically conductive nanomaterials (e.g., gold nanowires, carbon 
nanotubes and nanofibers), especially for potential in vivo applications.   
e-SiNW-reinforced 
cardiac spheroids 
cardiac spheroids 
without e-SiNWs 
A B 
 
Figure 3.2. Schematic overview of e-SiNWs reinforced cardiac spheroids. (A) 
Structure of cardiac spheroids without (top) or with (bottom) e-SiNWs: cardiac cells 
(red), nuclei (blue) and e-SiNWs (black). e-SiNWs (bottom) can act as bridges to 
electrically connect cardiac cells and create electrically conductive microenvironments 
throughout the spheroids. (B) Cardiomyocytes in the cardiac spheroids without e-SiNWs 
(top) form electrically isolated small beating clusters with random contractions, while 
cardiomyocytes in the e-SiNWs-reinforced cardiac spheroids can produce synchronized 
and enhanced contractions (bottom). Arrows represent the directions of contractile forces. 
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In this study, n-type SiNWs (Diameter ≈ 100 nm; length ≈ 10 m; 
Silane/Phosphane = 500) were prepared according to the previously established protocol 
[247] (Fig. 3.3A, B). The doping ratio and diameter of the e-SiNWs were chosen to 
obtain a high conductivity (150 - 500 S/m) compared to cell culture medium (~1.75 
S/m) and myocardium (~0.1 S/m) to create highly electrically conductive 
microenvironments within spheroids[191, 248]. The length of the SiNWs was selected to 
inhibit cell internalization. As shown in the Fig. 3.3C-E, both rat neonatal cardiac cells 
and cardiomyocytes derived from human induced pluripotent stem cells have been used 
to prepare e-SiNWed-reinforced cardiac spheroids. The rat left-ventricle neonatal cardiac 
cells were utilized in the initial study due to their ready availability. They were mixed 
with e-SiNWs at a ratio of around 1:1 (number of cells/number of e-SiNWs) and seeded 
into agarose microwells to prepare e-SiNW-reinforced rat-neonatal cardiac spheroids 
(Fig. 3.3C, D and Fig. 1). The ratio between e-SiNWs and cardiac cells was selected to 
minimize the interference of e-SiNWs on the self-assembly process of cardiac cells due 
to their high density and high stiffness (Fig. 3.4). Notably, TEM images of e-SiNW-
reinforced cardiac spheroid indicated the e-SiNWs located in the extracellular space in 
the spheroids, which supported our selection of dimensions of e-SiNWs (Fig. 3.3E). 
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Figure 3.3. Electrically conductive silicon nanowires (e-SiNWs) introduced to 
cardiac spheroids. (A) Transmission electron microscopy (TEM) image of an e-SiNW 
(diameter ≈ 100 nm; length ≈ 10 µm) and (B) high-resolution TEM image of the e-SiNW. 
(C) Schematic representation of spheroid fabrication using rat-neonatal cardiac cells or 
human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes at a ratio 1:1 
(number of cells/number of e-SiNWs) with or without electrical stimulation. (D) Bright 
field image of hiPSC spheroid with e-SiNWs. (E) TEM image of hiPSC spheroid with e-
SiNWs, black arrow indicates the e-SiNWs located in the extracellular area.  Scale bars: 
(A) = 0.2 µm; (B) = 5 nm; (D) = 100 µm; (E) = 500nm. 
 
Although few spontaneous contractions have been found in many rat-neonatal 
cardiac spheroids after 4 days in culture, both contraction frequency and amplitude can be 
significantly enhanced by electrical stimulation (Fig. 3.5A-D). To recapitulate the 
electrical pulses of native myocardium, the spheroids were stimulated at 15 V at 1 Hz, 2 
ms[249]. To independently investigate the effects of e-SiNWs and electrical stimulation, 
four samples have been prepared and examined: rat-neonatal cardiac spheroids without e-
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SiNWs and without electrical stimulation (i.e., r-NC spheroids), rat-neonatal cardiac 
spheroids with e-SiNWs but without electrical stimulation (i.e., r-WC spheroids), rat-
neonatal cardiac spheroids without e-SiNWs but with electrical stimulation (i.e., r-NS 
spheroids), and rat-neonatal cardiac spheroids with e-SiNWs and with electrical 
stimulation (i.e., r-WS spheroids).   
 
Figure 3.4. Changes in diameter of rat-neonatal cardiac spheroids using different ratios 
of cells to e-SiNWs on Day 0; n = 6 spheroids per condition. Asterisks (*) represent 
statistical significance with p<0.05; error bar represents standard deviation. 
 
Video analysis revealed that the chronically stimulated spheroids (i.e., r-NS and r-
WS spheroids) contract regularly and periodically, while the non-stimulated spheroids 
(i.e., r-NC and r-WC spheroids) did not contract consistently. As shown in Fig. 3.5A-D, 
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the average contraction amplitude gradually increased over time for the chronically 
stimulated spheroids (i.e., r-NS and r-WS) and was several-fold higher than the non-
stimulated spheroids (i.e., r-NC and r-WC) with/without stimulation during measurement, 
which is consistent with the previous report [249]. When comparing r-NS spheroids with 
r-WS spheroids, significant improvement in the contraction amplitude and 
synchronization were found in the r-WS spheroids (Fig. 3.5 B, D), which indicate e-
SiNWs can facilitate synchronized electrical signal propagation throughout the spheroids.  
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Figure 3.5. Functional and structural analysis of rat-neonatal cardiac spheroids. (A) 
Averaged fractional area change (i.e., contraction amplitude) over 3 days for r-NS 
spheroids and (B) a characteristic beating profile on day 3 for r-NC, r-NC under 
stimulation during measurement, and r-NS spheroids. (C) Averaged fractional area 
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change over 3 days for r-WS spheroids and (D) a characteristic beating profile on day 3 
for r-WC, r-WC under stimulation during measurement, and r-WS spheroids. (E) Western 
blot analysis (averaged data of three separate experiments) of protein expression levels 
relative to GAPDH expression after 7 days with or without electrical stimulation 
normalized to the r-NC group. (F, G) Immunofluorescent staining of cardiac-specific 
contractile and conductive proteins for all groups after 7 days. r-NC= rat-neonatal cardiac 
spheroids, no e-SiNWs, no stimulation; r-NS= rat-neonatal cardiac spheroids, no e-
SiNWs, with stimulation; r-WC= rat-neonatal cardiac spheroids, with e-SiNWs, no 
stimulation; r-WS= rat-neonatal cardiac spheroids, with e-SiNWs, with stimulation. n = 6 
spheroids per condition (A-D). Asterisks (*) represent statistical significance with 
p<0.05; error bars represent standard deviation. Scale bars: (F) = 100 µm; (G) = 20 µm. 
 
To understand the effects of e-SiNWs and chronic stimulation, the expressions of 
several key cardiac-specific proteins in all four different spheroids were examined using 
western blotting and immunofluorescence staining (Fig. 3.5E-G and Fig. 3.6A, B).  
Among them, connexin-43 (i.e., Cx-43) forms gap junction channels that regulate 
electrical signal propagation between cardiomyocytes[250, 251].  Cardiac -sarcomeric 
actinin (-SA) and cardiac troponin I (cTnI) are cardiac-specific contractile proteins, and 
-myosin heavy chain (-MHC) is neonatal isoform of myosin heavy chain in rat 
cardiomyocytes[249]. As shown in the Fig. 3.5E, F and Fig. 3.6A, B, chronic stimulation 
can significantly increase the expressions and assembly of contractile proteins (e.g., -
SA and cTnI), in agreement with the previous report [249]. On the other hand, the 
incorporation of e-SiNWs led to enhanced expression and clustering of Cx-43 (Fig. 3.5E, 
G), also consistent with the previous literature [146, 147, 252, 253].  The combination of 
SiNWs and chronic stimulation can result in the reduced expression of -MHC, which 
indicates a transition from the neonatal isoform of myosin protein to the adult 
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isoform[249]. This could be attributed to the up-regulated Cx-43 expression (Fig. 3.6 E, 
G) and/or the increased contraction amplitude (Fig. 3.5 D).  
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Figure 3.6. Protein expression analysis of rat-neonatal cardiac spheroids after 7 days of 
treatment. (A) Western blot of cardiac-specific proteins after 7 days for all 4 groups. (B) 
Protein expression levels based on fluorescent signal-covered area per nuclei normalized 
over r-NC expression; n = 3 picture regions; 50 µm x 80 µm picture regions, at least 
containing >24 nuclei. r-NC= rat-neonatal cardiac spheroids, no e-SiNWs, no 
stimulation; r-NS= rat-neonatal cardiac spheroids, no e-SiNWs, with stimulation; r-WC= 
rat-neonatal cardiac spheroids, with e-SiNWs, no stimulation; r-WS= rat-neonatal cardiac 
spheroids, with e-SiNWs, with stimulation. Asterisks (*) represent statistical significance 
with p<0.05; error bar represents standard deviation. 
 
The results from rat-neonatal cardiac spheroids led to the development of hiPSC 
cardiac spheroids (i.e., cardiac spheroids prepared from hiPSC-derived cardiomyocytes, 
Fig. 3.3C). Unlike the rat-neonatal cardiac spheroids, strong spontaneous contractions 
with consistent contraction frequency were found for the non-stimulated hiPSC cardiac 
spheroids. Notably, a significant decrease in contraction amplitude was found for 
electrically stimulated hiPSC-derived cardiac spheroids (i.e., hiPSC-NS and hiPSC-WS 
spheroids) (Fig. 3.7A). TUNEL staining (marker of early apoptosis) of the spheroid 
sections revealed significant increase in cell death at the center of hiPSC-NS and hiPSC-
WS spheroids, while not in the r-NS and r-WS spheroids (Fig. 3.8). Given the similar 
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sizes of the rat-neonatal and hiPSC cardiac spheroids, the increased cell death at the 
center of stimulated hiPSC-derived cardiomyocytes was attributed to the increased 
metabolic demands of the hiPSC-derived cardiomyocytes compared to rat-neonatal 
cardiac cells [254-256]. Accordingly, strong expression of the assembled cardiac 
contractile proteins (e.g., -SA and c-TnI) can only be found on the periphery of the 
hiPSC-NS and hiPSC-WS spheroids (Fig. 3.9A, B). 
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Figure 3.7. Functional analysis of hiPSC-derived cardiomyocyte spheroids. (A) 
Average contraction amplitude from Day 1 to Day 7 of each group. Double asterisk (**) 
represents statistical difference between all groups. (B, C) Representative fractional area 
change (i.e., contraction amplitude) of spontaneously beating spheroids with and without 
e-SiNWs at time points Day 0 and Day 6; n = 6 spheroids per condition. (D, E) 
Representative calcium transient imaging of 7 regions of interest (colored circles) per 
spheroid for each group. Fluorescence amplitude, F/F0, refers to measured fluorescence 
intensity normalized to background fluorescence intensity. (F) Comparison of the peak 
value of F/F0 for each group. (n=3) (G) Comparison of calcium release duration for each 
group. (n=3) hiPSC-NC= human induced pluripotent stem cell cardiac spheroids, no e-
SiNWs, no stimulation; hiPSC-WC= human induced pluripotent stem cell cardiac 
spheroids, with e-SiNWs, no stimulation. Asterisks (*) represent statistical significance 
with p<0.05; error bar represents standard deviation. Scale bars = 100 µm. 
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Figure 3.8. TUNEL staining for the frozen sections of spheroids. Blue color is DAPI 
staining for nuclei, which indicates the viable cells in spheroids. Green color is TUNEL 
staining for fragments of DNA, which indicates the apoptosis of cells in spheroids. Scale 
bars: 50µm. 
 
On the other hand, the addition of e-SiNWs into hiPSC cardiac spheroids without 
electrical stimulation (i.e., hiPSC-WC spheroids) can lead to significant improvement in 
contraction amplitude and synchronization. As shown in the Fig. 3.7 A, the contraction 
amplitude of the hiPSC-WC spheroids averaged more than 55% higher than the hiPSC-
NC spheroids from Day 1 to Day 7. The sharper peaks of fractional area change of the 
hiPSC-WC spheroids over the hiPSC-NC spheroids strongly indicated the enhanced 
contraction synchronization (Fig. 3.7B, C). This is further supported by calcium transient 
imaging of whole spheroids (Fig. 3.7D, E). The quantification of calcium imaging of 
spheroids revealed the hiPSC-WC spheroids have the increased overall amplitude (F/F0) 
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of calcium levels and the accelerated time to peak of the calcium transient (Fig. 3.7 F, G), 
which supported the enhanced synchrony during spontaneous contraction. The significant 
improvement in contraction amplitude and synchronization of hiPSC-WC spheroids is 
remarkable, considering only a trace amount of e-SiNWs (i.e., 0.004% w/v) was utilized 
to create e-SiNW-reinforced cardiac spheroids.  
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Figure 3.9. Cellular organization of hiPSC-derived cardiomyocyte spheroid cross-
sections after 7 days of treatment. (A) Low and (B) high magnification confocal images 
(green, α-sarcomeric actinin (α-SA); red, troponin I; blue, DAPI nuclear stain) that 
display the difference in the sarcomere expression and organization within spheroids. (C) 
Protein expression analysis based on fluorescent signal-covered area per nuclei 
normalized over hiPSC-NC expression; n = 3 picture regions; 75 µm x 130 µm picture 
regions, at least containing >50 nuclei. (D) Characteristic images of hiPSC-NC and 
hiPSC-WC treatments to reveal differences in sarcomere alignment of each whole 
spheroid (dotted line = spheroid border). hiPSC-NC= human induced pluripotent stem 
cell cardiac spheroids, no e-SiNWs, no stimulation; hiPSC-NS= human induced 
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pluripotent stem cell cardiac spheroids, no e-SiNWs, with stimulation; hiPSC-WC= 
human induced pluripotent stem cell cardiac spheroids, with e-SiNWs, no stimulation; 
hiPSC-WS= human induced pluripotent stem cell cardiac spheroids, with e-SiNWs, with 
stimulation.  Error bars represent standard deviation. Scale bars: (A) = 100 µm; (B) = 20 
µm; (D) = 5 µm. 
 
The enhanced contraction amplitude and synchronization of the hiPSC-WC 
spheroids resulted in improved functional maturation. As shown in the Fig. 3.10A-C and 
supplementary Fig. 3.10C, D, the immunofluorescence staining indicated the significant 
increase in expression level and assembly of both conductive and contractile proteins 
(e.g., Cx-43, α-SA, and cTnI) in the hiPSC-WC spheroids, which was further supported 
by the increased expression of conductive gene GJA1 (Cx-43) and contractile gene 
MYL2 (ventricle isoform of myosin light chain) (Fig. 3.11). In addition, the Fig. 3.7 D-G 
showed the improved peak calcium amplitude and the speed of calcium release, which 
suggest the improved calcium handling channels and indicates increased maturation. This 
is further supported by the increased ratio of gene expression of the calcium channel L-
type/T-type subunits (CACNA1C/CACNA1G) (Fig. 3.11). The improved calcium 
handling properties can be attributed to the enhanced organization of the sarcomere 
structures in the hiPSC-WC spheroids[257]. 
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Figure 3.10. Structural analysis of hiPSC-derived cardiomyocyte spheroids. (A) 
Immunofluorescent staining of alpha sarcomeric actinin (α-SA) and troponin I (cTn I). 
(B) Immunofluorescent staining of connexin-43 (Cx-43) and beta myosin heavy chain (β-
MHC). (C) Protein expression analysis based on fluorescent signal-covered area per 
nuclei normalized over hiPSC-NC expression (n = 3; 75 µm x 130 µm picture regions, at 
least containing >50 nuclei) based on (A, B). hiPSC-NC= human induced pluripotent 
stem cell cardiac spheroids, no e-SiNWs, no stimulation; hiPSC-WC= human induced 
pluripotent stem cell cardiac spheroids, with e-SiNWs, no stimulation. Asterisks (*) 
represent statistical significance with p<0.05; error bar represents standard deviation. 
Scale bars = 20 µm. 
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Figure 3.11. qPCR analysis of mRNA expression of conductive and contractile genes in 
hiPSC-NC and hiPSC-WC spheroids. GJA1 – connexin-43; MYL2 – myosin light chain 
ventricular isoform; CACANA1C – calcium L-type channel; CACNA1G – calcium T-
type channel. Asterisks (*) represent statistical significance with p<0.05; error bar 
represents standard deviation, n = 3. 
 
To confirm the effects of e-SiNW-reinforced 3D cell culture on the structural and 
contractile maturation of hiPSC-derived cardiomyocytes, monolayer cells were obtained 
from hiPSC cardiac spheroids by seeding them onto gelatin-coated substrates, which was 
thought to minimize dramatic stress usually associated with mechanical/enzymatic 
spheroid dissociation processes. Sarcomere length and Z-band width were measured as 
they were known as effective indicators of twitch force generated by cardiomyocytes[258, 
259] (Fig. 3.12). As shown in Fig. 6A-C and G, cardiomyocytes harvested from both 
hiPSC-NC and hiPSC-WC spheroids showed significant improvement in Z-band width 
when compared to pre-spheroid hiPSC-derived cardiomyocytes. This indicates that 3D 
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culture can provide supportive microenvironments for the maturation of hiPSC-derived 
cardiomyocytes. Moreover, the hiPSC-WC cardiomyocytes showed significant 
improvement in both sarcomere length and Z-band width when compared to the hiPSC-
NC cardiomyocytes (Fig. 3.12F, G).  These improvements were attributed to the 
enhanced contraction of the hiPSC-WC spheroids.  Notably, the alignment of Z-band in 
hiPSC-WC cardiomyocytes showed remarkable resemblance with adult rat 
cardiomyocytes (Fig. 3.12C-E, H). The increased sarcomere alignment in the hiPSC-WC 
spheroids was attributed to the e-SiNW-induced synchronized contractions (Fig. 3.7 B, 
C), which was hypothesized to provide an anisotropic mechanical environment to direct 
the assembly of contractile machinery of hiPSC-WC cardiomyocytes.   
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Figure 3.12. Single cell analysis of hiPSC-derived cardiomyocytes before and after 
spheroids, and rat-neonatal and adult cardiomyocytes. (A) Fluorescent confocal 
images (green, α-sarcomeric actinin (α-SA); red, troponin I; blue, DAPI nuclear stain) of 
single cells harvested before hiPSC spheroid fabrication, (B) after 7 days from hiPSC-NC 
spheroids, (C) and after 7 days from hiPSC-WC spheroids. (D) Rat-neonatal 
cardiomyocyte and (E) adult left ventricular cardiomyocyte for morphological 
comparison. (F) Sarcomere length measured as distance between α-SA-stained Z-line 
structures from cardiomyocytes with visible sarcomere structures; n = 9 cells per 
condition. (G) Z-line width measurements based on α-SA-stained Z-line structures in 
comparison to neonatal and adult rat cardiomyocyte references; n = 10 cells per 
condition. (H) Z-line alignment calculations were based on a fraction (±20° of the peak 
orientation degree) of aligned α-SA-stained structures; n = 12 cells (hiPSC), 4 cells (rat) 
per condition. hiPSC-NC= human induced pluripotent stem cell cardiac spheroids, no e-
SiNWs, no stimulation; hiPSC-WC= human induced pluripotent stem cell cardiac 
spheroids, with e-SiNWs, no stimulation. Asterisks (*) represent statistical significance 
with p<0.05; error bars represent standard deviation. Scale bars = 25 µm. 
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5. Conclusion: 
For the first time, we incorporated a trace amount of e-SiNWs into rat-neonatal 
and hiPSC cardiac spheroids to create electrically conducting microenvironments and 
induce synchronized and enhanced contraction, which was shown to promote structural 
and contractile maturation. Although powerful, the addition of e-SiNWs into the human 
cardiac spheroids alone may not be able to derive fully matured hiPSC-derived 
cardiomyocytes. A longer term experiment (i.e., 3 weeks) was explored, and the 
improvements in hiPSC-WC spheroids in contraction amplitude and sarcomere structure 
seen at Day 7 were maintained through Day 21 (Fig. 3.13). However, the extended 
culture did not indicate further improvements in the maturation of hiPSC-derived 
cardiomyocytes. The sarcomere structure and nuclear shape in hiPSC-WC spheroids and 
hiPSC-NC spheroids at Day 21 resembled that of the Day 7 spheroids (Fig. 3.9 and Fig. 
3.13). Our future research will combine additional chemical/physical stimuli (e.g., growth 
factors, miRNA) with e-SiNW-reinforced human cardiac spheroids to produce fully 
matured hiPSC-cardiomyocytes.[145, 257]  
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Figure 3.13. Analysis of hiPSC-derived cardiomyocyte spheroids after 3 weeks culture. 
(A) Low and (B) high magnification confocal images (green, α-sarcomeric actinin (α-
SA); red, troponin I; blue, DAPI nuclear stain) that display the difference in the 
sarcomere expression and organization within spheroids after 21 days in culture. (C) 
Average contraction amplitude (i.e., fractional area change) of spontaneously beating 
spheroids with and without e-SiNWs and/or electrical stimulation after 21 days in culture; 
n=6 spheroids per condition.  (D) Protein expression analysis based on fluorescent signal-
covered area per nuclei normalized over hiPSC-NC expression; n = 3 picture regions; 40 
µm x 40 µm picture regions. hiPSC-NC= human induced pluripotent stem cell cardiac 
spheroids, no e-SiNWs, no stimulation; hiPSC-NS= hiPSC cardiac spheroids, no e-
SiNWs, with stimulation; hiPSC-WC= hiPSC cardiac spheroids, with e-SiNWs, no 
stimulation; hiPSC-WS= hiPSC cardiac spheroids, with e-SiNWs, with stimulation. 
Asterisk (*) represents statistical difference between groups with p<0.05; error bar 
represents standard deviation. Scale bars: (A) = 50 µm; (B) = 20 µm. 
 
Recently, nanocomposite scaffolds composed of electrically conductive 
nanomaterials and hydrogels have been developed for cardiac tissue engineering 
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applications[146, 147, 191, 253].  The research reported here is the first demonstration of 
using nanoscale semiconductors to promote cardiac tissue formation and cardiomyocyte 
maturation without involving conventional scaffolding materials (e.g., polymers and 
hydrogels). Also, this research is the first example to directly utilize silicon-based 
nanomaterials for tissue engineering applications.  Our results suggest that silicon-based 
nanomaterials can have major impacts in tissue engineering. Notably, e-SiNW induced 
synchronized contraction could have major implications in cell-based cardiac therapy, 
considering that arrhythmia caused by unsynchronized contraction is a major concern in 
cardiac surgery [170, 174]. Our future research will also include the transplantation of e-
SiNW-reinforced hiPSC cardiac spheroids into infarcted hearts to examine their electrical 
integration with the host myocardium.   
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CHAPTER FOUR 
CELL NUMBER PER SPHEROID AND ELECTRICAL CONDUCTIVITY OF 
NANOWIRES INFLUENCE THE FUNCTION OF SILICON NANOWIRED 
HUMAN CARDIAC SPHEROIDS 
 
1. Abstract: 
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) 
provide an unlimited cell source to treat cardiovascular diseases, the leading cause of 
death worldwide.  However, current hiPSC-CMs retain an immature phenotype that leads 
to difficulties for integration with adult myocardium after transplantation. To address this, 
we recently utilized electrically conductive silicon nanowires (e-SiNWs) to facilitate self-
assembly of hiPSC-CMs to form nanowired hiPSC cardiac spheroids. Our previous 
results showed addition of e-SiNWs effectively enhanced the functions of the cardiac 
spheroids and improved the cellular maturation of hiPSC-CMs. Here, we examined two 
important factors that can affect functions of the nanowired hiPSC cardiac spheroids: (1) 
cell number per spheroid (i.e., size of the spheroids), and (2) the electrical conductivity of 
the e-SiNWs. To examine the first factor, we prepared hiPSC cardiac spheroids with four 
different sizes by varying cell number per spheroid (~0.5k, ~1k, ~3k, ~7k cells/spheroid). 
Spheroids with ~3k cells/spheroid was found to maximize the beneficial effects of the 3D 
spheroid microenvironment. This result was explained with a semi-quantitative theory 
that considers two competing factors: 1) the improved 3D cell-cell adhesion, and 2) the 
reduced oxygen supply to the center of spheroids with the increase of cell number.  Also, 
the critical role of electrical conductivity of silicon nanowires has been confirmed in 
improving tissue function of hiPSC cardiac spheroids. These results lay down a solid 
 96 
foundation to develop suitable nanowired hiPSC cardiac spheroids as an innovative cell 
delivery system to treat cardiovascular diseases. 
2. Introduction: 
Cardiovascular diseases are the leading cause of death and disability worldwide 
[232, 260]. Due to limited regeneration capacity of adult human hearts, human embryonic 
stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) have emerged as 
a powerful cell source for cardiac repair due to their proven capacity to produce 
functional human cardiomyocytes [124, 153, 165-169, 172, 261]. To this end, significant 
efforts have been devoted to transplanting hESC/hiPSC-derived cardiomyocytes 
(hESC/hiPSC-CMs) into damaged hearts to improve their functions in animal models [97, 
104, 124, 153, 174-178, 262]. In particular, Murry and coworkers have demonstrated the 
injection of hESCs-CMs into the injured myocardium led to cardiac muscle regeneration 
in a non-human primate model [153]. Despite the progress, the current hESC/hiPSC-CMs 
retain an immature phenotype, including poorly organized sarcomere structures (i.e., 
functional units of the contractile machinery). This leads to difficulties for electrical and 
mechanical integration with human adult myocardium after transplantation and poses an 
arrhythmic risk [145, 153, 263, 264]. To address this challenge, we recently utilized 
electrically conductive silicon nanowires (e-SiNWs) to facilitate self-assembly of hiPSC-
CMs to form nanowired human cardiac spheroids for heart repair [148]. We 
demonstrated that addition of e-SiNWs into the human cardiac spheroids creates an 
electrically conductive microenvironment and improves tissue function and cellular 
maturation of hiPSC cardiac spheroids. In addition, recent research has shown that 
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cellular spheroids/aggregates improve cell retention and survival after transplantation due 
to their 3D microtissue configuration [177, 183, 265]. In this manuscript, we aim to 
examine two major factors that can affect the functions of the nanowired human cardiac 
spheroids: (1) the number of cells per spheroid (i.e., size of the spheroids), and (2) the 
role of the electrical conductivity of the e-SiNWs in improving tissue functions of the 
spheroids.  
The optimal cell number in the spheroids is affected by two competing factors: 1) 
the improved 3D cell-cell adhesion, and 2) the reduced oxygen supply to the center of 
spheroids with the increase of cell number. In the first part of the study, we 
experimentally identified the optimal cell number in the spheroids and developed a semi-
quantitative theory to explain the finding. In our previous report, we showed the addition 
of e-SiNWs in the human cardiac spheroids improved cellular maturation and tissue 
function [148]. However, the role of electrical conductivity of the e-SiNWs has not been 
examined. In the second part of the manuscript, we prepared three types of the spheroids: 
spheroids without the addition of nanowires (NC), spheroids with the addition of 
phosphorus doped silicon nanowires (WCD), and undoped silicon nanowires (WCN). We 
studied the functions of these three different types of spheroids and confirmed the critical 
role of electrical conductivity of e-SiNWs in improving tissue functions of the hiPSC 
cardiac spheroids. 
3. Materials and methods: 
3.1  Cell culture 
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The hiPSC-CMs (Cellular Dynamics International, Madison, WI, USA) were 
cultured according to the manufacturer's protocol. Briefly, hiPSC-CMs were seeded on 
0.1% gelatin coated 6-wells plate with plating medium (Cellular Dynamics International) 
at a density of about 3 × 105 to 4.0 × 105 cells per well and incubated at 37 °C / 5% CO2 
for two days. Two days after plating, the plating medium was removed and replaced with 
4 ml of maintenance medium (Cellular Dynamics International) for another 2 days. After 
4 days of monolayer pre-culture, cells were detached using trypLE Express (Gibco Life 
Technologies, Grand Island, NY) and harvested for spheroid fabrication. 
3.2 Spheroid fabrication 
The agarose hydrogel molds were prepared using commercial master micro-molds 
from Microtissues, Inc (Providence, RI, USA) as negative replicates to create non-
adhesive agarose hydrogels molds containing 35 concave recesses with hemispheric 
bottoms (800 μm diameter, 800 μm deep) to facilitate the formation of tissue cell 
spheroids. 330 μl 2% sterile agarose solution were pipetted into the master micro-molds 
and then carefully detached after gelation from the master mold and transferred into one 
well of an 8-well tissue culture plate. 75 μl of the cell suspension with different 
concentrations were pipetted into each agarose mold. After the cells had settled down into 
the recesses of the mold (10 min), additional media was added (5 ml) and exchanged 
every 2 days for the length of the experiment. 
3.3 Video and image analysis of beating spheroids 
Videos of 6 spheroids from each group were recorded using Zen 2011 software 
(Zeiss, Göttingen, Germany) with capture rate of 14 frames per second. Then the videos 
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were converted to a series of TIFF formatted pictures by Adobe Premiere (Adobe, San 
Jose, CA). Threshold edge-detecting in ImageJ software (National Institutes of Health) 
was used on high contrast spheroid pictures and graphed to realize contraction profiles, 
from which other quantifiers were calculated (e.g., fractional area change of single 
spheroids). 
3.4  Histological and immunofluorescent analysis of spheroids 
Freshly collected spheroids (~30-35) were placed onto a pre-labeled tissue base 
mold, and the entire tissue block was covered with OCT. Immediately, the base mold 
containing spheroids were transferred into pre-cooled ethanol with dry ice to ensure that 
the spheroids were frozen quickly and completely. Frozen spheroids were cryosectioned 
into 7 μm thick layers onto glass slides for immunohistochemistry. The sections were 
fixed with pre-cooled acetone (-20 °C) for 10 min. After washing (3 times at 5 min) in 
PBS with 0.1% Triton X-100 (PBST), 100 μl blocking buffer were added (10% goat 
serum in PBST) onto the sections of the slides and incubated in a humidified chamber at 
room temperature for 1 h. Sections were incubated with appropriately diluted primary 
antibody: alpha sarcomeric actinin (Abcam, Cambridge, UK), troponin I (Santa Cruz, 
Dallas, TX), connexin-43 (Sigma Aldrich, St. Louis,MO), and COX IV (Abcam) 
overnight at 4 °C. After washing in PBST (3 times at 5 min), tissues were incubated with 
coordinate secondary antibodies diluted in PBST for 1 h at ambient temperature. After 
washing in PBST (3 times at 5 min), nuclei were stained with DAPI (Molecular 
Probes/Invitrogen, Eugene, OR) diluted in PBST for 15 min at ambient temperature. 
Following the final wash procedure (PBST, 3 times at 5 min), cover slips were added to 
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the slides using Fluoro-Gel (Electron Microscopy Sciences, Hatfield, PA). Finally, TCS 
SP5 AOBS laser scanning confocal microscope (Leica Microsystems, Inc., Exton, PA) 
was for fluorescent imaging. 
3.5 TUNEL staining for the frozen section of spheroids 
In Situ Cell Death Detection Kit (Roche, Penzberg, Germany) was used to 
determine the viability of the cell in the frozen section of spheroids based on the Roche 
protocol. Briefly, the frozen sections of spheroids were fixed with 4% paraformaldehyde 
in PBS for half hour at room temperature. Following washing in PBS for 30 minutes, 
samples were incubated in a permeabilization solution (0.1% Triton X-100 and 0.1% 
sodium citrate in PBS) for 2 minutes on ice. Then 50 µl of the TUNEL reaction mixture 
were added to samples and incubated in 37 °C for 1 h. After washing in PBST (3 times at 
5 min), nuclei were stained with DAPI (Molecular Probes/Invitrogen, Eugene, OR) 
diluted in PBS for 15 min at ambient temperature. Following the final wash procedure 
(PBS, 3 times at 5 min), glass cover slips were added to the slides using Fluoro-Gel 
(Electron Microscopy Sciences, Hatfield, PA). Finally, a TCS SP5 AOBS laser scanning 
confocal microscope (Leica Microsystems, Inc., Exton, PA) was used to obtain 
fluorescent images. 
3.6 Calcium transient imaging of cardiac spheroids 
Fluo-4 Direct Calcium Assay Kits (Life Technologies, Carlsbad, CA) was used to 
label calcium ion in the whole spheroids based on the protocol from Life Technologies. 
Briefly, spheroids were seeded onto 0.1% gelatin-coated glass cover slips and incubated 
at 37 °C, 5% CO2, 20% O2.  Cell culture medium was changed every other day. After 
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four days culture, the spheroids were rooted on the cover slips. Then cover slips with the 
spheroids were put into 12-well plates with 2 ml calcium dye solution per well and 
incubated at 37 °C, 5% CO2, 20% O2 for 1 h. TCS SP5 AOBS laser scanning confocal 
microscope (Leica Microsystems, Inc., Exton, PA) was used to collect the videos of the 
calcium transient of whole spheroids at room temperature with a capture rate of 14 
frames per second. Notably, temperature influences the calcium transient dynamics, 
indicated by changes in the beat rate of cardiac spheroids with temperature (Figure 4.1).  
Finally, we used the LAS AF software (Leica) to conduct quantification of videos 
collected by confocal imaging. 
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Figure 4.1. The beat rate of the spheroid’s spontaneous contraction is dependent on 
the temperature. The relationship between beat rate (BPM – beats per minute) and 
medium temperature.  
 
3.7 Transmission Electron Microscopy 
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Spheroids were fixed with 2.5% glutaraldehyde, postfixed in PBS buffered 1% 
osmium tetroxide with 1.5% K+ ferricyanide, dehydrated in graded ethanol and 
Acetonitrile, and embedded in PolyBed 812 (Polysciences). 70 nm thick spheroid 
sections were prepared using a Leica UltraCut R and a diamond knife, stained with 
Hanaichi Pb citrate and uranyl acetate, and imagined using a JOEL 200 CX transmission 
electron microscope. 
3.8 Numerical modeling of oxygen transport in cardiac spheroids 
The oxygen transport within spheroids under static culture conditions mainly 
depends on diffusion [266]. A finite element model of oxygen diffusion within cardiac 
spheroids was developed based on Fick‟s second law. In a spherical coordinate system, 
the oxygen concentration profile in cardiac spheroids is governed by: 
   
where C is oxygen concentration, r is radial distance from spheroid center, D is 
oxygen diffusivity, and R is oxygen consumption rate. The oxygen diffusivity through 
cells is significantly less than that through water. As used in previous studies [267, 268], 
D=3.0×10
-6
 cm
2
/s for cardiomyocytes in suspension was adopted in the model. The 
concentration-dependent oxygen consumption rate (OCR) of cardiomyocytes can be 
modeled by the Michaelis-Menten equation: 
  
where ρ_c is spheroid cell density, V_max is the maximum OCR, and K_m is the 
Michaelis-Menten constant. As the oxygen consumption rates of hiPSC-CMs or human 
cardiomyocytes are not readily availablein the previous literatures, the oxygen 
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consumption rate (V_max=5.44×10
-8
) nmol/cell/s and K_m=3.79 nmol/mL) of rat 
neonatal cardiomyocytes in a quiescent condition was used in the model [255]. The 
boundary condition is that on the spheroid surface, the oxygen concentration maintains 
constant at 20% O2 (185 nmol/mL) [267]. The oxygen transport finite element model was 
numerically solved by the software COMSOL Multiphysics (COMSOL Inc, Burlington, 
MA). The oxygen concentration profiles were determined in spheroids with radius of ~70, 
~100, ~150, and ~200 µm, corresponding to ~0.5k, ~1k, ~3k, and ~7k cells/spheroid.  
3.9 Oxygen Consumption Rate Measurement 
OCR of spheroids was measured according to the previous report [269]. Briefly, 
30-60 spheroids of each group were placed in the OCR chamber equipped with fiber 
optic sensors (Instech Laboratories, Plymouth Meeting, PA), which could measure the 
declining oxygen partial pressure (pO2) over time. OCR measurements were conducted 
in high glucose DMEM medium without FBS at 37°C. The liquid volume in chamber 
was known as 175 μl, so the OCR (mol O2 per unit time) of spheroids could be 
calculated from the linear slope of the measured pO2. Each measurement usually took 90 
minutes. Since the cell number of spheroids is known, the OCR value was normalized 
with cell number for each measurement with unit (pmol/hour/cell). 
3.10 Statistics Analysis 
Differences between experimental groups were analyzed using an independent 
Student T-test, one-way or two-way ANOVA followed by Tukey‟s post-hoc test. P<0.05 
was considered significantly different for all statistical tests. 
4. Results and Discussion 
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The scaffold-free 3D spheroids provide a conductive microenvironment to 
promote cell-cell interactions and electrical coupling, leading to enhanced maturation of 
hiPSC-CMs [270]. The number of cells in a spheroid plays a key role in its function. 
When a spheroid contains too many cells, the supply of nutrient and oxygen to the cells 
in the spheroid center will be limited or insufficient to maintain cellular viability and/or 
normal function. When a spheroid contains a too small number of cells, the benefit of the 
improved 3D cell-cell adhesion over 2D culture will diminish. In this study, we 
fabricated hiPSC-CM spheroids with four different cell numbers per spheroid (i.e., ~0.5k, 
~1k, ~3k, ~7k cells/spheroid) with and without the addition of 1:1 e-SiNWs (number of 
cells : number of e-SiNWs) using our previously established method [148].  Spheroids 
without and with e-SiNWs were designated as “NC” and “WCD”, respectively. As in the 
previous study, n-type SiNWs (Diameter ≈ 100 nm; length ≈ 10 µm; Silane/Phosphane = 
500) were used to prepare WCD spheroids (Figure 4.2 A-C). The length of the SiNWs 
was selected to inhibit cell internalization, and the doping ratio and diameter of the e-
SiNWs were chosen to obtain a high conductivity (150 - 500 µS/µm) to create highly 
electrically conductive microenvironments within spheroids [191, 248]. The addition of 
the e-SiNWs into the cardiac spheroids did not significantly influence the sizes of the 
spheroids at all four cell number/spheroid (Figure 4.3 A-B). This indicates the addition of 
e-SiNWs should not significantly affect the nutrient and oxygen supply to the cells in the 
spheroid center.  
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Figure 4.2. Fabrication of silicon nanowired human cardiac spheroids. (A) Bright field 
image of silicon nanowires (diameter ≈ 100 nm; length ≈ 10 µm). (B) Bright field images 
of silicon nanowired human cardiac spheroids in agarose molds. (C) Confocal image of 
frozen section of silicon nanowired human cardiac spheroids at Day 0 (Blue – DAPI; 
Green – α-SA: alpha sarcomeric actinin; Yellow-silicon nanowires). Scale bars: (A) = 10 
µm; (B) = 100 µm; (C) = 10 µm. 
 
Previous studies have shown that spheroids with a radius over 250 µm became 
apoptotic or necrotic over the time [271]. In addition, Radisic and coworkers have shown 
the diffusion of oxygen in the cardiac tissue engineering constructs is limited to 150~200 
µm [256]. Thus, the ~7k cells per spheroid (~200 µm radius) was chosen to be the upper 
limit in this study. On the other hand, our data showed the lowest contraction amplitude 
(i.e., fractional area change) in spheroids with ~0.5k cells/spheroid (Figure 4.3 C), which 
is in agreement with previous research that indicates the beneficial impact of the 3D cell-
cell adhesion is limited for smaller spheroids [272]. In addition, it is difficult to process 
and section these smaller spheroids. Therefore, this study mainly focused on the three 
larger sizes of spheroids (i.e., 1k, 3k and 7k cells/spheroid). As seen in Figure 4.4 A-B, 
TUNEL staining of the spheroid sections revealed a high level viability of hiPSC-CMs 
(>90%) for all three sizes after 7 days culture [205]. These results support our selection of 
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the range of cell numbers in the spheroids. In addition, the high cell viability of the WCD 
spheroids supports the high biocompatibility of e-SiNWs, which is consistent with the 
previous reports [195, 273, 274]. 
 
Figure 4.3. Human cardiac spheroids with controlled size and functional analysis. (A) 
Bright field images of spheroids with different cell number (0.5k, 1k, 3k, 7k) per spheroid. 
(B) Averaged radius of spheroid based on statistics (n=14). (C) Average fractional area 
change from Day 1 to Day 7 of each group (n=7). NC – without e-SiNWs; WCD – with 
e-SiNWs. Scale bars: (A) = 100 µm. Asterisks (*) represent statistical significance with 
p<0.05; error bars represent standard deviation. 
 
As in our previous report, contraction amplitude (i.e., fractional area change) of 
the spontaneous, rhythmic beating of hiPSC-CM spheroids was used to examine the 
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functions of the spheroids [148]. Figure 4.3 C shows that the presence of e-SiNWs in 
WCD spheroids significantly increased the average contraction amplitude of 1k, 3k and 
7k spheroids when compared with that of NC spheroids. This shows that the beneficial 
effects of adding e-SiNWs into human cardiac spheroids is not limited to a specific 
spheroid size, and this further supports our hypothesis that the addition of e-SiNWs into 
hiPSC cardiac spheroids creates an electrically conductive microenvironment and 
improves cardiac tissue function. In addition, the Figure 2C shows the WCD-3k 
spheroids, the WCD spheroids with ~3k cells/spheroid, have the highest fractional area 
change among all the groups.  
 
Figure 4.4. Viability analysis of spheroids using TUNEL staining. (A) TUNEL staining 
of the frozen sections of NC and WCD spheroids at day 7. Blue – DAPI; Green-TUNEL 
(apoptosis marker). (B) Quantification of viability from TUNEL staining (viability: blue 
colored area is divided by total colored area). NC – without e-SiNWs; WCD – with e-
SiNWs. Error bars represent standard deviation. Scale bars: (A) = 100 µm. 
 
The results from contraction amplitude analysis are further supported by the 
immunohistochemistry (IHC) analysis of cardiac contractile (α-SA : α-sarcomeric actinin) 
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and conductive (Cx-43: Connexin-43) proteins of the spheroids sections (Figure 4.5).  α-
SA was selected as it is a key component of the cardiac sarcomere structure, and 
connexin-43 (i.e., Cx-43) was selected as it forms gap junction channels that regulate 
electrical signal propagation between cardiomyocytes [250, 251].  Notably, the 
specificity of the Cx-43 antibody was confirmed by the staining of hiPSC-CMs in 2D 
culture, where cell-cell borders were more clearly visible than in 3D spheroid cross-
sections (Figure 4.6). Consistent with functional analysis, structural analysis showed 
more organized structure and higher expression of contractile proteins (α-SA) (Figure 4.5 
A-B) and cell-cell gap junction protein (Cx-43) (Figure 4.5 C-D) in the WCD spheroids, 
when compared with the NC spheroids. Notably, hallmarks of structural maturation (i.e., 
Cx-43 and α-SA structures) did not show a strong correlation with nanowires location 
(Figure 4.8). In addition, WCD-3k spheroids showed a highly organized sarcomere 
structure and highest expression level of α-SA and Cx-43 (Figure 4.5 A-D). To 
additionally support the functionality of Cx-43, the co-staining of spheroid cross sections 
with Cx-43 and N-cadherin (N-cad), a membrane junction protein, as shown in the Figure 
S4, in which the co-localization of N-cad and Cx43 indicates the formation of functional 
cellular junctions [275]. These results indicate the WCD-3k spheroids can maximize 
synergistic effects of the appropriate cell number per spheroid and the presence of e-
SiNWs. It is also important to note that all the spheroids after 7 days culture (Figure 4.5 
A) showed significantly improved sarcomere structure, when compared with that of the 
newly form spheroids (Figure 4.2 C). This result shows spheroids provide a supportive 
3D microenvironment for the development of hiPSC-CMs.  
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Figure 4.5. Histological analysis of spheroids. (A-B) Immunofluorescent staining and 
quantification of cardiac-specific contractile proteins (α-SA) for all groups after 7 days 
cell culture. Blue – DAPI; Green – α-SA; NC – without e-SiNWs; WCD – with e-SiNWs. 
(C-D) Immunofluorescent staining and quantification of conductive proteins (Cx-43) for 
all groups after 7 days cell culture. Blue – DAPI; Red – Cx-43. NC – without e-SiNWs; 
WCD – with e-SiNWs. Fluorescent signal area per nuclei on cross section are normalized 
to the NC-1k condition (n=3; 75 μm × 130 μm picture regions, at least containing >50 
nuclei). Error bars represent standard deviation. Scale bars: (A)= 20 µm; (C)= 20 µm. 
Asterisks (*) represent statistical significance between WCD3k and other groups with 
p<0.05 
Changing the number of cells per spheroids (i.e., size of spheroid) can alter the 
oxygen supply throughout the spheroid, which can have direct effects on the metabolic 
activity of the hiPSC-CMs within the spheroids. As an indicator for metabolic activity, a 
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COX IV stain was used to show differences in mitochondrial expression between 
different spheroid size groups (Figure 4.4 and Figure 4.7). IHC analysis showed the 
presence of significantly more COX IV-positive structure in WCD-3k spheroids 
compared to WCD-7k and WCD-1k spheroids (Figure 4.7 A,B). To support the IHC 
analysis, oxygen consumption rate (OCR) measurements have been conducted for the 
WCD spheroids with different sizes. Consistent with the IHC analysis, the hiPSC-CMs in 
WCD-3k spheroids have highest OCR, demonstrating a high level of metabolic activity 
(Figure 4.7 C and Figure 4.10). Notably, the measured OCRs are 0.34, 0.51 and 0.21 
pmol/h/cell for the hiPSC-CMs in the WCD-1k, WCD-3k and WCD-7k spheroids 
respectively, which is similar to the reported OCR for hiPSC-CMs in 2D monolayer 
culture (0.71pmol/h/cell) [276]. While the size of 7k spheroids (i.e., radius: ~200 μm) 
approaches the diffusion limit of oxygen [256], the lower COX IV-stained structure and 
lower contraction amplitude of the WCD-1k spheroids suggests a functional limitation 
due to an insufficient amount of cells per spheroid. 
 
Figure 4.6 Specificity of immunofluorescent staining of Cx-43 and COX IV. (A) Cx-
43 (red) shows specific labeling at the cell junction of α-SA (green) stained 2D 
monolayer hiPSC-CMs. (B) Mitochondria staining of COX IV (green) for 2D monolayer 
hiPSC-CMs on gelatin-coated cover slips. Blue – DAPI. 
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Figure 4.7 Metabolic analysis of nanowired spheroids with different cell numbers per 
spheroid. (A) Confocal images of cross-sections of WCD spheroids with different cell 
numbers per spheroid (Blue – DAPI; Green – COX IV). (B) COX IV positive area per 
nuclei of WCD spheroid sections are normalized to the WCD-1k (n=3; 75 μm × 130 μm 
picture regions, at least containing >50 nuclei). 7k (i.e., 7000), 3k, and 1k indicate 
number of cells per spheroid. WCD – with e-SiNWs. (C) Quantification of oxygen 
consumption rate of WCD spheroids with different cell numbers per spheroid. Asterisks 
(*) represent statistical significance with p<0.05; error bars represent standard deviation. 
Scale bars: (A)=100μm 
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Figure 4.8 Immunofluorescent staining of α-SA/Cx-43 of the WCD-3k spheroid 
sections. Confocal imaging shows locations of α-SA (green) and Cx-43 (red) and e-
SiNWs (yellow) in the WCD-3k spheroid sections. The α-SA and Cx-43 structures are 
not localized to regions close to e-SiNWs. 
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Figure 4.9. Immunofluorescent staining of N-Cad/Cx-43 of the WCD-3k spheroid 
sections. The white circles show the co-localization of Cx-43 (red) and N-Cad (green) 
surrounded in nuclei in the WC-D3k spheroids. Blue – DAPI. 
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Figure 4.10 Metabolic analysis of the WCD spheroids with different cell numbers 
per spheroid. Oxygen consumption rate for WCD-1k, -3k and -7k spheroids were 
measured using Instech Oxygen Consumption Chamber. WCD1k_30: 30 x WCD-1k 
spheroids, WCD1k_60: 60 x WCD-1k spheroids, WCD3k_30: 30 x WCD3k spheroids, 
WCD3k_60: 60 x WCD-3k spheroids, WCD7k_30: 30 x WCD7k spheroids. 
 
The size of the spheroid (i.e., cell number per spheroid) influences both oxygen 
diffusion and 3D cell-cell interactions. As oxygen consumption rates of hiPSC-CMs at 
different oxygen concentrations are not readily available, we used the existing data of the 
oxygen consumption rate of rat neonatal cardiomyocytes to model oxygen concentration 
within spheroids with radii of ~50, ~100, ~150 and ~200 μm [255]. A finite element 
model of oxygen diffusion within the cardiac spheroids was developed based on Fick‟s 
second law. As shown in the Figure 4.11A, the amount of available oxygen is rapidly 
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reduced from the edge of the spheroids to the center of the spheroids, and larger 
spheroids have lower oxygen supply for the cells in the center of the spheroids. On the 
other hand, the volume to surface area ratio increases with cell number, equaling 33.8, 
47.5, and 66.0 for 1k, 3k, and 7k spheroids, respectively (Figure 4.11 B) [277]. This 
indicates an enhanced 3D cell-cell adhesion with the increase of cell number per spheroid. 
The existence of the two competing factors (reduced oxygen supply vs. enhanced 3D cell 
adhesion with the increase of cell number per spheroid) indicates there could be an 
optimal cell number for spheroid fabrication, and our experimental data indicates that 
spheroids contain ~3k cells maximizes the benefits of the 3D environment of nanowired 
spheroids (Figure 4.11 C).  
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Figure 4.11 Functionally optimized range of cell number per spheroid. (A) A 
mathematical model of oxygen percentage using rat neonatal cardiomyocyte data for 
oxygen consumption (ref. 29), showing the range of oxygen concentration throughout 
theoretical spheroids of different sizes. (B) The volume to surface area ratio of different 
sized spheroids represents the amount of 3D cell-cell interaction, as a larger volume to 
surface ratio indicates more cells inside the spheroid with higher chance of multi-
dimensional cell-cell interaction. (C) Data points from oxygen percentage and spheroid 
volume to surface area ratio at the 1k, 3k, and 7k cells per spheroid can be combined to 
summarize our findings on the size with maximized benefits centered around 3k cells per 
spheroid. 
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Using the newly established spheroid size (i.e., 3k cells per spheroid), we 
explored the role of the e-SiNWs in improving function and structural organization of 
hiPSC-CMs in spheroids, we fabricated three groups of human cardiac spheroids: 
spheroids without the addition of nanowires (NC), spheroids with the addition of doped 
silicon  nanowire (WCD), and undoped silicon nanowires (WCN). Compared to the 
conductivity of the doped silicon nanowires (150 - 500 µS/µm), the undoped silicon 
nanowires have a conductivity of 0.001-0.1 µS/µm that is lower than culture medium 
(∼1.75 μS/μm) and myocardium (∼0.1 μS/μm) [191, 248]. This allowed for the 
examination of both the necessity of the electrical conductivity of nanowires and the 
effects of the mere presence of a silicon nanowire structure within the spheroid. 
Contraction amplitude analysis showed that the average fractional area change of WCD-
3k group was significantly higher than that of NC-3k, while the average fractional area 
change of WCN-3k spheroids is significantly lower than that of NC-3k (Figure 4.12 A). 
These results confirmed the beneficial effects of electrically conductive silicon nanowires 
on function of spheroids. This was further supported by calcium transient imaging of 
whole spheroids (Figure 4.12 B-D). The WCD-3k spheroids showed a significantly 
increased overall amplitude of calcium transient levels during contraction and an 
accelerated time to peak of the calcium transient when compared with NC-3k, while 
WCN-3k showed a lower peak amplitude of calcium transient level than that of NC-3k. 
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Figure 4.12. The effects of electrically conductivity of silicon nanowires on the function 
of 3k spheroids. (A) Average fractional area change of NC-3k, WCD-3k and WCN-3k 
spheroids at Day 0, 2, 4, 6 and their averages (n=7). (B) Calcium transient of 7 regions of 
interest per spheroid for each group. Fluorescence amplitude, F/F0, refers to measured 
fluorescence intensity normalized to background fluorescence intensity. (C) Comparison 
of the peak value of F/F0 for each group (n=3). (D) Comparison of calcium release 
duration for each group (n=3). NC – without e-SiNWs; WCD – with doped SiNWs; 
WCN – with undoped SiNWs. Asterisks (*) represent statistical significance with p<0.05; 
error bar represents standard deviation. 
 
Consistent with the functional analysis, structural analysis showed that the WCD-
3k spheroids had higher organization of αSA-stained sarcomere structures as well as an 
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increase in Cx-43-positive stained area (Figure 4.13 and Figure 4.14). Also, the 
ultrastructural analysis conducted by using electron microscopic imaging revealed a 
significantly higher presence of I bands per Z disc, H zones per sarcomere and more 
desmosomes per area in WCD-3k spheroids (Figure 4.15). Notably, the WCD-3k 
spheroids showed a visible organization of mitochondria around sarcomere structures 
similar to that of adult cardiomyocyte phenotype, as shown in Figure 8A-middle [165]. 
This supported our previous report that the presence of electrically conductive silicon 
nanowires in the hiPSC cardiac spheroids promotes cellular maturation of hiPSC-CMs. 
Collectively, these data showed the critical role of the electrical conductivity of the 
silicon nanowires in improving the tissue functions of hiPSC cardiac spheroids. 
 
Figure 4.13 Immunofluorescent analysis of NC, WCD, and WCN-3k spheroids. (A-
B) Quantified expression of α-SA and Cx-43 of NC-3k, WCD-3k and WCN-3k 
spheroids, respectively. Fluorescent signal area per nuclei on cross section are normalized 
to the NC-3k condition (n=3; 75 μm × 130 μm picture regions, at least containing >50 
nuclei). NC – without e-SiNWs; WCD – with doped SiNWs; WCN – with undoped 
SiNWs. Asterisks (*) represent statistical significance with p<0.05; error bar represents 
standard deviation. 
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Figure 4.14 Immunofluorescent staining of NC, WCD, and WCN-3k spheroids. 
Contractile protein (α-SA) and conductive protein (Cx-43) staining were performed after 
7 days cell culture in spheroids without e-SiNWs (NC), with doped e-SiNWs (WCD), 
and undoped SiNWs (WCN). 
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5. Conclusion 
The silicon nanowired hiPSC cardiac spheroids hold remarkable promise as an 
effective cell delivery system to treat heart failure [185, 278, 279]. Using our previously 
established silicon nanowired hiPSC-CM spheroid system, we identified a cell number-
defined size of spheroids that advances the function and organization of hiPSC-CMs. The 
functional analysis of contraction amplitude, IHC analysis of contractile and conductive 
proteins, and metabolic investigation demonstrated that 3k spheroids maximize the 
beneficial effects of the 3D spheroid microenvironment. Additionally, the electrical 
conductivity of silicon nanowires was confirmed to play a critical role in accelerating 
structural and functional development of hiPSC-CMs in spheroids. 
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Figure 4.15 Ultrastructural analysis of NC, WCD, and WCN-3k spheroids. (A) 
Representative TEM images of NC-3k, WCD-3k and WCN-3k spheroids showing 
sarcomere structure (sarcomere, white bar; Z disks, Red arrows; H zones, white arrows; 
M, mitochondria; N, nucleus) and presence of desmosomes (D, desmosomes). Scale bar, 
1 μm. (B) Morphometric analysis (average ± s.d.; n =3-8 per group) showing ratio of I 
bands to Z disk, ratio of H zones to sarcomeres and number of desmosomes per 10
3
 um
2
. 
NC – without e-SiNWs; WCD – with doped e-SiNWs; WCN – with undoped SiNWs. 
Asterisks (*) represent statistical significance with p<0.05. 
 
While hiPSC-CMs hold remarkable promise to treat injured hearts, the current 
hiPSC-CMs retain an immature phenotype, which makes them difficult to integrate with 
adult myocardium and pose an arrhythmic risk. Further, the current utilization of 
dissociated single cells for cell transplantation leads to low cell retention and survival 
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[136]. To collectively address this challenge, we utilized e-SiNWs to facilitate self-
assembly of hiPSC-CMs to form nanowired hiPSC cardiac spheroids. We demonstrated 
the e-SiNWs improved the spheroid functions and cellular maturity of hiPSC-CMs. In 
addition, recent research has shown improved cell retention and survival when using 3D 
cellular spheroids/aggregates. In this study, we identified an optimal cell number-defined 
spheroid size (~3k/spheroid) and confirmed the critical role of electrical conductivity of 
e-SiNWs. As the hiPSC-CMs in the WCD-3k spheroids lack characteristics of adult 
cardiomyocytes (e.g., sarcomere M lines, T tubules) [145], our future research will focus 
on using additional physical/chemical stimuli (e.g., electrical stimulation and/or 
microRNA) to further improve the tissue functions and cellular maturity of the nanowired 
hiPSC cardiac spheroids. In addition, we will explore the addition of vascular cells (e.g., 
endothelial cells) to the nanowired spheroids to prepare pre-vascularized spheroids for 
the improved integration with host vasculature after transplantation. Results from these 
studies will allow for the development of suitable nanowired spheroids to repair damaged 
hearts and advance the field of cell-based cardiac regenerative medicine.  
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CHAPTER FIVE 
NANOWIRED HIPSC CARDIAC SPHEROIDS IMPROVE CELL RETENTION, 
ENGRAFTMENT AND INTEGRATION AFTER TRANSPLANTATION INTO 
ADULT RAT HEARTS 
 
1. Abstract 
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) hold 
remarkable potential as a powerful cell source to repair injured hearts. After significant 
efforts of injecting hiPSC-CMs into animal hearts, it has become clear that current cell 
delivery strategies are limited by low cell retention and low engraftment/integration. To 
address this, we recently pioneered the use of electrically conductive silicon nanowires 
(e-SiNWs) to facilitate the self-assembly of hiPSC-CMs to form nanowired spheroids as 
injectable microtissues to deliver hiPSC-CMs. Our previous data showed that the 
incorporation of e-SiNWs into the spheroids improved cell/tissue level function and 
maturation. Here, we reasoned that the presence of e-SiNWs in the injectable spheroids 
improves their ability to receive exogenous electromechanical pacing from the host 
myocardium to enhance their integration with host tissue post-transplantation. In this 
study, we examined the cardiac biocompatibility of the e-SiNWs and cell retention, 
engraftment and integration after injection of the nanowired hiPSC cardiac spheroids into 
adult rat hearts. Our results showed that the e-SiNWs caused minimal toxicity to rat adult 
hearts after intramyocardial injection. Further, the nanowired spheroids were shown to 
significantly improve cell retention and engraftment, when compared to dissociated 
hiPSC-CMs and unwired spheroids. The 7-days-old nanowired spheroid grafts showed 
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alignment with the host myocardium and development of sarcomere structures. The 28-
days-old nanowired spheroid grafts showed gap junctions, mechanical junctions and 
vascular integration with host myocardium. Together, our results clearly demonstrate the 
remarkable potential of the nanowired spheroids as cell delivery vehicles to treat 
cardiovascular diseases. 
2. Introduction 
Cardiovascular disease is the leading cause of death and disability worldwide 
[260]. Ischemic heart disease (IHD) and myocardial infarction (MI) are major 
contributors to cardiovascular morbidity and mortality and are associated with death of 
cardiomyocytes and permanent loss of heart function [232]. Due to the limited 
regeneration capacity of adult hearts, human induced pluripotent stem cell (hiPSC) has 
emerged as a powerful cell source for cardiac repair due to its proven capacity to produce 
patient-specific functional cardiomyocytes (hiPSC-CMs) [165-169]. In addition, recent 
progress in cardiac differentiation of hiPSCs allows for the derivation of the large number 
of hiPSC-CMs (>10
9
 cells/patient) needed for cardiac repair [124, 170-172]. To realize 
the therapeutic potential of hiPSC-CMs or hESCs-CMs (cardiomyocytes derived from 
human embryonic stem cells), significant efforts have been devoted to transplanting 
hiPSC-CMs or hESCs-CMs into damaged animal hearts to improve their functions [97, 
104, 124, 170, 173-178]. While significant efforts have been used to directly inject 
dissociated hESC-CMs into healthy/injured hearts, this approach is limited by low cell 
retention and survival after cell transplantation. Dissociated hiPSC-CMs are rapidly 
redistributed to other organs (e.g., lung) after injection due to mechanical dispersion of 
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beating hearts [140]. In addition, lack of cell-cell adhesion of single cells leads to cell 
death caused by anoikis and/or ischemia [179]. To improve the efficiency of cell 
delivery, significant efforts have been devoted to the development of tissue-engineered 
epicardial patches [175, 180-182]. In addition to the invasive surgical procedure to 
transplant the patches, recent research has shown the limited electrical integration 
between the transplanted patches and host myocardium, largely attributed to the chronic 
fibrotic response that occurs after transplantation [180-182]. This highlights an urgent 
need to develop an innovative platform to improve the retention, engraftment and 
integration of the injected hiPSC-CMs with adult myocardium.  
hiPSC cardiac spheroids have been proposed as an attractive cell delivery system 
for heart repair, given the recent literature showing spheroid/aggregate delivery improved 
cellular retention and survival after transplantation [183-189]. To this end, we recently 
utilized electrically conductive silicon nanowires (e-SiNWs) to facilitate the self-
assembly of hiPSC-CMs to form nanowired hiPSC cardiac spheroids and improve the 
functions of the microtissues [148, 280]. Here, we reasoned that the presence of the e-
SiNWs in the injectable spheroids improves their ability to receive exogenous 
electromechanical pacing from the host myocardium and enhance their integration with 
host tissues post-transplantation. This was inspired by our recent finding that the addition 
of e-SiNWs in hiPSC-CM spheroids are essential for exogenous electrical 
stimulation/pacing to promote hiPSC-CM development and maturation [190]. Further, 
the recent reports showed the presence of electrical nanomaterials (e.g., gold nanowires) 
in the cardiac tissue engineering constructs synergizes with exogenous electrical pacing 
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to improve the functions of the constructs [147, 191]. Compared to other electrical 
nanomaterials (e.g. gold nanowires, carbon nanotubes), e-SiNWs have distinct 
advantages, including their controllable electrical conductivity, tunable dimensions, and 
convenient surface tailorability [192, 193]. Further, both in vitro and in vivo 
biocompatibility studies have shown no significant cytotoxic effects for either undoped or 
n-type SiNWs [194-196]. Notably, the absence of a pre-aligned structure within the 
nanowired hiPSC cardiac spheroids has raised concerns over their suitability for 
transplantation. The ability of hiPSC-CMs from hiPSC cardiac spheroids to align and 
functionally engraft/integrate with the host tissue after transplantation is an open question 
that needs to be investigated. 
In this study, we injected nanowired hiPSC cardiac spheroids into adult rat hearts 
and examined cell retention, engraftment and integration. In addition, we examined the 
cardiac biocompatibility of e-SiNWs in the adult rat hearts. For the first time, we 
demonstrated that the nanowired spheroids significantly improve hiPSC-CM retention 
and engraftment after intramyocardial injection, when compared to the dissociated single 
hiPSC-CMs and unwired hiPSC cardiac spheroids. 7 days post-injection, the transplanted 
nanowired spheroids showed alignment with the local myocardium and improved the 
development of cellular contractile structures. By 28 days post-injection, the nanowired 
spheroid grafts formed electrical/mechanical/vascular junctions with the host 
myocardium, supporting functional integration with host myocardium.  
3. Materials and methods 
3.1 Cell culture 
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The hiPSC-CMs (Cellular Dynamics International, Madison, USA) were cultured 
according to the manufacturer's protocol. Briefly, hiPSC-CMs were plated on 0.1% 
gelatin coated 6-well plates in plating medium and incubated at 37 °C in 5% CO2 for 4 
days. Two days after plating, plating medium was removed and replaced with 4 mL of 
maintenance medium. After 4 days of monolayer pre-culture, cells were detached using 
trypLE (Life Technologies, Grand Island, NY) and prepared for spheroid fabrication. 
3.2 Fabrication of nanowired hiPSC cardiac spheroids 
The details of the fabrication process can be found in our recent publication (32). 
Briefly, the n-type SiNWs (Diameter ≈ 100 nm; length ≈ 10 µm; Si/P = 500) were 
prepared according to the previously established protocol (32). The length and diameter 
of the e-SiNWs were selected to inhibit cell internalization. The doping ratio was chosen 
to obtain a high conductivity (150 - 500 µS/µm) compared to cell culture medium (~1.75 
µS/µm) and myocardium (~0.1 µS/µm) to create highly electrically conductive 
microenvironments within the spheroids. 
3.3 Video and image analysis of beating spheroids  
Videos of 6 spheroids from each group were recorded using Zen 2011 software 
(Zeiss, Göttingen, Germany) with capture rate of 14 frames per second. Then the videos 
were converted to a series of TIFF format pictures by Adobe Premiere (Adobe, San Jose, 
CA). Threshold edge-detecting in ImageJ software (National Institutes of Health) was 
used on high contrast spheroid pictures and graphed to realize contraction profiles, from 
which the fractional area change was calculated. 
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3.4 Injection of e-SiNWs and nanowired cardiac spheroids into rat hearts  
To evaluate the cardiac biocompatibility of e-SiNWs, young male Sprague–
Dawley rats (8-10 weeks old) were prepared for surgery, anesthetized, given analgesia, 
intubated, and a left thoracotomy was performed to expose the heart. The pericardium 
was opened and 5 million silicon nanowires in 50 µl PBS were injected to the 3 different 
sites in left ventricular region using syringes with a 31-gauge needle. For nanowired 
hiPSC cardiac spheroid injection, athymic young male rats (8-10 weeks old) were 
prepared for surgery, anesthetized, given analgesia, intubated, and left thoracotomy were 
performed to expose the heart. The pericardium was opened and a total of ~30 nanowired 
hiPSC cardiac spheroids per rat (i.e., 30,000 hiPSC-CMs per rat) or 30,000 single hiPSC-
CMs in Matrigel were injected to three different sites (50 µl at each site) in the left 
ventricular region using 29-gauge needles. After injection, the thoracotomy incision was 
sutured and the animal was allowed to recover for 1 day, 7 days and 28 days before heart 
harvest for histological analysis. The influences of the injected e-SiNWs and cellular 
therapies on the rat cardiac function were examined on day -1, 1, 7 and 28 post-injection 
by using electrocardiogram and echocardiogram as described below. All the surgical 
procedures and pre-/post-operative care were performed following NIH guidelines for the 
care and use of laboratory animal (NIH publication No. 86-23, revised 1996), and they 
were under the supervision of the Institutional Animal Care and Use Committee 
(IACUC) of the Medical University of South Carolina (MUSC). 
3.5 Cardiac function measurement 
To examine rat echocardiography, the Vevo2100 imaging system (VisualSonics, 
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Toronto, Canada) was used with 22–55 MHz linear transducer probe (MS400 or MS250) 
for 2-D B-mode and M-mode analysis. During the measurement, heart rate was 
maintained at 300–400 bpm via isoflurane anesthesia. Left ventricular (LV) volume was 
calculated from Simpson‟s method of disks, the ejection fraction (EF) was determined 
from the equation: EF= (LV end diastolic volume – LV end systolic volume)/ (LV end 
diastolic volume) and the fractional shortening was calculated by the equation: FS = (LV 
end diastolic dimension - LV end systolic dimension)/ LV end diastolic dimension. 
Offline image analyses were performed using the dedicated VisualSonics Vevo2100 1.2.0 
software. Electrocardiogram (ECG) and rectal temperature (RT) were recorded by 
MouseMonitor S (Indus Instruments, Webster, TX). Briefly, the rats were anesthetized 
using 3% isoflurane and placed on the heated pad (37°C). The ECG (leads I, II, and III) 
and RT were obtained from four needle electrodes subcutaneously inserted into the four 
paws and one temperature probe placed in rectal location while the rat was in supine 
position. 
3.6 Histological analysis for in vitro cultured nanowired cardiac spheroids 
 The freshly collected spheroids (~30-35) were flash frozen in Tissue-Tek OCT 
compound (Sakura, Torrance, CA) and cryo-sectioned into 7μm thickness layers onto 
glass slides for immunohistochemistry. The frozen sections were fixed with pre-cooled 
acetone (-20 °C) for 10 min. The fixative was poured off and the acetone was allowed to 
evaporate from the sections for 20 min at room temperature. After washing (3 times at 5 
min) in PBS with 0.1% Triton X-100 (PBST), 100 μl blocking buffer (10% goat serum 
(Sigma) in PBST) was added onto the sections of the slides and incubated in a humidified 
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chamber at room temperature for 1 h. The sections were incubated with appropriately 
diluted primary antibody overnight at 4 °C. After washing in PBST (3 times at 5 min), 
tissues were incubated with coordinate secondary antibodies diluted in PBST for 1h at 
ambient temperature. After washing in PBST (3 times at 5 min), nuclei were 
counterstained with DAPI (Molecular Probes/Invitrogen, Eugene, OR) diluted in PBST 
for 15 min at ambient temperature. Following the final wash procedure (PBST, 3 times at 
5 min), glass cover slips were added to the slides using Fluoro-Gel (Electron Microscopy 
Sciences, Hatfield, PA). Finally, TCS SP5 AOBS laser scanning confocal microscope 
(Leica Microsystems, Inc., Exton, PA) was used to get fluorescent images. The detailed 
information of the antibodies used in this study was listed in the Table 5.1.  
Antigen Antibody type Company Catalog number Dilution 
Vimentin Rabbit polyclonal Abcam ab92547 1:200 
CD68 Mouse monoclonal AbD Serotec MCA341GA 1:200 
pan Troponin I Rabbit polyclonal santa cruz SC-15368 1:200 
connexin 43 Rabbit polyclonal sigma C6129 1:200 
alpha sacomeric actin Rabbit polyclonal abcam ab9465 1:200 
alpha sacomeric actin Mouse monoclonal Gene Tech GTX29465 1:200 
N cadherin Mouse monoclonal BD 610921 1:200 
Laminin Mouse monoclonal Sigma L9393 1:200 
Collagen I Rabbit polyclonal abcam ab34710 1:200 
Human Nuclear Mouse monoclonal abcam ab191181 1:200 
Isolectin B4 Alexa488 Conjugate   life Tech I21411 1:50 
DAPI   life Tech R37606 1:10 
Live/dead staining kit   life Tech L3224 EthD-1 (1:500) / calcein (1:2000) 
TUNEL staining kit   Roche 11684795910 enzyme solution: label solution=1:9  
Table 5.1: The details (vendor source, catalogue number and dilution ratio) of the 
antibodies used in this study. 
 
3.7 Histological analysis for the harvested cardiac tissues 
The fresh rat hearts were fixed overnight in 4% paraformaldehyde solution and 
embedded in a paraffin block. Using an automated microtome (LeicaRM2255, Leica, 
Exton, PA), paraffin embedded hearts were sectioned into 8 μm thickness ribbon with 
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~1000 sections per heart in total. Three sections were picked up with every 25 sections 
gap for mounting on the glass slide and 40 slides (~120 total sections per heart) were 
processed and stained for each rat heart in order to avoid missing the human spheroids in 
rat myocardium for staining. Paraffin-embedded hearts were sectioned (8 μm) dewaxed 
and processed with antigen retrieval solution (Vector Laboratories, Burlingame, CA) in 
pressure cooker for 10 min before staining. Sections were incubated with appropriately 
diluted primary antibody overnight at 4 °C. After washing in PBST (3 times at 5 min), 
tissues were incubated with coordinate secondary antibodies diluted in PBST for 1h at 
ambient temperature. After washing in PBST (3 times at 5 min), nuclei were 
counterstained with DAPI (Molecular Probes/Invitrogen, Eugene, OR) diluted in PBST 
for 15 min at ambient temperature. Following the final wash procedure (PBST, 3 times at 
5 min), glass cover slips were added to the slides using Fluoro-Gel (Electron Microscopy 
Sciences, Hatfield, PA). Finally, TCS SP5 AOBS laser scanning confocal microscope 
(Leica Microsystems, Inc., Exton, PA) was used to get fluorescent images. The average 
grafts per heart for spheroid transplantation was calculated as the number of slides per 
heart (out of ~30-40 total slides per heart) with visible grafts (N=5 rats, total of ~150 
observed slides per treatment). The detailed information of the antibodies used in this 
study was listed in the Table 5.1. 
3.8 TUNEL staining  
In Situ Cell Death Detection Kit (Roche, Penzberg, Germany) was used to 
determine the viability of the cells in the paraffin section of rat hearts and frozen sections 
of spheroids. Briefly, the paraffin sections of spheroids were dewaxed and processed with 
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antigen retrieval solution (Vector Laboratories, Burlingame, CA) in pressure cooker for 
10 min , then washed in PBS for 30 minutes.  For frozen section spheroids, sections were 
fixed in 4% paraformaldehyde solution for 10 min, then washed in PBS for 30 min. After 
PBS washes, sections were incubated in permeabilisation solution (0.1% Triton X-100 
and 0.1% sodium citrate in PBS) for 2 minutes on ice. Then 50 µl TUNEL reaction 
mixture samples was added and incubated in 37 °C for 1 hour. After washing in PBST (3 
times at 5 min), nuclei was counterstained with DAPI (Molecular Probes/Invitrogen, 
Eugene, OR) for 15 min at ambient temperature. Following the final wash procedure 
(PBS, 3 times at 5 min), glass cover slips were added to the slides using Fluoro-Gel 
(Electron Microscopy Sciences, Hatfield, PA). 
3.9 Transmission Electron Microscopy 
e-SiNWs were gently sonicated in isopropyl alcohol (IPA) and dispersed onto 
lacey carbon grids (Ted Pella Inc.). TEM imaging was conducted using a 300kv FEI 
Tecnai G2 F30 Super Twin Transmission Electron Microscope (Fig. 5.1). 
4. Results 
4.1 Cardiac compatibility of e-SiNWs 
Our previous in vitro research showed the minimal cytotoxicity of e-SiNWs (n-
type SiNWs: Diameter ≈ 100 nm; length ≈ 10 m; Silane/Phosphane = 500, Figure 5.1) 
when co-cultured with hiPSC-CMs [148, 190]. To use e-SiNW nanowired hiPSC cardiac 
spheroids for heart repair, in vivo cardiac biocompatibility of e-SiNWs must be 
established. In addition to cellular compatibility, functional compatibility in the heart 
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must be considered due to the possible electrical interference of the conductive e-SiNWs 
with the innate cardiac electrical signal conduction system. To examine these concerns, 5 
million e-SiNWs were injected into the healthy adult rat myocardium. The cardiac 
function of the rats injected with e-SiNWs and PBS (control) was examined using 
electrocardiogram (ECG) and echocardiography on day -1, 1, 7 and 28 post-injection 
(Fig. 5.2A-D). As shown in the Figure 2A, ECG results revealed no detectable 
arrhythmia of the rat hearts after e-SiNW injection. This indicates the injected e-SiNWs 
do not significantly affect the electrical conduction system of adult rat myocardium. In 
addition, left ventricle ejection fraction (EF) (~70%) and fractional shortening (FS) 
(~35%) of the rat hearts did not show significant differences between before and after e-
SiNW injection (Figure 5.2B-D). In addition, the left ventricle EF and FS of the e-SiNW 
injected rats were found to be very similar to that of the PBS injected control rats. These 
data strongly indicated the e-SiNWs do not alter the cardiac function after a high dose 
injection into adult rat myocardium.  
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Figure 5.1: Transmission electron micrograph of an e-SiNW. TEM image of a typical n-
type e-SiNW used in this study on a carbon grid. 
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Figure 5.2: Cardiac functional compatibility analysis after e-SiNWs injection into adult 
rat myocardium. (A) Representative ECG profiles of rats with 5 million e-SiNWs 
injection in the left ventricular myocardium at time points of before injection (D-1) and 
after injection (D1, D7 and D28). (B) Representative echocardiogram images in short 
axis of rat hearts with 5 million e-SiNWs injection in the left ventricular myocardium at 
time points of D-1 and D28. (C) Ejection fraction and (D) fractional shortening were used 
for quantitative analysis of cardiac function after e-SiNWs and PBS injection. Error bars 
represent standard deviation (N=4).  
 
In addition to evaluating the cardiac function, the blood samples of the rats 
injected with e-SiNWs and the control rats were collected on day -1, 1, 7, 14 and 28 post-
injection. As shown in Figure 5.3 and Table 5.2, the total white blood cell counts from 
the e-SiNW injected rats are in the normal physiological range without statistically 
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differences between the rats with the e-SiNW injections and the control rats. This showed 
that the intramyocardial injection of e-SiNWs did not significantly affect the 
hematological characteristics of the rats. Supported by a normal growth curve, heart beat 
rate and body temperature (Figure 5.4-5.5), our data indicated the intramyocardial 
injection of e-SiNWs resulted in a minimal global inflammatory response.  
Total White Blood Cells (k/ul)_ Normal range: 2.9~20.9 
Group 
Pre-surgery Post surgery 
Day -1 Day 1 Day 7 Day 14 Day 28 
5m e-SiNWs 
(n=5) 
15.80 16.82 16.06 15.76 14.60 
23.48 13.38 19.88 17.84 11.74 
7.76 12.98 18.66 12.18 11.36 
8.86 11.76 18.52 19.76 19.74 
16.10 11.90 19.74 13.96 13.32 
PBS  
(n=3) 
13.04 12.14 17.22 20.32 19.66 
16.46 17.24 12.32 22.78 19.20 
17.86 19.86 12.86 18.46 17.58 
 
Table 5.2: Total white blood cells counts for nanowires biocompatibility test. 
Hematology profiles of rats blood samples with 5 million e-SiNWs or PBS (control) 
intramyocardial injection at time points of before injection (D-1) and after injection (D1, 
D7 and D28) indicate minimal inflammation response post surgery. n=5 rats for e-SiNWs 
injection group and n=3 rat for PBS injection group. 
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Figure 5.3: Representative blood test result. The hematology profile of rat blood sample 
collected from tail vein was performed by Drew Scientific HemaVet 950FS Auto Blood 
Analyzer. The red boxed value is used to construct Table 1. 
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Figure 5.4: The rats followed a normal weight curve after e-SiNW injection. The rats 
with 5 million e-SiNWs or PBS (control) intramyocardial injection were weighed at time 
points of before injection (D-1) and after injection (D1, D7 and D28) to monitor the body 
growth. Error bars represent standard deviation. n=5 rats for e-SiNWs injection group and 
n=3 rat for PBS injection group. 
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Figure 5.5: The rats followed a normal physiological condition after receiving NWs 
injection. Heart beat rate and rectal temperature were recorded for the rats with 5 million 
e-SiNWs or PBS (control) intramyocardial injection at time points of before injection (D-
1) and after injection (D1, D7 and D28) to monitor the physiological condition. Error bars 
represent standard deviation. n=5 rats for e-SiNWs injection group and n=3 rat for PBS 
injection group. 
 
Histological analysis was conducted to examine e-SiNW retention and 
degradation, as well as the effects of the injected e-SiNWs on myocardium inflammation 
and fibrosis. As shown in the Figure 5.7 A-B, a significant decrease in the amount of e-
SiNWs was found in myocardium 7 days post-injection when compared to 1 day post-
injection. After 28 days, few e-SiNWs were found in the injected myocardium, which 
was attributed to biodegradation and redistribution [195, 246]. In addition, H&E staining 
showed a minor inflammation 7 days post-injection in the myocardium and no sign of 
inflammation 28 days post-injection. Naphthol AS-D chloroacetate esterase staining 
(Figure 5.7 C) and CD68 staining (Figure 5.7 D) showed neutrophil and macrophage 
infiltration in the myocardium 1 day post-injection, and the infiltrated 
neutrophils/macrophages decreased by day 7 and disappeared on the day 28 post-
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injection. Notably, CD68-positive macrophages at day 7 also showed colocalization with 
e-SiNWs, which supports the reported phagocytosis mechanism of internalization and 
biodegradation of the e-SiNWs (Figure 5.6) [196, 246]. These results clearly showed the 
injected e-SiNWs did not induce chronic inflammation or chronic foreign body response 
in the myocardium. In addition to inflammation, fibrosis after e-SiNW injection in the 
myocardium was examined. Vimentin staining (Figure 5.7 E) showed a minor fibroblast 
infiltration 7 days post-injection that disappeared by day 28 after e-SINW injection, 
which indicated the injected e-SiNWs did not induce a chronic fibrotic response. 
Collectively, our results showed the e-SiNW showed minimal toxicity to the adult 
myocardium after intramyocardial injection and lays down the foundation for the use of 
nanowired spheroids for heart repair.     
A B e-SiNWs 
CD68 
DAPI 
DAPI e-SiNW (scattered light) 
CD68 Merge  
Figure 5.6: Injected nanowires colocalize with macrophages at D7 post-transplantation. 
(A) Colocalization of e-SiNWs with CD68-positive (green) macrophages supports 
reported phagocytosis mechanism of internalization and degradation. (B) Large 
nanowires (arrow) were often found outside the macrophages in line with size-limited 
internalization. Scale bars= 10 µm. 
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Figure 5.7: Histological analysis after e-SiNW injection into adult rat myocardium. (A) 
H&E staining shows location and density of e-SiNWs that decrease and disappear over 
28 days after injection. (B) Confocal images of light scattering signal of e-SiNWs show 
similar results with H&E staining. (C) Neutrophils infiltration identified by naphthol AS-
D chloroacetate staining (dark brown) shows short-term increase in inflammatory 
response that diminished by day 28. (D) Macrophages infiltration identified by CD68 
staining shows short-term increase in inflammatory response that diminished by day 28.  
(E) Non-cardiomyocytes identified by vimentin staining in adult rat heart for 5 million e-
SiNWs injection at day 1, day 7 and day 28 to indicate fibroblast infiltration. Vimentin-
positive cells disappear by day 28 indicating no chronic fibrotic response. Scale bars: (A-
E)= 200 µm 
 
4.2 Fabrication and characterization of nanowired hiPSC cardiac spheroids 
for transplantation 
To prepare spheroids suitable for injection, we fabricated nanowired hiPSC 
cardiac spheroids containing ~1,000 cells/spheroid using our previosuly established 
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method (Figure 5.8 A-B) [148]. After 7 days of spheroid formation, the diameter of the 
nanowired spheroids decreased to ~180 µm, an injectable size (i.e., less than inner 
diameter of 29 gauge needle) for rat myocardium (Figure 5.8 C). Further extended culture 
did not significantly reduce the size of the spheroids. Consistent with the changes in 
spheroid size, the amplitude of the spontaneous contraction of the nanowired spheroids 
gradually decreased over the time and stabilized after 7-9 days spheroid culture (Figure 8 
D). The reduced size and contraction amplitude of the nanowired spheroids indicates the 
formation and stabilization/maturation of the human cardiac microtissues.  
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Figure 5.8: Fabrication and characterization of nanowired hiPSC cardiac spheroids for 
transplantation. (A) Bright field image images of nanowired hiPSC cardiac spheroids 
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after 7 days spheroid culture. (B) Transmission electron micrograph of nanowired 
spheroid section shows nanowire locates in extracellular space. Asterisk - nanowire 
location. (C) Diameter and (D) fractional area change of nanowired hiPSC cardiac 
spheroids from spheroid culture D0-D14. Error bars represent standard deviation (N=6). 
(E-I) Frozen sections of D0 and D7 spheroids characterize microtissue development 
according to cell junctions proteins (E: Cx-43; F: N-cadherin), ECM protein (G: laminin) 
and contractile proteins (H: alpha sacomeric actinin; I: troponin I). Scale bars: (A) =200 
µm, (B) =500 nm, (E-I) =100 µm. 
 
To validate the cardiac tissue formation and maturation, frozen sections of day 0 
and day 7 spheroids were immunofluorescently stained to examine the formation of 
cellular junctions, extracellular matrix (ECM) protein production and contractile protein 
development. Consistent with our previous work, day 7 spheroids showed significant 
increase of cellular junction formation, including electrically conductive channel 
proteins, Connexin-43 (Cx-43) (Figure 5.8 E), and mechanical junction proteins, N-
cadherin (N-cad), when compared to day 0 spheroids (Figure 5.8 F) [148]. In addition to 
cell-cell junctions, the cell-matrix interactions can facilitate cardiac tissue formation and 
development. Figure 5.8 F showed the abundant presence of basement membrane protein 
(laminin) in the nanowired spheroids (Figure 5.8 G). The formation and maturation of 
nanowired spheroids was also supported by significant development in the contractile 
protein such as alpha sarcomere actinin (Figure 5.8 H) and troponin I (Figure 5.8 I) in day 
7 spheroids, when compared to day 0 spheroids. In addition, we observed that day 7 
spheroids are mechanically stable for technical manipulations and intramyocardial 
injection protocols. Compared to dissociated hiPSC-CMs in Matrigel, the nanowired 
spheroids showed no significant difference in cell apoptosis (i.e., TUNEL) after a 29-
gauge needle extrusion into a petri dish (Figure 5.9). Together, these results clearly 
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showed the nanowired spheroids provided a supportive microenvironment to form 
injectable 3D hiPSC cardiac microtissues for transplantation.  
 
Figure 5.9: Viability of hiPSC-CMs in Matrigel and spheroids before and after needle 
extrusion. (A) Confocal images of Live/Dead staining of single hiPSC-CMs in Matrigel 
before and after extrusion through a 29 gauge syringe needle. Green- live cells; red- dead 
cells. (B) Quantification of the cell viability based on the Live/Dead staining. n=3. (C) 
Confocal images of TUNEL staining of spheroid sections before and after extrusion 
through a 29 gauge syringe needle. Green- apoptosis cells; blue- DAPI. (D) 
Quantification of the cell viability based on the TUNEL. n=3. Scale bars: (A, C)=50 µm. 
Asterisks (*) represent statistical significance with p<0.05; error bars represent standard 
deviation. 
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4.3 Nanowired hiPSC cardiac spheroid transplantation improve cell 
retention, engraftment and integration 
To examine the capacity of the nanowired hiPSC cardiac spheroids to improve 
cell retention and engraftment, we injected nanowired hiPSC cardiac spheroids into 
healthy Athymic rat hearts. Healthy rats were selected due to their effectiveness to study 
hiPSC-CM engraftment and integration without the confounding factors presented in the 
injured animal models (e.g., variation among different injured animals) [182]. In this 
study, we injected a small number of nanowired hiPSC cardiac spheroids into each 
animal (~30 spheroids/rat; ~30k hiPSC-CMs/rat) to examine individual hiPSC cardiac 
spheroids‟ integration with the host myocardium. In addition, we conducted ECG and 
echocardiography measurement for the rat hearts before and after the injection of the 
nanowired spheroids to examine the effects of the injected nanowired spheroids. As 
shown in Figure 10 A-C, the injection of the nanowired spheroids did not interfere with 
the electrical conduction system as well as the normal function of the rat hearts.  
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Figure 5.10: Nanowired spheroids transplantation improves cell retention and 
engraftment in adult rat myocardium. (A) Representative ECG profiles of rats with 
nanowired cardiac spheroids injection in the left ventricular myocardium at time points of 
before injection (D-1) and after injection (D1, D7 and D28) indicate healthy cardiac 
electrical signal propagation with no arrhythmias. (B) Ejection fraction and (C) fractional 
shortening as quantitative analysis for cardiac function for spheroids injection do not 
show deleterious effects of nanowired spheroid injection. Error bars represent standard 
deviation (N=4). (D) H&E staining of single cell injection sites (identified by Matrigel 
dense area – asterisk) and nanowired spheroids (WC1k) on D1 post transplantation. 
Dotted line encircles spheroid intramyocardial location. (E) Immunofluorescent staining 
of Matrigel dense regions of single cell and nanowired spheroids transplantation in 
myocardium on D1 indicate presence of troponin I (red) contractile protein in spheroid 
groups and minimal presence with HNA-positive cells (arrow) for single cell injection. 
Green-human nucleolar antigen (HNA); red-troponin I (TnI); blue-DAPI. (F) TUNEL 
staining (green) with high magnification inset of single cell injection sites (marked by 
Matrigel – asterisk) and nanowired spheroids on D1 post transplantation show a 
significantly reduced number of apoptotic cells in nanowired spheroid transplantation. 
Dotted line encircles spheroid intramyocardial location. Yellow-light scattered signal of 
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e-SiNWs, blue – DAPI nuclear stain. Scale bars: (D) top=50 µm, bottom= 100 µm; (E)= 
50 µm; (F)= 50 µm.   
 
The hearts were harvested on 1 day post-transplantation for histological analysis 
to examine spheroid retention and survival. Intramyocardial injections of dissociated 
hiPSC-CMs in Matrigel were used as a control [104]. As shown in Figure 5.10 D-E, the 
nanowired spheroids, identified by human nucleolar antigen (HNA) staining, did not 
dissociate upon injection and maintained their spherical shaped microtissue configuration 
after transplantation into beating hearts, which gave rise to excellent cell retention. In 
contrast, very few HNA-positive hiPSC-CMs were found in the myocardium, when 
single hiPSC-CMs were injected with Matrigel (Figure 5.10 D-E; Figure 5.11). In 
addition, all of these HNA-positive cells showed negative TnI staining. Further, an 
increase in TUNEL positive cells was found at the dissociated hiPSC-CM injection sites 
located by Matrigel dense regions, while few TUNEL positive cells were found within 
and around the transplanted spheroids (Figure 5.10 F). Scarcity of viable hiPSC-CMs 
after injection of dissociated hiPSC-CMs is consistent with the literature and was 
attributed to injection-induced and/or anoikis-mediated cell death pathways [173]. The 
improved cell retention and survival of the nanowired spheroid injection was attributed to 
the enhanced 3D cell-cell adhesion and stable microtissue configuration to better resist 
redistribution caused by the mechanical stress of the beating heart. 
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Figure 5.11: Limited cell retention using single hiPSC-CMs injection with Matrigel. 
Immunofluorescent staining of single cell injection on D1 post-transplantation in 
myocardium indicate presence of a small amount of human nucleolar antigen-positive 
cells that lack troponin I (red) contractile protein expression. Green-human nucleolar 
antigen (HNA); red-myocardium marker (troponin I); blue-DAPI. Scale bar = 50 µm 
 
By 7 days post-transplantation, the injected nanowired spheroids showed 
excellent cellular engraftment (Figure 5.12). Compared with day 1 grafts, the day 7 grafts 
showed strong evidence of alignment with the host myocardium (Figure 5.12 A-B) and 
development of sarcomere structures (Figure 5.12A, C). The graft alignment with the 
host myocardium indicated that the grafts adapted to the local electrical/mechanical 
stimuli after transplantation. Alignment also serves as a structural foundation for the 
mechanical graft-host integration, supported by the improved expression and organization 
of contractile proteins in day 7 grafts. Together with no detection of arrhythmia (Figure 
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5.10 A), these results suggest the possibility of contractile integration of the transplanted 
spheroids with host myocardium.  
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Figure 5.12: Nanowired spheroid transplantation improves the cell alignment and 
structural maturation. (A) Confocal images of the engraftment in rat myocardium on D7 
for nanowired spheroids (WC1k) transplantation. Insets (right) reveal improved 
contractile development in nanowired spheroid grafts. Green-human nucleolar antigen 
(HNA); red-troponin I (TnI); yellow-e-SiNWs; blue-DAPI. (B) WC1k graft sections 
displayed aligned single cells from nanowired spheroids with host myocardium. Green-
HNA; red-TnI; blue-DAPI. (C) WC1k spheroid grafts stained with alpha sarcomeric 
actinin (αSA) staining reveal sarcomere development by D7. (D) Average grafts per heart 
for unwired spheroids (NC1k) and nanowired spheroids (WC1k) transplantation 
calculated as number of slides per heart (observed using 30-40 total slides per heart) with 
visible grafts (N=5 rats, total of ~150 observed slides). (E) Average size of grafts in heart 
for NC1k and WC1k spheroids transplantation reveal increased graft size in WC1k 
treatment. (N=5 rats). Confocal imaging showed that NC1k grafts with poorly developed 
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contractile structure identified by TnI (F) and αSA (G) staining. Green-HNA; blue-DAPI. 
Scale bars: (A-C)= 50 µm; (F-G) = 50 µm. Asterisks (*) represent statistical significance 
with p<0.05; error bars represent standard deviation. 
 
Notably, significantly less (Figure 5.12 D) and smaller (Figure 5.12 E) grafts have 
been found after the transplantation of unwired spheroids. Compared to the nanowired 
spheroids, the transplantation of the unwired spheroids led to the less developed 
contractile proteins (Figure 5.12F-G). In some cases, no detectable expression of 
contractile proteins was found for the unwired spheroid grafts (Figure 5.13). This 
difference strongly suggests the e-SiNWs in the spheroids can facilitate the 
electromechanical integration with the host myocardium. It is worth to note that we can 
reliably detect hiPSC-CM grafts with the nanowired spheroid injection of ~30k hiPSC-
CMs/rat, whereas the literature uses ~5 million dissociated hESC-CMs/rat to detect 
hESC-CM engraftment in healthy myocardium [173]. This highlights the remarkable 
potential of using nanowired hiPSC cardiac spheroids as a cell delivery system for heart 
repair. 
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Figure 5.13: The unwired spheroids lose the cardiac phenotype identified by negative 
staining for troponin I by D7 post-transplantation. Confocal imaging showed that some 
NC1k grafts show no troponin I contractile protein staining. Green-human nucleolar 
antigen (HNA); red-troponin I; blue-DAPI. Scale bars: 50 µm. 
 
By 28 days post-transplantation, nanowired hiPSC cardiac spheroids showed 
strong evidence of functional integration with host myocardium. As shown in Figure 5.14 
A-C, nanowired spheroids have shifted from the original spherical shape on day 1 post-
injection to a cardiac muscle bundle-like structure on day 28 post-injection. This 
indicates that the spherical configuration of nanowired hiPSC spheroid microtissues does 
not prevent alignment with the host myocardium after transplantation and suggests 
functional integration. This was further supported by histological analysis showing the 
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formation of electrical cellular junctions, Cx-43 (Figure 5.14 D), and mechanical cellular 
junctions, N-cad (Figure 5.14 E), between the transplanted spheroids and host 
myocardium. In addition, Isolectin B4 staining revealed capillary-like lumen structures 
that contained blood cells within the day 28 spheroids grafts (Figure 5.14 F). As the 
transplanted spheroids do not contain endothelial cells, this demonstrated the infiltration 
of the host vasculature into the transplanted spheroid grafts. Together, these results 
provided strong evidence that the electromechanical stimuli of host myocardium can 
effectively condition transplanted nanowired spheroids and facilitate electrical, 
mechanical, and vascular integration of the injected nanowired spheroids with the host 
myocardium by 28 days after transplantation.    
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Figure 5.14: Nanowired spheroid transplantation improves functional integration with rat 
host myocardium. (A-C) Confocal images of nanowired spheroid grafts in rat 
myocardium at D1, D7 and D28 post-transplantation display adaptation and alignment of 
spherical microtissue over time. Green-human nucleolar antigen (HNA); red-troponin I 
(TnI); blue-DAPI. (D-F) Nanowired spheroid grafts integrate with host myocardium. The 
D28 post transplantation sample shows the presence of connexin-43 (Cx-43) staining (D) 
for graft-host gap junctions formation and N-cadherin staining (E) for mechanical 
integration between graft and host myocardium. Isolectin B4 (IB4) staining (F) shows 
capillary-like structures (arrow) with blood cells within the nanowired spheroid graft. 
Blood cells are identified by unspecific staining with TnI and IB4 (orange). Scale bars: 
(A-C)= 100 µm; (D-F) =100 µm, inset = 25µm. 
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As recent research has shown that chronic fibrosis can prevent electrical 
integration between the transplanted hiPSC-CMs epicardial patches and the host 
myocardium [182], we examined the fibrosis around the transplanted nanowired 
spheroids. As shown in the Figure 5.15, we observed minimal fibrosis on day 1, high 
fibrosis on day 7 and decreased fibrosis on day 28 post-injection. We reasoned that the 
reduced fibrosis around the day 28 grafts allowed for the formation of electrical and 
contractile integration of the grafts with host myocardium shown in the Figure 7. 
Notably, few e-SiNWs were found in the nanowired spheroid graft 28 days post-
injection, which is consistent with the results from the e-SiNW intramyocardial injection 
experiments (Figure 5.7 A-B).  The e-SiNWs in the day 28 grafts (Figure 5.14 D inset) 
are significantly smaller than the e-SiNWs in the day 1 graft (Figure 10 F inset), which 
has been attributed to the biodegradation of e-SiNWs [246].  
 
Figure 5.15: The fibrosis decreases on day 28 post nanowired spheroids transplantation. 
Collagen I staining (red) of human engraftment in rat myocardium with nanowired 
spheroids transplantation on D1, D7 and D28 post-transplantation indicated typical short 
term increase in fibrotic response that decreases by D28 for improved integration. Scale 
bars: 100 μm. 
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5. Discussion 
In this study, we examined the cardiac biocompatibility of the e-SiNWs and cell 
retention, engraftment and integration after the injection of the nanowired hiPSC cardiac 
spheroids into adult rat hearts. The absence of major cell death or chronic 
inflammation/fibrosis from the e-SiNW intramyocardial injection indicated their high 
cardiac biocompatibility and is consistent with recent work by Zimmerman and 
coworkers demonstrating the biological interactions with SiNWs [196]. The observed 
cardiac functional biocompatibility of e-SiNWs seen by healthy ECG and 
echocardiogram characteristics was in line with previous studies using conductive 
nanomaterials in the heart [146]. The high cardiac compatibility of e-SiNWs supports the 
in vivo use of nanowired hiPSC cardiac spheroids for transplantation.  
To this end, nanowired spheroids were then injected into rat hearts that led to the 
enhanced electrical/mechanical/vascular integration with the host tissue in contrast with 
single hiPSC-CM and unwired spheroid injections. We reasoned that the improvements 
seen in the nanowired spheroids treatment are partially due to the enhanced microtissue 
formation and maturation prior to transplantation [148]. Microtissue formation and 
maturation over 7 days in an in vitro spheroid culture allows for the development of cell-
cell and cell-matrix interactions, which improved the cellular delivery, retention, and 
engraftment of spheroid injection. Although Matrigel provides a matrix/growth factor 
enriched microenvironment for dissociated hiPSC-CMs to reduce anoikis-related 
apoptosis and shear force-induced cell death from intramyocardial injection, our study 
has shown that the nanowired spheroids can better support cell viability and significantly 
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reduce the risk of these common cellular injection challenges [181]. Notably, even with 
the formation and maturation of spherical cardiac microtissues prior to transplantation, 
the nanowired spheroids did not inhibit adaptation and alignment with the host 
myocardium after transplantation. This directly addresses concerns over the suitability of 
the nanowired hiPSC spheroids based on the pre-alignment criteria. 
In addition to alignment, nanowired spheroids showed significantly improved 
cellular integration and contractile development than single cell hiPSC-CM injections and 
unwired cardiac spheroid injections. The high electrical conductivity of e-SiNWs (150 - 
500 µS/µm) in cardiac spheroids may lead to an enhanced ability to receive exogenous 
electromechanical pacing signals to initiate simultaneous contraction with the host 
myocardium. This was supported by the banded sarcomeric structures in the nanowired 
spheroid grafts. In comparison, the unwired spheroid grafts showed significantly less 
sarcomere development. Further, our recent report showed that e-SiNWs are essential for 
the use of electrical stimulation to promote contractile development of hiPSC cardiac 
spheroids [190]. In addition, previous studies have shown that the addition of electrically 
conductive gold nanowires to electrically insulating alginate hydrogels improves the 
range of the electrical propagation under exogenous electrical stimulation [147]. This 
may indicate that the presence of electrically conductive nanowires in the spheroids may 
enhance graft-host electrical coupling for improved contractile mechanics throughout 
integration. In addition, our results showed the e-SiNWs in the nanowired spheroids 
degrades over 28 days after transplantation. As non-biodegradable electrical 
nanomaterials (e.g., carbon tubes) can permanently stay in the myocardium after 
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transplantation and pose arrhythmogenic risk by interfering with the innate electrical 
conduction system [146], the biodegradability of e-SiNWs makes them an ideal 
nanoscaffolding material to promote hiPSC-CMs engraftment and integration with host 
myocardium.   
The previous studies have clearly showed that there are diverse sets of challenges 
facing cardiac cell therapy. Most notably, cell therapy approaches using hiPSC-CMs have 
consistently resulted in insufficient cell retention to effectively remuscularize injured 
heart models. However, the reason for low cell retention is confounded by numerous 
factors, such as anoikis-mediated cell death, inflammation, ischemic microenvironment 
and variation among different injured animals. In this study, we aimed to improve the 
fundamental understanding of improving hiPSC-CM cellular retention and integration. 
To minimize the additional injury-induced variables and to effectively evaluate our 
hypothesis on the cell retention and integration of nanowired spheroids, we used a 
healthy rat heart model with a stringent cell injection condition (~30k cells/rat). The 
healthy rat model provides an ideal model to compare treatment-induced differences in 
cell retention and integration. Our data showed the use of injectable microtissues improve 
cell retention, consistent with the previous studies. Further, our data showed the 
nanowired spheroids improvements in graft-host integration after transplantation over 
unwired spheroids or single cell injections due to the presence of e-SiNWs in the 
nanowired spheroids. Notably, injectable nanowired spheroids provide a minimally 
invasive approach to deliver tissue constructs and induce mild fibrosis as opposed to 
surgically transplanted epicardial patches [175, 182]. Further, the effective engraftment 
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and integration of the nanowired hiPSC cardiac spheroids with ~30k hiPSC-CMs/rat 
hearts clearly demonstrated its potential to cost-effectively deliver the large number of 
hiPSC-CMs needed to treat injured human hearts [170]. While future studies will focus 
on injecting nanowired spheroids into injured rat hearts to examine their 
therapeutic/functional efficacy, it should be noted that these nanowired hiPSC spheroids 
may still pose an arrhythmogenic risk after transplantation due to their spontaneous 
contractions (~0.5Hz) [153]. While this cannot be directly addressed in the rat model due 
to the anti-arrhythmogenic nature of rat heart [182], we plan to use extended conditioning 
strategies (e.g., exogenous electrical stimulation) to decrease the spontaneous beating of 
the nanowired spheroids with the goal of preparing electrically quiescent hiPSC cardiac 
spheroids for transplantation [180, 190]. 
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CHAPTER SIX 
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
1. Summary of my research 
MI causes a significant amount (around 25%) of irreversible cardiac cells death 
within the LV myocardium. So far, current clinical interventions have shown to slow 
down the progression of heart failure, none of them can reverse this deleterious process 
and regenerate new myocardium to replace the necrotic regions of the LV. Recent 
researches on MI treatment are focusing on cell therapies aiming to reverse heart 
remodeling and reduce scar formation with transplantation of various stem/ progenitor/ 
terminally differentiated cells. Among all the cell types of cell therapies for MI treatment, 
hiPSCs have emerged as a more promising cell resource for heart repair due to their 
proven capacity to produce patient-specific functional hiPSC-CMs. In addition, recent 
progress in cardiac differentiation of hiPSCs allows for the derivation of a large number 
of hiPSC-CMs (>10
9
 cells/patient) needed for cardiac repair.  
1.1 Accelerate structural and contractile maturation of hiPSC-CMs in 
nanowired spheroids system 
The immature phenotypes of hiPSC-CMs pose a potential risk for 
arrhythmogenicity in vivo, which could hamper host conducting system and functional 
integration of transplanted cardiomyocytes with the host myocardium. In the past decade, 
physical stimuli (e.g. electrical and mechanical stimulation) has been applied to advance 
the immature cardiomyocytes towards more matured phenotypes with more organized 
sarcomere structures (width, length and alignment) and unregulated expression level of 
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gap junction protein (Connexin-43). In order to mimic the electrically conductive 
properties of native myocardium, conductive nanomaterials (gold nanowires, carbon 
tubes) have been used as scaffolding materials to fabricate engineered cardiac tissue with 
stronger contractile and electrical properties for promoting cardiomyocyte maturation in 
vitro and in vivo. However, above mentioned gold or carbon based conductive 
nanomaterials are non-biodegradable, which may hold potential risk of arrhythmogenicity 
and chronic immune response induce by these permanently resident foreign materials in 
the heart. 
For the first time, we incorporated a trace amount of e-SiNWs into rat-neonatal 
and hiPSC cardiac spheroids to create electrically conducting microenvironments and 
induce synchronized and enhanced contraction, which was shown to promote structural 
and contractile maturation. e-SiNWs were selected because of their controllable electrical 
conductivity, tunable dimensions, and convenient surface tailorability. Further, the recent 
research showed SiNWs are biodegradable, and their degradation products are found 
mainly in the form of Si(OH)4 and are metabolically tolerant in vivo. This makes them 
advantageous over other non-biodegradable, electrically conductive nanomaterials (e.g., 
gold nanowires, carbon nanotubes and nanofibers), especially for potential in vivo 
applications. We demonstated that e-SiNWs could facilitate the self-assembly of hiPSC-
CMs to form nanowired hiPSC cardiac spheroids and improve the functions of the 
microtissues, which lead to  significantly more advanced cellular structural and 
contractile maturation of hiPSC-CMs in nanowired spheroids system.  
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1.2 Optimize the size of nanowired spheroids and confirm the critical role of 
electrical conductivity of e-SiNWs in improving the function of cardiac spheroids 
We demonstrated that addition of e-SiNWs into the human cardiac spheroids 
creates an electrically conductive microenvironment and improves tissue function and 
cellular maturation of hiPSC cardiac spheroids. In addition, recent research has shown 
that cellular spheroids/aggregates improve cell retention and survival after transplantation 
due to their 3D microtissue configuration. In my research, we try to examine two major 
factors that can affect the functions of the nanowired human cardiac spheroids: (1) the 
number of cells per spheroid (i.e., size of the spheroids), and (2) the role of the electrical 
conductivity of the e-SiNWs in improving tissue functions of the spheroids.  
The optimal cell number in the spheroids is affected by two competing factors: 1) 
the improved 3D cell-cell adhesion, and 2) the reduced oxygen supply to the center of 
spheroids with the increase of cell number. Firstly, we experimentally identified the 
optimal cell number in the spheroids and developed a semi-quantitative theory to explain 
the finding. The functional analysis of contraction amplitude, IHC analysis of contractile 
and conductive proteins, and metabolic investigation demonstrated that spheroids with 3k 
cells per spheroids maximize the beneficial effects of the 3D spheroid microenvironment. 
In our previous report, we showed the addition of e-SiNWs in the human cardiac 
spheroids improved cellular maturation and tissue function. However, the role of 
electrical conductivity of the e-SiNWs has not been examined. Secondly, we prepared 
three types of the spheroids: spheroids without the addition of nanowires, spheroids with 
the addition of phosphorus doped silicon nanowires (electrically conductive), and 
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undoped silicon nanowires (none electrically conductive). We studied the functions of 
these three different types of spheroids and confirmed the critical role of electrical 
conductivity of e-SiNWs in improving tissue functions of the hiPSC cardiac spheroids. 
Additionally, the electrical conductivity of silicon nanowires was confirmed to contribute 
to accelerate structural and functional development of hiPSC-CMs in spheroids. 
1.3 Injected nanowired spheroids improve cell retention, survival, 
maturation, long term engraftment and functional integration with rat hearts 
While most of research utilized direct injection of the dissociated hiPSC-CMs into 
the injured myocardium, the success of this single cell delivery is limited by low cell 
retention and survival after cell transplantation. Additionally, lack of cell-to-cell adhesion 
amongst single cells leads to cell death caused by anoikis and/or ischemia. To improve 
the efficiency of cell delivery, significant efforts have been devoted to the development 
of tissue-engineered epicardial patches. The cardiac patch provides a better method to 
deliver cardiac cells to the injured myocardium to achieve better outcomes such as higher 
cell retention and survival, larger and more controlled infarction area coverage, reduced 
LV remodeling post MI. However, regarding this invasive surgical procedure as patches 
transplantation, recent research has shown there is limited electrical integration between 
the transplanted patches and host myocardium, largely attributed to the chronic fibrotic 
response that occurs after transplantation. In addition, the human engraftment formed 
from transplanted patch is totally isolated from host tissue by fibrosis and it does not 
contribute to functional improvements in MI model. This highlights an urgent need to 
develop a less invasive delivery approach to improve the retention, engraftment and 
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integration of the transplanted hiPSC-CMs with the host myocardium upon 
transplantation.  
hiPSC cardiac spheroids have been proposed as an attractive cell delivery system 
for heart repair, given the recent literature showing spheroid/aggregate delivery improves 
cellular retention and post transplantation survival as less invasive approach (injectable). 
To this end, we recently utilized e-SiNWs to facilitate the self-assembly of hiPSC-CMs to 
form nanowired hiPSC cardiac spheroids and improve the functions of the microtissues, 
resulting in significantly more advanced cellular structural and contractile maturation of 
hiPSC-CMs. Here we reasoned that the presence of the e-SiNWs in the injectable 
spheroids improves their ability to receive exogenous electromechanical pacing from the 
host myocardium and enhances their integration with host tissues post-transplantation. 
This theory was inspired by our recent finding that the addition of e-SiNWs in hiPSC-CM 
spheroids are essential for exogenous electrical stimulation/pacing to promote hiPSC-CM 
development and maturation. Furthermore, recent reports showed the presence of 
electrical nanomaterials (e.g., gold nanowires) in cardiac tissue engineering constructs 
synergizes with exogenous electrical pacing to improve the function of the constructs. 
Compared to other electrical nanomaterials (e.g. gold nanowires, carbon nanotubes), e-
SiNWs have distinct advantages, including their controllable electrical conductivity, 
tunable dimensions, and convenient surface tailorability. Additionally, both in vitro and 
in vivo biocompatibility studies have shown no significant cytotoxic effects for either 
undoped or n-type e-SiNWs. Notably, the absence of a pre-aligned structure within the 
nanowired hiPSC cardiac spheroids has raised concerns over their suitability for 
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transplantation.  
We examined the cardiac biocompatibility of the e-SiNWs and cell retention, 
engraftment and integration after the injection of the nanowired hiPSC cardiac spheroids 
into adult rat hearts. The absence of major cell death or chronic inflammation/fibrosis 
from the e-SiNW intramyocardial injection indicated their high cardiac biocompatibility, 
which supports the in vivo use of nanowired hiPSC cardiac spheroids for transplantation. 
More importantly, our research showed the injected nanowired spheroids improve cell 
retention, survival, maturation, long term engraftment and functional integration with the 
host tissue compared with single cell and unwired spheroid transplantation.  
2. Challenges and limitations   
Past literatures indicates that mammalian heart consists of 30% cardiomyocytes 
and 70% non-cardiomyocytes (cardiac fibroblasts, endothelial cells, smooth muscle cells) 
[281]. Cardiac fibroblasts (CFs) play a critical role in maintaining normal heart function 
and LV remodeling post MI. In addition, CFs significantly contribute to the synthesis and 
deposition of ECM, cell–cell communication affecting the electrophysiological 
properties, secretion of growth factors and cytokines, and angiogenesis in the heart [282]. 
The extra vascular cells (endothelial cells, smooth muscle cells) could provide necessary 
components for new blood vessels formation in vivo. However, there is only  
cardiomyocytes in our nanowired cardiac spheroids system, which may be not the 
optimal cell resource for transplantation. We plan to add non-cardiomyocytes (cardiac 
fibroblasts, endothelial cells, smooth muscle cells) in our nanowired cardiac spheroids 
system to achieve better therapeutic outcomes upon transplantation in MI models. 
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It should be noted that nanowired hiPSC spheroids may still pose an 
arrhythmogenic risk after transplantation due to their spontaneous contractions (~0.5Hz). 
While this cannot be directly addressed in the rat model due to the anti-arrhythmogenic 
nature of rat heart, we plan to use extended conditioning strategies (e.g., exogenous 
electrical stimulation) to decrease the spontaneous beating of the nanowired spheroids 
with the goal of preparing electrically quiescent hiPSC cardiac spheroids for 
transplantation. 
3. Future directions 
3.1 Application of cardiac regenerative medicine 
The future studies will focus on injecting nanowired spheroids into injured rat 
hearts to examine their therapeutic/functional efficacy. We will create a MI model on 
athymic adult rats, and delivery the injectable nanowires cardiac spheroids into the 
infarcted rat heart to investigate 1) whether these cardiac spheroids can survive and form 
engraftment in the ischemic environment in rat MI model; 2) whether these cardiac 
spheroids can reduce the fibrosis in MI site and form functional integration with host 
myocardium to replace the damaged heart tissue; 3) whether these cardiac spheroids can 
improve the heart function evaluated by echo measurement. If we could reach our 
experiment goals, this will be the great advance in the cardiac regenerative medicine by 
combined application of nanomaterials (electrically conductive silicon based nanowires), 
stem cells (hiPSCs derived cardiomyocytes) and engineering methods (non-invasive 3D 
scaffold-free spheroid delivery).  
3.2 Potential application in brain tissue regeneration 
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Persistent cell dysfunction and poor neural regenerative capabilities at the lesion 
site after ischemic stroke lead to the formation of a cavity that is associated with 
prolonged neurological impairment. Transplantation of stem cells represents a promising 
strategy to reconstruct the lesion cavity and promote tissue regeneration after ischemic 
stroke. Despite the advances in deriving hiPSCs into neurons and specific functional 
subtypes, the progress in demonstrating cell engraftment, improving angiogenesis and 
promoting the integration of the differentiated neurons with the host tissue is limited.  
We have established nanowired hiPSC-derived cardiac spheroids as a less-
invassive injectable appoach to deliver cardiomyocytes with enhanced cell retention, 
engraftment, and functional integration with rat host myocardium. Since stem cell 
therapies for the treatment of MI and ischemic stroke have similar issues need to be 
addressed, such as low cell survival, lack control of cell differentiation, and low cell 
maturation and integration with host tissue, I propose to develop a nanowired 
prevascularized neural spheroid (NPNS) system based on hiPSC-derived neural stem 
cells and endothelial cells and to deliver this NPNS for brain tissue regeneration after 
ischemic stroke. This project will establish a framework to support the survival, 
maturation, and integration of transplanted cells to treat stroke-damaged brain tissue.  
The overall objective of this project is to develop NPNS as a unique cell delivery 
system to transplant hiPSC-derived neural/progenitor stem cells (NSCs) at the lesion site 
following ischemic stroke for neural regeneration. We will examine whether the hiPSC-
derived neurons can display specific patterns of axonal projections and dendritic 
outgrowth, and whether they integrate functionally with the host synaptic circuitry. We 
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will optimize the ratio of e-SiNWs, hiPSC NSCs and hiPSC ECs in vitro. We will 
examine the survival, organization, differentiation, maturation, and integration of 
transplanted NPNS, and demonstrate advantages of NPNS in promoting structural repair 
and functional recovery of stroke-injured brain.  
We hypothesize that the NPNS system consisting three key elements to maximize 
regeneration outcomes after transplantation in the animal model of middle cerebral artery 
occlusion (MCAO). The first element in NPNS is e-SiNWs, which offer distinct 
advantages as nanoscaffolding materials for conductive tissue engineering (heart and 
brain), including their controllable electrical conductivity, tunable dimensions, and 
convenient surface tailorability. The e-SiNWs in the NPVS is capable of receiving the 
host electrical signal to stimulate the differentiated cells from the transplanted hiPSC 
NSCs at the lesion site of MCAO and enhance the electrically integration of the 
regenerated neurons with the host tissue. The second element in NPNS is 3D spheroid 
mainly consist of hiPSC NSCs, which have capability to differentiate to neurons, 
astrocytes and oligodendrocytes for in vivo regeneration. The spheroids act as a bridge 
between traditional 2D cell culture and in vivo tissue because they mimic in vivo 
microenvironment with enhanced cell-cell and cell-ECM interaction, which lead to 
spheroid‟s resistance to anoikis-mediate cell death pathways after transplantation in vivo. 
The last element in NPNS is hiPSC derived endothelial cells, which could form vascular 
structures in vitro and in vivo to improve nutrients and oxygen supply to maintain the 
survival of hiPSC NSCs in long term in vivo.   
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